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Abstract 
Early research concentrated on the relationship between a solute’s physicochemical 
properties and its skin permeation, mostly from simple solutions. Relatively less is known 
about how vehicles, particularly complex ones, might also affect skin permeation by altering 
the properties of the skin, although this is an area that has attracted much interest. Key 
requirements for topical delivery is understanding the relationships between drug-vehicle, 
drug-skin or drug –vehicle –skin interaction. In this project, understanding this relationship 
was crucial to designing novel formulations able to deliver drugs with different lipophilicity 
topically or systemically. The first aim was to explore the impact of various solution 
compositions on skin permeation of some model drugs. I compared in vitro maximum 
penetration fluxes (Jmax) and solubilities of the vehicles (Sv) and of the stratum corneum 
(SSC) and derived diffusivities (D*) for four drugs (caffeine, minoxidil, lidocaine and 
naproxen) having a range of lipophilicities. I used a range of solvent vehicles that were 
hypothesised to affect the skin to differing degrees to evaluate vehicle effects on 
permeability parameters.  
If neither the vehicle nor the solute alters the properties of the skin, maximum (or saturated) 
solute flux is independent of both the vehicle composition and the solute’s saturated 
solubility in that vehicle. These findings were confirmed in this study for all four drugs used. 
The permeation of caffeine, minoxidil, lidocaine and naproxen were found to be selectively 
enhanced by vehicles containing specific excipients that were hypothesised to alter the 
properties of the skin. The greatest effects were seen on flux and diffusivity by the eucalyptol 
(EU) and oleic acid (OA) vehicles on the more hydrophilic compounds, caffeine and 
minoxidil. We concluded that enhanced solute fluxes were mainly driven by increased 
diffusivity in the stratum corneum. 
I also examined the extent of skin permeation enhancement of the hydrophilic drug caffeine 
and lipophilic drug naproxen applied in nanoemulsions incorporating skin penetration 
enhancers. Infinite doses of fully characterised oil-in-water nanoemulsions containing the 
skin penetration enhancers oleic acid or eucalyptol as oil phases and caffeine (3%) or 
naproxen (2%) were applied to full-thickness skin and human epidermal membranes in 
Franz diffusion cells, along with aqueous control solutions. Caffeine and naproxen fluxes 
were determined over 8 h. Solute solubility in the formulations and in the stratum corneum, 
as well as the uptake of product components into the stratum corneum were measured. 
The nanoemulsions significantly enhanced the skin penetration of caffeine and naproxen 
compared to aqueous control solutions. The maximum flux enhancement of caffeine was 
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associated with a synergistic increase in both its solubility in the stratum corneum and skin 
diffusivity. Enhanced skin penetration in these systems is largely driven by uptake of 
formulation excipients containing the active compounds into the stratum corneum. Fluxes of 
caffeine and naproxen absorbed into the receptor from full-thickness skin compared with 
epidermis were similar. Therefore, the amount of caffeine permeating the dermis and 
hypodermis was not affected by these structures although the stratum corneum only 
provided the barrier against penetration. In addition to lipids, the vesicle excipients included 
eucalyptol or oleic acid as penetration enhancers, and decyl polyglucoside (DPGluc) as a 
non-ionic surfactant. Vesicle particle sizes ranged between 135 and 158 nm and caffeine 
encapsulation efficiencies were between 46% and 66%. Caffeine penetration and 
permeation was measured using high performance liquid chromatography (HPLC). We 
found that niosomes, which are liposomes containing a non-ionic surfactant and 
transferosomes (ultraflexible vesicles) showed significantly greater penetration into the skin 
and permeation across the stratum corneum. Significant enhancement of caffeine 
penetration into hair follicles was found for transferosomes and those liposomes containing 
oleic acid. 
The third aim was to investigate the effectiveness of our nanoemulsion formulations of 
caffeine and minoxidil for transfollicular delivery. Nanoemulsions were applied to full-
thickness excised human abdominal skin in Franz diffusion cells for 24 h. Minoxidil 
concentrations in receptor fluid, tape strip extracts, follicular casts and homogenised skin 
extracts were analysed. The oleic acid formulation was the best at promoting minoxidil 
retention into the superficial skin compartments (stratum corneum and hair follicles). The 
eucalyptol formulation was the best for deeper penetration into and through the skin. In the 
second part, caffeine in nanoemulsion formulations containing OA or EU and in controls was 
topically applied and the amount of caffeine retained in the stratum corneum, hair follicles, 
in the skin and in the receptor was analysed. The hair follicles and the area around them 
were imaged by a LaVision Multiphoton Microscope. Oleic acid nanoemulsion showed the 
highest transfollicular delivery of caffeine. Less caffeine in skin layers and storage in hair 
follicles was found after blocking the hair follicles. 
In conclusion, this project provided information to understand the mechanisms of chemical 
penetration enhancers on the human skin and the results of this PhD will help to improve 
the design of new formulations or to develop current formulations containing model drugs.   
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Chapter 1 
Literature Review 
Enhanced skin delivery of topically applied drugs: A review 
 
1.1 Abstract   
There is substantial interest in the skin as a route of drug delivery for local or systemic 
effects. However, the stratum corneum forms a formidable barrier to solute penetration, 
limiting topical and transdermal bioavailability. Many techniques have been used to enhance 
the permeability of drugs and increase the penetration of drugs that are used for topical 
delivery. This review describes the skin structure and the various techniques that have been 
used to enhance drug delivery across human skin. 
 
1.2 Introduction 
The skin is the largest organ of the body; it forms a protective layer over the underlying 
tissues such as ligaments, muscles and internal organs, preventing exposure to exogenous 
particles and mechanical and radiation-induced injuries. In addition, the skin plays a role in 
immunity and metabolism, controls body temperature and comprises sensory nerve endings 
for the perception of temperature, touch, pressure and pain. Skin is made up of viable and 
non-viable epidermis, dermis and hypodermis (subcutaneous) layers. 
Topical application of drugs has been investigated as an alternative to intravenous or 
parenteral routes, but transdermal delivery is frequently limited by poor drug penetrability. 
This low permeability can be mostly attributed to the outer layer of the skin, the stratum 
corneum, which serves as a rate-limiting lipophilic barrier to the uptake of exogenous 
chemical and biological substances and to the loss of water. This means that some drugs 
need penetration enhancers included in formulations to enable efficient delivery of 
therapeutic agents. Penetration enhancers are chemicals that reversibly reduce the barrier 
function of the stratum corneum, to facilitate drug delivery to and through the tissue. Ideally, 
they should be odourless, colourless, pharmacologically inert and chemically and physically 
stable.  
After extensive research, the success of this technique remains limited, with many issues 
still to be solved. Recently, advanced formulations such as liposomes and nanoemulsions 
have also been used to help drugs penetrate the skin. This review describes the skin 
structure; routes of penetration, how drug properties affect permeation, permeation 
enhancement techniques and advanced formulations. 
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1.3 Skin structure: 
The skin is the outer layer and largest organ in the body, accounting for about 16% of body 
weight with surface area of approximately 1.8 m² in adults (1). The skin plays an essential 
role for the survival of the human body in a relatively hostile environment. The most vital role 
is providing a physical barrier to the environment, it maintains homeostasis by limiting the 
loss of water, electrolytes and heat and protects against micro-organisms, toxic agents and 
ultraviolet radiation (2). It consists of three basic layers: the epidermis, the dermis and the 
subcutaneous layer. Hair, nails, sebaceous, sweat and apocrine glands are considered as 
skin derivatives or appendages. Even though it is structurally continuous throughout the 
body, skin varies in thickness according to the age of the individual and the anatomical site 
(3). 
 
1.3.1 Epidermis 
The epidermal layer is formed from squamous epithelium. Keratinocytes are the main cells 
of the epidermis that can produce the keratin protein. Protein bridges named desmosomes 
attach the keratinocytes and are in a constant state of moving from the deeper layers to the 
superficial. The separate layers of the epidermis are defined by the degree of keratinisation. 
The layers of the epidermis from bottom layers to the surface are the stratum basale (basal 
cell layer), the stratum spinosum (spinous or prickle cell layer), the stratum granulosum 
(granular cell layer) and the stratum corneum (horny layer) (4), (see Fig1.1). Both the stratum 
spinosum and stratum granulosum are occasionally mentioned as the Malphigian layer (1, 
5) 
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Fig1.1 Structure and Function of the Skin blog.mediligence.com 
 
1.3.1.1 Stratum basale 
The deepest layer of the epidermis which lies next to the dermis contains columnar or 
cuboidal cells, that are connected to the basement membrane by hemi-desmosomes (3). 
The nuclei of these cells is large and occupies most of the cell (3). These cells are 
functionally heterogeneous and can work as stem cells that divide and proliferate to remain 
attached to the basement membrane (6). These cells reproduce continuously by mitosis to 
produce daughter cells that keep the epidermis replenished. In normal human skin, the 
turnover and replacement of these cells takes around 30 days depending on age, area of 
the body and disease states (3). Keratinocytes are the predominant cells in the basal layer. 
The main function of keratinocytes is forming a barrier against environmental damage 
caused by heat, pathogenic bacteria, UV radiation and water loss. The cornified 
keratinocytes that form the outermost layer are constantly shed and replaced by new cells 
(7). 
 
1.3.1.2 Stratum spinosum 
As a result of replication and maturation of basal cells, they transfer to the outer layer of 
skin, firstly forming the stratum spinosum which is connected by intercellular bridges and the 
desmosomes (8, 9). Langerhans cells are dendritic (immune cells) of skin. They are found 
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throughout the epidermis but are mostly prominent in the middle of this layer. In case of skin 
infection, the Langerhans cells engage in and process microbial antigens to be fully 
functional antigen-presenting cells (10-12).  
 
1.3.1.3 Stratum granulosum 
During their migration to the surface, the cells progressively collapse and lose their nuclei 
and cytoplasm, so that they seem granular at this level(1). A typical feature of this layer is 
the presence small lamellar granules known as lamellated bodies or membrane coated 
granules (3). These granules are smaller than mitochondria and differ in size according to 
variation in species from 0.1-0.5 µm (9) or from 0.3-0.7 µm (8). 
 
1.3.1.4 Stratum corneum 
The stratum corneum results from the migration of cells from the basal layer to the skin 
surface by the process known as keratinisation. The final result of keratinocyte maturation 
is the stratum corneum, which is formed from hexagonal-shaped layers, non-viable cornified 
cells named corneocytes. In most skin sites, there are 10-25 layers of stacked corneocytes 
which are non-hydrated cells lying parallel to the skin surface (2). Every cell is enclosed by 
a protein envelope and filled with water-retaining keratin proteins. The form and location of 
the keratin proteins give strength to the stratum corneum. The thickness varies according to 
the physical interaction and environment, as for example, these cells are thicker on palms 
of the hands and soles of the feet. Moreover, the absorption of solutes through these areas 
is slower than other parts of the body(13). Each stratum corneum cell contains keratin 
(~70%) and lipid (~20%). The region between cells consists of lipid and desmosomes for 
corneocyte cohesion. The stratum corneum acts as a barrier to prevent the loss of internal 
body components such as water. The layer of corneocytes can absorb three times its mass 
in water if its water content falls below 10% but it no longer remains flexible and cracks. The 
epidermal cells take 2-3 weeks to transfer to this layer (13). 
Epidermal stem cells are responsible for everyday regeneration of the different layers of 
the epidermis. These stem cells are found in the basal layer of the epidermis. The main 
functions of epidermal cells are: 
- Melanocyte cells are responsible for regeneration of melanocytes, a type of pigment 
cell. Melanocytes produce the pigment melanin, and therefore play an important role 
in skin and hair follicle pigmentation. It is not yet certain where these stem cells are 
found in humans 
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 Keratinic cells play an essential role in serving to anchor the epidermis to the Basal 
membrane (6, 13). 
 Langerhans cells have important roles in the skin’s immune system. (6, 13) 
 
Desquamation of skin cells 
Desquamation is an important factor in maintaining skin integrity and smoothness of the 
stratum corneum. It is the process of cell shedding from the surface of the stratum corneum, 
and balances proliferating keratinocytes that form in the stratum basale. These cells migrate 
through the epidermis towards the surface in a journey that takes approximately fourteen 
days. The keratinocytes are denucleated during the process and corneodesmosomes are 
broken down to allow the cells to be shed (3). 
 
1.3.2 Dermis 
The dermis differs in thickness, from almost 0.1 -0.5 cm. It is located underneath the 
epidermis and is composed of a firm, supportive cell matrix. The dermis contains two layers: 
thin papillary layer and thicker reticular layer (1, 13). The papillary dermis lies under and 
connects to the epidermis. It comprises thin, free organised collagen fibres. The thicker 
collagen bundles are equivalent to the surface of the skin in the deeper reticular layer, and 
spread from the base of the papillary layer to the subcutaneous tissue. The dermis consists 
of fibroblasts, which create collagen, elastin and structural proteoglycans, both with immune 
capable mast cells and macrophages. Collagen fibres form more than 70% of the dermis, 
providing strength and hardness and elastin gives elasticity and flexibility whereas 
proteoglycans provide viscosity and hydration. The dermal vasculature, lymphatics, nervous 
cells and fibres are embedded in the fibrous tissue of the dermis in addition to the sweat 
glands, small numbers of striated muscles and hair roots. The dermis has an extensive 
vascular network, hair follicles, and sweat glands. Therefore, the major function of the 
dermis is providing nutrition and immune response to the skin. It also plays an important role 
in regulating the temperature, pressure and pain. Moreover, the papillary layer in the dermis 
provides a support system for the epidermis (1, 13). 
 
1.3.3 Subcutaneous 
The subcutaneous (hypodermis) layer is the deepest layer of the skin, and is formed from 
loose connective tissue and fat (50% of the body fat), which may be more than 3 cm thick 
on the abdomen. Its function is absorption of shock and as storage for energy in addition to 
its work as a heat insulator as it carries the vascular and neural systems for the skin. The 
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hypodermis layer is linked to the dermis by interconnecting collagen and elastin fibres in a 
loose arrangement, allowing flexibility and free movement of the skin over the underling 
structure (3). The main cells in this layer are fibroblasts and macrophages. (1, 13). 
 
1.3.4 Derivative structures of the skin (Appendages) 
1.3.4.1 Hair 
Hair is found in varying thickness over most of the body surface, with a few exceptions 
including the soles of the feet, palms of the hands, lips and some other areas. Every hair 
follicle is surrounded by germinative cells, which provide keratin and melanocytes and 
produce pigment. The free part of the hair above the skin surface is called the hair shaft and 
the part within the follicle is called the hair root, with a terminal hollow knob called the hair 
bulb (3). The hair shaft contains an outer cuticle, a cortex of keratinocytes and an inner 
medulla (1, 3) and is accompanied by arrector pili muscle that contracts the hair shaft in 
case of fear, emotion and cold, giving the skin “goose bumps” (1). The hair density is 
different in various body sites; on the forehead the hair follicles are small but high in density, 
while on the calf area, the density is low but the follicles are larger (14, 15). 
 
1.3.4.2 Sebaceous glands  
The sebaceous glands are derived from epidermal cells and accompany hair follicles, 
particularly those of the scalp, face, chest and back. These cells are not found in hairless 
areas. Sebaceous glands are small in children, growing and becoming active during 
adolescence. An oily sebum is produced from these glands by holocrine secretion, 
consisting of triglyceride, free fatty acids and waxes. The sebum function is to protect and 
lubricate the skin as well as maintain the skin pH at around 5 (13). Other functions of sebum 
are maintaining the epidermal permeability barrier, carrying antioxidants to the skin surface, 
and also regulating steroidogenesis and androgen (3, 16) 
1.3.4.3 Sweat glands 
Sweat glands are believed to number more than 2.5 million on the human skin surface. They 
are classified into apocrine and eccrine sweat glands depending on their function and shape. 
The apocrine gland is bigger and has ducts which empty into the hair follicles. It is found 
throughout the skin in most domestic animals but in humans it occurs in restricted areas 
only (axillae, areola and nipples, external ear canal, eyelids, inner nostrils, perianal region, 
and some parts of the external genitalia). The eccrine gland is the dominant form in humans 
and is distributed in most other areas of the body (4). Eccrine glands open directly onto the 
skin surface. The eccrine glands excrete watery fluid containing lactic acid, chloride, fatty 
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acids, urea, mucopolysaccharides and glycoproteins and are necessary for fluid and 
electrolytes homeostasis. Also, they secrete a dilute salt solution in case of high 
environmental temperature and emotional stress. Apocrine glands become active in 
adolescence, producing an odourless protein-rich secretion which when acted upon by skin 
bacteria emits a characteristic odour (1, 3).  
 
1.4 Barrier function 
stratum corneum, the result of epidermal terminal differentiation, is an important mediator of 
defensive function of the skin (17) and a biosensor which recognises and responds to 
changes in external humidity and pH. Thermoregulation is achieved by keeping a constant 
body temperature through alterations in blood flow in the cutaneous vascular system and 
sweat evaporation from the surface. UV protection is provided by the melanocytes, in the 
basal layer, producing melanin which absorbs UV radiation and protect the cell nuclei from 
DNA  damage (18) .(1). Melanin particles in the epidermal inner layers form defensive 
shields over the keratinocyte nuclei in the outer layers, and are more regularly distributed. 
As well as acting as a physical barrier, skin also has an essential immunological role. It 
incorporates all the elements of cellular immunity, with the exception of B cells. Immune 
components of the skin are given in Table 1.1 (19). The skin is also working as a barrier by 
controlling the loss of water, electrolytes and other body components, in addition to inhibiting 
the entry of harmful and unwanted molecules from the external environment. This function 
may be attributed to the unique structure of the stratum corneum, which consists of multiple 
layers of nucleate, proteinaceous corneocytes embedded in an expanded, extracellular 
matrix of enriched lipid forming a model similar to “bricks and mortar”(20). The function of 
corneocytes is mechanical friction resistance which is attributed to the rigid , highly cross-
linked cornified envelope (21).   
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Table 1.1 Immune components of the skin (19) 
Defence type Component Immune action 
Structure Skin Impenetrable physical barrier to most external 
organisms 
 Blood and Lymphatic vessels Provision of transport network for cellular defence 
Cellular Langerhans cells 
T lymphocytes          
Mast cells                 
Antigen presentation 
Facilitate immune reactions. Self-regulating through 
the action of T suppressor cells. 
Facilitate inflammatory skin reactions. 
  Keratinocytes Secrete inflammatory cytokines; have ability to 
express surface immune 
Systemic molecules Cytokines and Eicosanoids 
 
 
 
 
Cytokines: cell mediation chemicals produced by 
components of the cellular defence system 
Eicosanoids: non-specific inflammatory 
 Mediators produced by mast cells, 
Macrophages and keratinocytes. 
Increase the number of cellular defence facilitators in 
an area by binding to T cells. 
 
 Adhesion molecules Complement 
Cascade 
Activation of this initiates a host of destructive 
mechanisms, including opsonisation, lies, 
chemotaxis and mast cell degranulation. 
Immunogenic 
antigens 
Major Enables immunological recognition of Major 
Histocompatibility Complex (MHC) 
 
1.5 Routes of drug delivery via human skin 
When designing a topical delivery system, it is important to understand the possible 
penetration pathways. Drug molecules, in contact with skin, penetrate by three potential 
routes: directly through the stratum corneum (intercellular and transcellular) (Fig 1.2), via 
the sweat ducts, and through the hair follicles and sebeaceous glands (the shunt or 
appendageal route) (Fig 1.2). The importance of the appendageal route versus transport 
through the stratum corneum has been debated by researchers for many years (22, 23) as 
its determination is complicated by the absence of suitable experimental models to allow 
separation of these three routes. The pilosebaceous pathway penetrating through hair 
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follicles may be portal for penetration of large polar molecules which have difficulty diffusing 
through the stratum corneum.  
 
Fig 1.2 Main routes of penetration: 1. through the sweat gland; 2. directly across the stratum corneum 
(transcellular); 3. via the hair follicles; 4. Intercellular (modified from (24)). 
 
1.5.1 Cutaneous delivery  
Designing drug delivery systems has become a major focus of activity in the pharmaceutical 
industry and transdermal administration is one of the important delivery routes currently 
under consideration. The stratum corneum is very selective with respect to what it permits 
to be transported through the skin; consequently, only penetrants with particular 
physicochemical properties in a narrow range can pass through the skin adequately under 
passive conditions. This causes the variety of potential drugs that can be administrated 
topically to be limited, which highlights the value of incorporating permeation enhancers into 
formulations to help in the active delivery of a larger diversity of drugs (25). The aim is to 
deliver active substances to targeted sites through the skin at an acceptable rate to produce 
the desired pharmacological effect.(26). 
 
1.5.1.1 Advantages of cutaneous delivery 
Cutaneous administration has numerous advantages and can be summarised as follows: 
1. This route of administration means that the hepatic first pass metabolism and the 
gastrointestinal tract metabolism are avoided (27) 
2. It offers an alternative pathway for patients who have oral dosing issues, such as in 
unconscious patients (28). 
3. It is painless and convenient (29).  
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4. Cutaneous delivery can provide direct access to the diseased or target site such as 
for fungal skin disease or eczema (30).  
5. It has fewer side effects related to systemic toxicity compared to other routes of 
administration (28, 31).  
6. As the drug would normally be delivered by an external device, medication can be 
ceased at any point by the removal of the device. Of course, any substance that has 
already partitioned into the skin cannot be easily removed but only this substance 
can enter the body once the device is removed from the skin (26).  
 
1.5.1.2 Limitations of using cutaneous delivery 
The most obvious limitation for topical drug delivery is that the solute should be able to 
penetrate the skin. This means that the physicochemical properties of the drug play an 
important role in penetration, for example, the molecular weight should be less than 500 Da 
to diffuse through the stratum corneum (32), (33). 
The skin is a multilaminate membrane and changes from a lipophilic material (the outer most 
stratum cormeum) to a very aqueous internal structure (viable epidermis and dermis). 
Therefore, successful permeation of solutes requires molecules, which are soluble in the 
lipophilic environment of the stratum corneum and in the hydrophilic environment of the 
viable epidermis and dermis. A drug lipophilicity (log P (Octanol/Water) should be between 
1-3 in order to permeate  through the variable epidermis and underlying layers successfully 
(34). These limitations apply only to passive delivery and the point of developing enhanced 
delivery systems is to circumvent the limitations. 
 
1.5.1.3 Factors responsible for releasing a drug from a cutaneous system 
The events which may occur after administration of formulation to the skin are shown in 
Figure 1.3. Studies of cutaneous drug delivery and transdermal absorption have 
demonstrated six events which are responsible for drug transfer from the system of 
transdermal application to the blood circulation(26): 
1. Transport of drug from formulations to the stratum corneum. 
2. Partitioning of drug from formulations into the stratum corneum. 
3. Drug diffusion within the stratum corneum. 
4. Partitioning of drug into the more aqueous epidermal tissues (Viable epidermis: VE).  
5. Drug diffusion within the tissues of viable epidermis.  
6. Drug absorption into the dermal and blood vessels.  
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Initially, the drug must be released from the vehicle followed by partitioning into the SC. 
Molecules will subsequently diffuse (as a result of a concentration gradient) through the SC 
before a further partitioning process into the viable epidermis, and further diffusion through 
the viable epidermis towards the dermis. Following uptake by the vasculature and lymphatic 
vessels in the dermis, the drug enters the systemic circulation to be distributed to tissues 
and organs and eventually cleared.(26, 35). 
 
 
Fig 1.3 Diagrammatic representation of the drug transport into and through the skin from a 
topical applied formulation (36). 
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1.5.2 Appendageal Drug Delivery 
The important role of hair follicles as penetration routes and reservoirs for topically applied 
substances has been validated in several animal models and in humans (37). The 
pilosebaceous unit describes the combined structure of the hair follicle, the adjoining 
arrector pili muscle and associated sebaceous gland (38), containing more than 20 various 
cell populations (39), which regulate different immunological, biochemical and metabolic 
activities.  
Previously, layers of stratum corneum have been considered to be the main permeation 
pathway into and through the stratum corneum, while the skin appendages were supposed 
to play a secondary role by representing only 0.1% of the entire skin surface area (40). 
Further studies have concentrated on the hair follicle as a possible pathway for both 
systemic and localised drug delivery. Initial experiments on this idea were reviewed by Barry 
(41), and more contemporary methods involve fluorescence microscopy and confocal laser 
scanning microscopy applied to a variety of drugs in a range of vehicles. Therefore, a better 
understanding of the structure and function of the hair follicle may lead to more rational 
design of drug formulations to target follicular delivery (42). Efforts have been made to 
improve techniques that enhanced follicular penetration rates, in order to reach the 
maximum concentration of topically administration compounds in and around the hair follicle. 
A study by Lademann et al in 2003 suggested that large particles (e.g., 750, 1500nm) may 
be used to deposit high concentrations of drugs in the follicular duct, while small particles of 
about 40 nm especially in barrier disrupted skin, may be used to release active moieties to 
specific cell populations such as stem cells and multiple precursor cells (Fig1.4) (43), (44). 
Also for evaluation and quantification of the transfollicular process, a knowledge of variations 
of hair follicle parameters in various body sites is important. Different ways have been used 
to investigate the hair follicle as a potential follicular reservoir such as cyanoacrylate skin 
surface biopsy (15), (45). One aim of follicular targeting is to treat alopecia by growing new 
follicles bioengineered from the stem cells of patients (46).  
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                   A 750nm, 1500nm                     B 40 nm particles 
 
Fig 1.4 Penetration depths and capacity to penetrate the epithelium depend on the particle 
size (43) 
  
Infundibulum 
Bulge Stem 
cells 
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1.6 Skin penetration enhancement 
Substances which enhance drug diffusion through the stratum corneum and viable 
epidermis, are known as penetration enhancers, accelerants or promoters (47). 
Extensive studies have focused on improving drug delivery through skin, by reducing the 
resistance of the stratum corneum to drug penetration (27). However, the main problem is 
in trying to improve the flux of drug through human skin. Therefore, it is essential to develop 
new methods or formulations that could remove the skin barrier resistance reversibly and 
accelerate the penetration of a drug. Numerous advances have included iontophoresis, 
sonophoresis, microneedle, chemicals and vesicular systems such as liposomes, 
transferosomes, neosomes etc. (48). Figure 1.5 shows the intercellular lipid domain of the 
stratum corneum as the main target of action for chemical penetration enhancers (49).  
 
Fig.1.5 Actions of penetration enhancers within the intercellular lipid domain (49) 
 
1.6.1 Chemical enhancers 
The use of chemical penetration enhancers over other strategies has many benefits, 
including design flexibility with formulation chemistry. Chemical penetration enhancers 
should ideally be pharmacologically inert, nontoxic, non-irritant, non-allergic, odourless, 
tasteless, colourless, compatible with most drugs and excipients and inexpensive (49). 
Moreover, they should work rapidly and act unidirectionally. That is, they should allow 
therapeutic agents into the body while preventing the loss of endogenous material from the 
body. In addition, the barrier properties should return both rapidly and fully once the 
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enhancers are removed from the skin. Another prerequisite feature is that they should be 
cosmetically acceptable. A broad range of vehicles have been tested, such as alcohols and 
polyols (ethanol, propylene glycol); surfactants, fatty acids (oleic oil), lactams (azone), 
terpenes (limonene), sulfoxides (dimethyl sulfoxide) and esters (50). 
Chemical enhancers work by different mechanisms: 
A- Interaction with intracellular lipids. The enhancer disrupts the stratum corneum lipid 
organisation, making it permeable (51, 52), thereby increasing the drug diffusion coefficient. 
The enhancer substances jump into the bilayer, vibrating, translocating and increasing the 
free volume available for drug diffusion. Without accelerant, the free volume fraction is 
lowest (D lowest) near the bilayer interface. Many enhancers operate in this way such as 
azone, terpenes, fatty acid and so on. It was believed that such enhancers would penetrate 
into and mix homogenously with the lipid. Nonetheless, oleic acid and terpenes pool within 
lipid domains at high loadings, permeable pores form, and polar molecules are allowed 
access to the viable epidermis (53). 
B- Interaction with intracellular protein and denaturation of keratin (54). Ionic surfactant 
(sodium laurate sulphate (SLS)), and decylmethyl sulphoxide (DCMS) interact with keratin 
in corneocytes, opening up the dense protein structure and making it more permeable and 
consequently increasing diffusivity (51). Some molecules may also modify peptide/protein 
material in the bilayer domain. 
C- Increasing partitioning and solubility in the stratum corneum. A large number of solvents 
entering the stratum corneum, change their solution properties by altering the chemical 
environment, and thus increase the partitioning and solubility of a molecule in the stratum 
corneum, for example, transcutol, ethanol and propylene glycol (24). In theory, nonsolvent 
enhancers that mainly act to raise drug diffusivity by lipid action mechanism, should also 
increase the partitioning coefficient of lipid drugs by disordering the lipid interfacial domain; 
they increase the free volume and make a large fraction of the bilayer available for solute 
partitioning (52). 
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Table 1.2 Common chemical penetration enhancers (CPEs); mechanisms, safety and side effects and their features (modified from (55)) 
Mechanism of 
action 
Example of CPE Safety and side effects Features 
Interaction with 
intracellular lipids 
and produce lipid 
disruption and 
fluidisation. 
 
 
 
 
 
 
 
 
 
 
 
1-Fatty acids (FA), 
oleic acid 
(unsaturated) and 
Lauric acid 
(saturated) 
 
 
 
 
 
 
-High concentration 
can cause skin 
redness and mild 
irritation. 
-Disruption of the densely packed lipid that fill the extracellular spaces of stratum 
corneum and form ion pairs. 
-Increase drug solubility and partitioning. 
-Promote both lipophilic and hydrophilic drugs delivery at high concentration. 
-Previous study on hairless mouse and using hydrocortisone as a model has been 
found that unsaturated F.As have high enhancement potency when have been used 
in free form. Another study on Lauric acid and other saturated F.As, using different 
physicochemical properties of model drugs has shown that drug solubilisation in the 
vehicle increased partitioning, increased barrier disruption and solvent penetration in 
the presence of F.As; the mechanism differ with the adjuvant, the drug and the vehicle. 
 
 
 
 
2-Azone (1-dodecyl-
azacycloheptan-2-one) 
 
-May cause mild 
irritation and toxicity at 
low concentration 
-Its Log O/W partitioning coefficient is 6.6. 
-Non polar, no protein interacting. 
-Promote penetration at low concentration (1-5%) for lipophilic and hydrophilic drugs. 
-It affects the fluidity of structured lipids in the intercellular channels of the skin. 
 
 3-Terpenes such as 
Menthol and 1-
Carvone 
 
 
-FDA classified them as 
safe, free toxicity and 
has low irritancy 
potential. 
-They are often the components of volatile oil. 
-They are a synergistic effect with co-solvents such as ethanol and propylene glycol. 
- Good penetration enhancer for both lipophilic and hydrophilic drugs. 
-Act by disrupting the ordered lipid structure of the stratum corneum and increase 
partitioning of the drug from its aqueous vehicle in the stratum corneum.  
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Interaction with 
intercellular protein 
(keratin), It is 
believed that these 
chemicals interact 
with keratin into 
coenocytes to alter 
the diffusion 
coefficient and 
increase the 
permeability. 
However, other 
studies claim that 
these compounds 
can also work on the 
various regions such 
as protein or peptide 
in the domain of the 
lipid to increase 
permeability. 
1-Decylmethyl 
sulphoxide 
(DCMS) 
 
 
 
 
 
 
 
 
- It acts at low concentrations, even below 0.1%. 
- It accelerates polar drug more than non- polar. 
-DCMS use as a solvent, altering protein conformation and thus opening up aqueous 
cannels and also increase lipid fluidity. 
- DCMS use combination with 15% DCMS in PG or 4% in water. 
 
2-Surfacants (Sodium 
laurate sulphate (SLS)) 
 
-Cause some problems 
such as swelling and 
skin irritation. 
-SLS disrupt the entire membrane affecting both lipid and protein structure. 
-Previous study has been shown that 0.1-1% SLS solution grossly swell the stratum 
corneum, uncoiling and extending alpha-keratin helices and the opening up the 
protein-controlled polar pathway. 
3-Polymers 
(Dendrimers) 
-No skin rotation has 
been reported (safe). 
-These chemicals act by interacting with keratin and lipid in the stratum corneum in 
addition to increase the drug partitioning.  
 
Increasing 
partitioning and 
solubility in the 
stratum corneum 
-They act by 
extracting lipids from 
the stratum corneum 
and forming aqueous 
channels within the 
stratum corneum that 
increase 
permeability. 
-Alcohol (ethanol) 
 
High concentration 
causes skin 
dehydration. 
 
-High concentration of ethanol causes extraction lipids from stratum corneum. 
-Low concentration of ethanol alters the organisation of intercellular lipids, thus 
increasing skin permeability. 
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1.6.2 Natural Enhancers  
While various synthetic chemicals are often employed as penetration enhancers by the 
pharmaceutical industry, some of these are associated with irritation and other adverse 
effects. Consequently, safe and effective alternative enhancers are sought and there is 
much interest in substances of natural origin. These offer potential advantages, such as 
renewable mass production from sustainable resources and lower cost, depending on the 
extraction process. Some examples of natural penetration enhancers are fatty acids, 
essential oils, including terpenes and polysaccharides (56). 
 
1.6.2.2 Terpenes 
Terpenes are components of essential oils which are derived biosynthetically from isoprene 
units. They are commonly used as penetration enhancers for hydrophilic and lipophilic drugs 
in the pharmaceutical industry and are generally regarded as safe for use on human skin. 
Different classes, various physiochemical features and various mechanisms of action make 
these compounds useful for transdermal delivery of drugs. Terpenes are classified 
according to the number of isoprene units (C₅H₈ ) in the molecule (56). It is reported that 
hydrocarbon terpenes are less effective enhancers for hydrophilic drugs than ketone or 
alcohol containing terpenes and the oxide terpenes have shown the greatest enhancement 
activity with hydrophilic drugs (57). Eucalyptol has been found to increase the permeation 
of several lipophilic drugs across hairless mouse skin (58). Some monocyclic monoterpenes 
such as limonene and menthol enhanced the penetration of indomethacin (59) and 
diazepam (60) respectively, across rat skin. Also, spectroscopic evidence has suggested 
that terpenes may be retained within spatial domains in the stratum corneum lipids (53). 
 
1.6.2.3 Fixed oils/ Fatty acids 
These oils are formed from an aliphatic hydrocarbon chain which may be either saturated 
or unsaturated and have a terminal carboxyl group. They are effective skin penetration 
enhancers and considered nontoxic and safe for human skin use. Examples include fish oil, 
fatty acids from algae and phospholipids (56). The effects of fatty acids as penetration 
enhancers depends on their structure, alkyl chain and degree and type of unsaturation (61). 
Aungst has extensively studied a range of fatty acids as penetration enhancers, and 
suggests that saturated alkyl chain lengths of around C10-C12 attached to the polar head 
group produce potent enhancers. Compared to penetration enhancers containing 
unsaturated compounds, the bent cis configuration disrupts intercellular lipid packing more 
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than the trans arrangement (62), (63). The most commonly used unsaturated fatty acid is 
oleic acid; it has been shown to increase the flux of many drugs such as salicylic acid 28-
fold and 5-flourouacil flux 65-fold through human skin in vitro (64).  
 
1.6.3 Adverse effects of chemical and natural enhancers in skin 
Although the goal is to use chemical penetration enhancers that have no adverse effects, it 
is unlikely that chemicals that cause disruption to the organisation of the stratum corneum 
lipids will have no measurable side effects. Penetration enhancers may cause reversible 
damage or alter the physicochemical properties of the skin. One of side effects associated 
with penetration enhancers is skin irritancy. In addition, enhancers may work by multiple 
mechanisms and combinations of enhancers may induce synergistic responses. This lack 
of understanding causes unease, without a known mechanism or understanding the barrier 
repairs /restores over time. Another area that creates concern is the extrapolation of the 
activity of enhancers to biological effects. The effects of enhancers on biological, 
immunological and inflammatory cascades have received little attention.  
Herbal preparations are becoming more popular and are frequently used for treatment of 
dermatological conditions. Hence, dermatologists need to know about their potential to 
cause adverse effects. A review by Ernst in 2000 (65) showed that many Chinese herbal 
creams were adulterated with corticosteroids. Nearly all herbal medicines are mixtures of 
chemicals and can cause allergic reactions and several can be responsible for 
photosensitisation. Several herbal medicines, in particular Ayurvedic medicines, contain 
arsenic or mercury that can produce skin lesions. Other common remedies that can cause 
dermatological side-effects include St John's Wort, kava, aloe vera, eucalyptus, camphor, 
henna and yohimbine. The adverse effects of herbal medicines are an important although 
neglected subject in treatment of skin diseases, which deserves a more systematic 
investigation.  
 
1.6.4 Other methods of enhancing skin penetration 
1.6.4.1 Water as penetration enhancer (Effect of hydration) 
Water is the most used and safest way to increase the rate of percutaneous passage of  
lipophilic drugs (66). The water content of human stratum corneum is normally about 15-
20% of the tissue by dry weight (54). Elevated stratum corneum hydration will swell the 
compact structure of the stratum corneum continuously, absorbing as much as ten times the 
dry weight, the water bound within the intercellular keratin, leading to a rapid increase in the 
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permeability and then a slow down to a steady- state diffusion (67). Hydration can be 
increased by occlusion with parafilm or oils, waxes as components of ointment, and water 
in oil emulsions which prevent transepidermal water loss (51). In occlusion, the water 
content in the outer membrane can increase 400% compared to tissue dry weight (57). Solid 
state nuclear magnetic resonance (NMR) has been used to show the movement of skin 
compounds in the presence of water (68). Hikima and Maibach (69) examined the ratio of 
fluxes and lag time for a range of solutes and concluded that hydration enhancements were 
independent of lipophilicity and molecular weight. These finding were consistent with the 
summary reported by Roberts and Walker, (70) who noted that the effects of hydration on 
solute penetration were equivocal, with some reporting increasing of up to ten fold for some 
substances, and others showing a very small effect. They commented that the major effect 
of hydration may be in solubility in skin lipids, citing the greater enhancement of pure glycol 
salicylate relative to methyl or ethyl salicylate by hydration using the human in vivo data of 
Wurster and Kramer (71). Bucks and Maibach (72) found that lipophilic steroids showed 
greater enhancement by occlusion than more polar ones. 
 
1.6.4.2 Supersaturation 
Supersaturation acts directly in the drug to increase skin permeation without alteration of 
stratum corneum architecture. The mechanism of enhancement is by increasing the 
thermodynamic activity of the drug in the vehicles. For example an increased driving force 
for transit out of the formulation and into and across the stratum corneum (73). Once drug 
concentration is increased above the saturation, the system become thermodynamically 
unstable and the supersaturation formulation will be typically subject to recrystallization of 
drug molecules and concomitant loss of the enhancing effect. Even when the stability of 
supersaturation formulations is improved by the use of polymers (74, 75), stability remains 
the limiting factor for achieving enhanced skin permeation, which can be seen only for as 
long as the formulations are supersaturation (75). The dependence in thermodynamic 
activity has been shown by Twist and Zatz (76). Silicone membrane was used to determine 
the diffusion of saturated parabens in different solvents. As the saturated solubility of 
parabens is different in these solvents, the concentration differed over two orders of 
magnitude. However, thermodynamic activity was constant due to continuous saturated 
conditions during the experiment and the same flux of paraben from all solvents was 
obtained (24). There are several ways to achieve supersaturation such as, heating and 
cooling (77), evaporation of a volatile components of the vehicle (78) or by mixing of two 
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solvents where the drug is significant more soluble in one solvent than the other (79) (54). 
Also, water can act as an solvent in the case of it being imbibed from skin into the vehicles, 
and the thermodynamic activity of the solute will increase (80). Many studies have reported 
increases in drug flux 5 to 10 times that of supersaturated solutions (75, 81). A study by 
Megrab et al (79) suggested that the oestradiol flux of a saturated system was increase 18-
fold through human skin. However, in silastic membrane the increase was only 13-fold. They 
revealed that the components of the stratum corneum (fatty acids, cholesterol and ceramide 
etc.) may produce an antinucleating effect thus stabilising the supersaturated system. 
 
1.6.4.3 Physical enhancement 
Physical penetration enhancement transiently circumvents the normal barrier function of the 
skin and can permit the passage of macromolecules (82). There are different physical 
methods for enhancement and they share the common aim of creating pathways for 
molecules to penetrate. The most common strategy is iontophoresis. Iontophoresis is a 
process using low DC current via an electrode in contact with the drug and the skin; a 
grounding electrode completes the circuit. It works by two mechanisms, i) the driving 
electrode repels ions: ii) the flow of the current may decrease the resistance of the skin so 
as to increase its permeability. Another more recent method for delivery of macromolecules 
is microneedle-enhanced delivery (83). This technique uses tiny needle-like structures to 
produce pathways for macromolecules to penetrate the horny layer without breaking it. This 
system can enhance the permeation, up to 100,000 fold, of macromolecules across the skin 
(52), also offering painless delivery of drugs (84).  
 
1.6.4.4 Vesicular system enhancement 
Vesicular system enhancement uses prodrugs (85), chemical modifications (86), vascular 
systems or colloidal particles (87) to increase skin penetration. From these techniques, 
liposomes (phospholipid-based artificial vesicles), niosome (non-ionic surfactant vesicles) 
and transferosomes which contain phospholipids, cholesterol and edge activators- 
surfactant substances, such as sodium cholate, are extensively used to deliver drugs 
through human skin. Such systems act by one of the following mechanisms: 1- penetration 
of the stratum corneum by free drug or drug release from vesicles and then penetrates the 
skin independently. 2- Release lipids from carriers and then interact with stratum corneum 
lipids. 3- Improve drug uptake by skin. 4- Control drug input by different enhancement 
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efficiencies (82). These systems will be examined in more detail in section 1.9 which 
describes some specific colloidal formulations. 
 
1.7 Selection of drug models with optimal physiochemical properties for skin 
penetration  
Earlier studies (88, 89) found that solubility, lipid-water partition coefficient, melting point and 
molecular weight are significant determinants of the permeability of drugs across the skin. 
These studies confirm that the role of molecular weight, lipophilicity and melting point are 
more important than the other properties. 
 
1.7.1 Molecular weight and shape  
Several prior studies (90, 91) found that molecular size (weight, volume and radius) have an 
important role in determining skin permeability. Magnusson et al’s (92) study of a large 
literature dataset has shown that molecular weight was the dominant determinant of 
maximum flux (Fig 1.5). Also, it has been indicated that small molecular weight drugs 
(preferred <500Da) can penetrate the skin more easily (93). A study in transdermal delivery 
claims that molecular weight has an inverse relationship with diffusivity (D) of molecules; 
this means that molecular weight increases exponentially when diffusivity decreases (94). 
However, Mitragotri suggested a logarithm for KP based on molecular radius (95) 
D=D⁰.e (-B.MW) 
D⁰=diffusivity of molecule at zero molecular volume, B= constant. 
 
Fig 1.6 Relationship between log Jmax and MW for solutes from aqueous solutions that 
passed through human epidermal membranes (n=87). The regression line (solid line) 
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describes the relationship: log Jmax=-3.90-0.019 MW (p<0.001, r²=8.847). The dashed lines 
show 95% confidence limits (92)  
 
1.7.2 Lipophilicity 
Previous studies claimed that drug lipophilicity is the most important determinant of skin 
permeation with small compounds, such as alcohols (90), and phenols (96). Scheuplein (97) 
found that the membrane-solvent partition coefficient of a drug was a measure of the 
interaction and was an essential determinant of permeability. These partitioning coefficients 
have been measured by partitioning between olive oil and water (97) and most frequently 
by octanol and water (96) as a measure of drug lipophilicity. This is expressed as the log of 
octanol-water partitioning coefficients, log KO/W or Log P. Pugh et al suggested that octanol 
was the better solvent for drug partitioning into the stratum corneum (98). The interaction  
between the drug and the lipid domain would be expected to have an important effect on 
drug transport (99). 
 
1.7.3 Hydrogen Bonding 
It has been reported in many studies (100), (92) as a determinant of solute skin transport, 
that hydrogen bonding related inversely with permeability, expressed in terms of the donor 
and acceptor parameters, Hd and Ha (101). Previous work (102) thought that permeability 
relied on the group’s number of hydrogen bonding found on the molecule while recent 
studies (103) believed that permeability depended on mathematical treatments of each 
hydrogen–bonding group and where the large numbered hydrogen bonding group was 
found. Some reports considered that good penetration occurred with <5 hydrogen binding 
sites. Studies have found that melting point also is a guide to the ability of hydrogen bonding 
and often permeability depends on this parameter (92), (104). Lag time is relayed to the type 
and number of hydrogen bonding groups, claiming an effect on diffusion due to solute 
retardation by binding to polar head groups of the stratum corneum lipid domain. When 
hydrogen bonding solutes bind with polar groups into the lipid bilayer, the non-hydrogen 
groups diffuse freely across the lipid domain (105). 
From the above, it is clear that lipophilicity and molecular size are essential determinants of 
skin penetration as well as hydrogen bonding. A study done by Zhang et al (2009) on human 
epidermal penetration used phenols with Log P values of 1.8-3.54 and molecular weight and 
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hydrogen bonding the same; they found that the fluxes were decreased for the high lipophilic 
solutes which confirms the relationship between Jmax and Log P (106). 
 
1.8 Assessment of skin penetration 
1.8.1 Maximum Flux (Jmax) 
The majority of research has assessed skin permeation in terms of permeability coefficients 
(Kp, unit of distance/time, usually cm/h) from simple solutions, including aqueous solutions 
(88, 99). Nonetheless, other studies have used maximum (or more correctly, saturated) flux 
(Jmax, units of amount/area/time). Jmax describes the rate of penetration through a membrane 
from saturated solutions or pure substances and as such, should theoretically be 
independent of the vehicle (67, 107). On the other hand, KP is dependent upon the vehicle 
in which the penetrant is dissolved. Therefore, Jmax allows a comparison to be made between 
permeation data that may have been obtained under different vehicle conditions (108). Also, 
the importance of using Jmax is that it is an invariant in the thermodynamic activity of the 
permeation process, while Kp, relies on formulation applied to the skin (106). 
 
1.8.2 Drug-vehicle-skin interactions 
Any approach with topical delivery should start with consideration of the stratum corneum 
and as mentioned in this review that the transport of molecules throughout the skin is a 
complex phenomenon including chemical, physical and biological interactions. Higuchi was 
the first one to progress equation about the relationship between thermodynamic activity 
and skin absorption from ointments and creams (104). Barry has considered on relating 
numerous models with percutaneous absorption from binary vehicles (105) and he has 
defined the solute-vehicle–skin interaction depending on the theoretical model described by 
Poulsen (2). First theory is, the ideal case when neither SC solubility nor diffusivity is affected 
by either the vehicle or the drug. The maximum solubility of the drug in this vehicle, produced 
release from that vehicle is not diffusion limited. High effect may be achieved by adding 
other drugs with the similar action to the solvent system. Secondly (105), a vehicle or solute 
leads to increase in drug solubility in the SC. For example, a study by Kadir et al (106) 
suggested that addition of paraffin oil to propionic acid solutions increased the flux of either 
theophylline or adenosine by enhancing the flux of propionic acid into the skin and 
accelerating the partitioning of the solutes in the modified skin barrier. There are many 
agents which can enhance or retard skin penetration. For instance, Azone analogue N-0915 
has been identified as a penetration retarder, for which the mode of action is believed to be 
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an increase in the order of the SC lipids (107). Also, when the solubility of solute in the 
vehicle increase, the flux should decline due to reduction in skin/vehicle partitioning 
coefficient. There are many factors effect drug-vehicle-skin interaction relationship such as, 
the applied area, type of the vehicle (induce hydration to the SC or not), solubility of the 
solute in the vehicle, concentration of the solute in the vehicle, length time of contact 
application and the condition of skin itself (the outer SC intact or not) (108). Understanding 
barrier characteristic of the skin, can help understanding the mechanism of vehicles and 
drugs on skin for optimized the design of formulations with solutes from the drug-vehicle-
skin interaction point of view. 
1.8.3 Animal skin vs. human skin 
Human skin is clearly the best choice but is not always readily available. Otherwise, pig skin 
can be used because it shares vital permeation features with human skin (109). Rat skin is 
2 to 10 times more permeable than human skin (110) which may result in an overestimation 
of dermal absorption. Mouse, guinea pig or rabbit skins also have reduced barrier function 
compared to human skin (57, 111). The use of cultured or reconstructed skin models is 
under development and those systems are not yet recommended for in vitro testing on the 
basis of their inadequate barrier function (112).  
 
1.8.4 Skin integrity 
Barrier integrity is essential for skin penetration experiments, and should therefore be 
measured. This is achieved by either measuring the penetration of a marker molecule, such 
as tritiated water, caffeine or sucrose, or by physical methods, such as determination of 
Transepidermal water loss (TEWL) or Transcutaneous Electrical Resistance (TER). 
 
1.8.5 Solubility parameters  
Solubility parameters are useful to describe features of materials, such as compatibility, 
miscibility and adsorption. Solubility parameter values for various excipients allow 
forecasting of the magnitude of interactions between the compounds of formulation in 
addition to the stability of a product. The term solubility parameter is connected to cohesive 
energy density (CED), which indicates the energy of vaporisation per unit volume (113) and 
is important to the pharmaceutical material scientist as it determines physicochemical 
properties such as solubility and melting point of the solutes and excipients.  
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                      (1) 
Where δ is the solubility parameter, R the gas constant, T the temperature, ΔH the enthalpy 
of vaporisation, Vm the molar volume, and ΔE is the free energy of vaporisation. The 
solubility parameter defined by Eq. (1) is named Hildebrand solubility parameter or 
Hildebrand parameters (114). The supposed Hansen solubility parameter (HSP) is an 
extension of the Hildebrand solubility parameter to polar and hydrogen bonding 
systems(115). Hansen expected that cohesive energy could be measured as a sum of 
contributions from dispersive (Ed), polar (Ep) and hydrogen bonding (Eh) interactions (113, 
115-117). 
Ecoh= Ed+ Ep+ Eh                                                                         (2) 
And the total solubility parameter (δT) is expressed as  
δ²T = δ²d+ δ²p+ δ²h                                                                          (3) 
Where δd, δp, and δh represent the dispersive, polar and hydrogen bonding, respectively. 
According to Hansen's interpretation, it can be expected that for the spontaneous mixing 
process between liquids, the values of HSP compounds for one liquid should be close to the 
other liquid. Various approaches can be used for estimating solubility parameters. The 
solubility parameter can be found from energy of evaporation for volatile materials and, by 
using Eq. (1), this only gives total solubility parameter not Hansen solubility parameters. For 
low- or non-volatile compounds, measuring the solubility parameter straight from the energy 
of evaporation, and comparing it to liquids, is impossible. The HSP can be used to describe 
relationships among all kinds of organic and inorganic substances. and they have been 
applied to many practical and industrial issues (118). 
 
1.9 Colloidal delivery system  
New nano-delivery systems such as emulsions, lipogels, rigid or flexible liposomes and so 
on are being assessed for their ability to provide improved delivery of therapeutic, 
prophylactic and diagnostic agents (119). Active ingredients in these nano-sized systems, 
such as phospholipids, fatty acids, surfactants, etc., are combined to accelerate penetration 
across the skin leading to more rapid absorption of the drug. While some of the older 
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chemical enhancers caused skin irritation (120), more recent systems using emulsions and 
liposomes are more biocompatible (121). In addition to the components of the vehicle, it is 
worth remembering that frequently a simple alteration in properties, such as pH, viscosity, 
water or surfactant content in an emulsion, the relative amount of oil, droplet size; ionic 
nature or the method of preparation may affect skin absorption. Table 1.3 provides some 
examples of advanced formulations. 
Table 1.3 Nano delivery systems (122). 
Technique Principle Deliverables 
Nano emulsion or 
micro emulsion 
System of water, oil and an 
amphiphile, which forms a single 
optically isotropic solution 
Plasmid DNA, Ketoprofen, 
amphorphine, oestradiol and 
lidocaine  
Liposomes Vesicles formed by one or multiple lipid 
bilayers made of mixture of 
phospholipids 
Cosmetics, antibiotics and vaccine 
adjuvants 
Niosomes Mixture of non-ionic surfactants, 
cholesterol and phospholipids 
Tretinoin, peptide drugs and 
zidovudine 
Ethosomes Increase skin penetration by increasing 
the elasticity of the lipidic vesicle, 
contain up to 20-45% of ethanol 
5-ALA(Aminoolevulinic acid), 
salbutamol, finasteride and anti-HIV 
therapy 
Transferosomes Phospholipids with surfactants, that 
acts to provide vesicle elasticity and 
deformability 
Vaccines, 5-fluoruoracil, IL-2  
SECosomes or 
nanosomes 
Mixture of surfactants, ethanol, 
cholesterol 
siRNA 
SLN(solid lipid 
nanoparticles) 
Produced with one single solid lipid 
and surfactant , with perfect crystalline 
lattice  
CoQ-10, glucocorticoids, minoxidil 
and oxybenzone 
NLC(nanostructured 
lipid carriers) 
Produced with liquid and solid lipid and 
surfactants, with distorted crystalline 
lattice 
Targeted tumour delivery, 
phospholipaseA2 inhibitors, 
benzocaine, lidocaine and psoriasis 
treatment 
Polymeric 
nanoparticles 
Consist of micro and nano spheres or 
capsules developed to control the 
release of the entrapped drug 
Chlorhexidine, indomethacin, 
melatonin and poorly soluble drugs 
 
Microemulsions are clear, thermodynamically stable, isotropic liquid mixtures of oil, water 
and surfactants, often in combination with a co-surfactant, with droplet sizes typically in the 
10-100 nm range. They may be a water in oil (W/O) type, with water dispersed in a 
continuous oil phase; oil in water (O/W), with the oil phase dispersed in a continuous 
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aqueous phase; or bi-continuous (121),(123). Multi-phase systems such as W/O/W or 
O/W/O are also possible. In all kinds of emulsions, the interface is stabilised by a proper 
combination of surfactants with or without co-surfactants. The choice of oils and surfactants 
for an emulsion system for topical delivery is limited by their potential irritation and toxicity. 
A significant difference between macro-emulsions and micro- or nanoemulsions is that 
macro-emulsions are unstable thermodynamically and phase separation will eventually 
occur. In addition, the macroemulsion droplet size will increase with time. Furthermore, the 
larger droplet size in macroemulsions makes them cloudy, unlike the clear liquids formed 
with the micro or nano-sized droplets. Whereas, macroemulsions require the input of energy 
for preparation, microemulsions do not, because they are created spontaneously when their 
components are brought into contact (121). While, nanoemulsions need Low or high energy 
methods, in high energy methods, large disruption forces are provided by the use of 
mechanical devices such as ultrasonicators, microfurdisers and high pressure 
homogenizers which produce small droplet size. In low energy, no external force is provided, 
instead it makes use of intrinsic physiological properties of the system for production of 
nanoemulsions (124). Finally, macro-emulsions are more viscous than micro- or 
nanoemulsions (121). Nanoemulsions combined some of the important requirements of a 
liquid delivery system, such as thermodynamic instability, ease of formation, high viscosity 
and small droplet size (125). They can be given orally, topically or nasally as an aerosol for 
direct administration into the lungs (125). Characterisation of a microemulsion may be done 
by assessing viscosity (126, 127) conductivity (127), NMR spectra (128) and dynamic light 
scattering (DLS) (129). Benefits of topical nanoemulsions include avoidance of hepatic 
metabolism, simple and convenient administration methods and immediate removal if 
necessary (125). Nanoemulsions work by different mechanisms. For instance, denaturation 
of intercellular proteins causes swelling and increased skin hydration (49), modification of 
lipid bilayers reduces resistance to penetration (49) and changing the solvent properties of 
the stratum corneum modify solute partitioning (49). 
Liposomes are enclosed spherical vehicles that are organised in one or several concentric 
phospholipidic bilayer/s with an aqueous core (130). The liposomal membrane is mainly 
supported by edge activators, a type of surfactant, which destabilise the lipid bilayer of the 
liposomes and increase the elasticity bilayer at the same time (131). Researchers believe 
that the mechanism of action of liposomes on skin is by either forming a thin lipid film on the 
skin surface or increasing the total lipid content of the skin by forming a liquid crystalline on 
the uppermost skin layer (132). There are many types of liposomes such as niosome (non-
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ionic surfactant) and transferosomes (phospholipid and surfactants) (133). The presence of 
surfactant will increase the elasticity of the lipid bilayer (134). El Maghraby et al in 2006 
reported that flexible liposomes are more effective in transdermal drug delivery (135). It is 
reported that surfactants (edge activators) are able to impart deformability to the nano-
carrier which permits improved transcutaneous delivery of drugs (136). Liposomes are able 
to exert various functions after topical administration (135). They are able to improve drug 
deposition within the skin at the action site where the aim is to decrease systemic absorption 
and thus reduce side effects. They also are able to produce targeted delivery to skin 
appendages as well as having potential for transepidermal delivery (135).  
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Chapter 2 
2.1 Aims and Hypotheses  
My PhD project is entitled “Targeted skin delivery of topically applied drugs by optimised 
formulation design”. Each of the three aims is detailed below. 
Aim 1  
A) To gain mechanistic understanding of the factors that drive skin permeation rates: Effect 
of vehicle composition. 
Hypothesis 
The skin permeation flux of solutes should be identical unless the vehicle has affected the 
skin. 
B) To determine if enhanced solute permeation is due to combinations of increased solubility 
of the compounds in the stratum corneum and increased diffusivity in the skin 
In this study, we examined how skin penetration fluxes are affected by vehicles reported to 
interact with the skin barrier to various degrees. We compared in vitro penetration fluxes 
(Jmax) and solubilities in the vehicles (Sv) and stratum corneum (SSC) for caffeine, minoxidil, 
lidocaine and naproxen from various solvent vehicles (with or without penetration 
enhancers) to evaluate vehicle effects on permeability parameters. To separate and quantify 
this effect, we also examined the relationship between maximum fluxes, solubility of solute 
into the stratum corneum with the solubility parameters of the solvents. We also examined 
whether the solvent of solutes uptake into the stratum corneum related to the solubility of 
the solutes in the stratum corneum. Further study was done with caffeine to determine the 
relationship between skin parameters and solubility parameters after pretreatment of skin 
with a range of vehicles for 2 h. 
 
Aim 2  
To investigate the efficacy of incorporating penetration enhancers into advanced 
formulations (e.g. flexible liposomes, microemulsions) for enhanced skin penetration / 
permeation of model compounds. 
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Hypothesis  
Targeted delivery of topically applied drugs to skin compartments, including hair follicles, 
can be achieved by design of an optimised drug delivery system. 
The second aim was to investigate the efficacy of incorporating penetration enhancers into 
advanced formulations (e.g. flexible liposomes and microemulsions) on the skin permeation 
of model compounds. I prepared and characterised nanoemulsion formulations with caffeine 
(hydrophilic model) and naproxen (lipophilic model), using oleic acid and eucalyptol as 
combined oil phases / penetration enhancers. The nanoemulsions were evaluated 
according to their particle size, conductivity, viscosity and refractive index. Permeation 
through epidermal membrane and full-thickness excised human skin was measured for 
caffeine and naproxen. Evaluations were also undertaken to prove that the maximum flux of 
the compounds may be enhanced by either increasing its solubility in stratum corneum lipid 
components or by increasing the diffusivity of the solutes in the stratum corneum. The 
amount of caffeine and naproxen in receptor fluid, extracts of tape strips (20 times) and skin 
was quantified using high performance liquid chromatography (HPLC). The effect of 
nanoemulsion formulation on the skin and the delivery route was determined using 
Multiphoton microscopy (MPM). I also prepared and characterised liposomes, 
transferosomes and neosomes with caffeine using oleic acid, eucalyptol and decyl glucoside 
as combined edge activators. The liposomes were evaluated according to their particle size, 
zeta potential, and dispersity index and drug efficiency. Permeation through full-thickness 
excised human skin, retention in the stratum corneum and in the skin was measured for 
caffeine. All samples were analysed using HPLC. 
 
Aim 3 
To investigate the effects of penetration enhancers on follicular penetration of model 
compounds. 
Hypothesis  
Hair follicles are pertinent and efficient penetration pathways and reservoirs for topically 
applied chemicals/drugs  
This study aimed to develop substances which can be topically applied and able to penetrate 
into hair follicles. In this aim, we have tested the penetration of model drugs (caffeine and 
minoxidil) into hair follicles, using the same nanoemulsion and liposome formulations used 
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in Aim 2. For follicular localisation of drug molecules, we have been measured the amount 
of drug that penetrates into the follicle by a technique available in our lab called follicular 
casting (a non-invasive method). We examined targeted delivery of solute molecules 
specifically to hair follicles, and the difference between normal, open and block hair follicles 
in permeation using solution and nanoemulsion formulations. We also imaged the 
penetration depth of Acriflavine (a dye) into the hair follicles and the area around the hair 
follicles. 
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Chapter 3 
 
Effect of Penetration Enhancers; Solution Studies 
 
A- The impact of chemical penetration enhancers on permeation of solutes 
through human epidermal membranes in vitro: Mechanistic investigations 
 
B- The effect of vehicle pretreatment on the flux, retention and diffusion of 
topically applied caffeine in vitro: understanding the relationship between 
solvent and solute penetration using human skin. 
 
3.1 Abstract 
This study aimed to explore the mechanism by which skin permeation fluxes are affected by 
a range of vehicles reported to interact with the skin barrier to different degrees. We 
compared in vitro penetration fluxes (Jmax) and solubilities in the vehicles (Sv) and stratum 
corneum (SSC) for caffeine, minoxidil, lidocaine and naproxen of various solvent vehicles to 
evaluate the vehicle effects on permeability parameters. Solutions of four drugs with log P 
ranging from -0.07 (caffeine) to 3.18 (naproxen) were dissolved in a range of vehicles and 
applied to heat separated human epidermal membranes in Franz diffusion cells. The 
vehicles either contained substances known to enhance skin penetration (e.g., ethanol, oleic 
acid, eucalyptol, sodium lauryl sulphate) or were known to have no effect on skin. We 
measured the solubility of these solutes in the vehicles (Sv) and in the stratum corneum 
(SSC). We also examined whether the solubility of the solutes in the stratum corneum was 
determined by the uptake of solvent, in which the solutes were dissolved, into the stratum 
corneum. For the pretreatment study, the flux of caffeine was measured over 8 h through 
heat-separated human epidermis pretreated for 2 h with water, 20, 40, 60% ethanol/water 
and 5% oleic acid (OA), 5% eucalyptol (EU) or 1% SLS in 60% ethanol, mineral oil (MO) 
and microemulsions with eucalyptol or silicone oil as the oil phase. Enhancement was 
greater after pretreatment with vehicles containing penetration enhancers (oleic acid and 
eucalyptol in 60% ethanol and in the eucalyptol microemulsion). For vehicles that had no 
effect on the skin, the Jmax values were the same, regardless of the Sv. Similarly, there was 
a linear relationship between Jmax and SSC for these vehicles, whereas vehicles containing 
penetration enhancers caused deviations from linearity. The treatment study indicates that 
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the solubility model has a good correlation between the predicted SSC and measured SSC for 
caffeine, minoxidil and lidocaine. It provides a linear shape with R2= 0.8, 0.7, 0.8, 
respectively. However, we could not find the same correlation with naproxen. There was 
significant enhancement following pretreatment with 40% and 60% ethanol vehicles relative 
to controls (water and 20% ethanol, MO and silicone oil). The enhancement rate was related 
to Hanson solubility parameters. 
We conclude that the solubility of a solute in the skin can be correlated to its solubility in the 
vehicle and the amount of vehicle absorbed by the stratum corneum. This study observed 
that changes in both diffusivity and solubility of solute (caffeine) in the stratum corneum can 
be affected by vehicle absorption in the skin.  
 
3.2 Introduction 
Topical administration products account for an increasingly significant percentage of solute 
delivery candidate compounds under clinical evaluation (106). To be useful, topical products 
must provide efficient delivery of actives to either the systemic circulation or to the skin, but 
for most substances, the uppermost layer of the skin, the stratum corneum presents a 
substantial barrier to their penetration. However, the barrier may often be overcome to meet 
therapeutic or cosmetic goals by judiciously designed delivery systems (137), taking into 
account the active’s potency, its physicochemical properties and the properties of the vehicle 
and its interaction with the skin.  
In this study we investigated some of the factors that influence the penetration and 
permeation of topically applied substances through skin and sought to relate the observed 
permeation fluxes to the physicochemical properties of the actives and the vehicles, as well 
as the various active-vehicle, active-skin and vehicle-skin interactions that occurred. 
Techniques previously applied to relate drug flux to solute-skin, solute-vehicle, and vehicle-
skin interactions include maximum flux studies, (64, 96), and relating the membrane fluxes 
to solute uptake in the stratum corneum (138). The maximum or saturation flux (Jmax) is 
defined as that occurring when a solute is applied to the skin in a saturated solution. The 
important of Jmax is that for a given solute, it is an invariant in the thermodynamic description 
of the permeation process (106).  By definition, if neither the vehicle nor the solute affect the 
membrane, the same maximum flux will be observed for the solute from a range of vehicles 
regardless of its concentration in them (138). For example, Twist and Zatz (139) found that 
methyl paraben had the same flux from a range of saturated solutions in different vehicles 
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applied to inert polydimethylsiloxane membranes that were not affected by the vehicles 
(139). Physicochemical properties including molecular size, melting point, lipophilicity, 
solubility and hydrogen bonding acceptor ability have been considered to be important in 
determining permeation flux (89, 140). 
Maximum flux is determined by the solubility of the drug in the stratum corneum (SSC) 
according to the equation: 
Jmax = D*.SSC = D*.KSCSV        
Where D* is the diffusivity, SSC is the solubility in the stratum corneum, KSC is the epidermal 
permeability coefficient and Sv is the solubility in the vehicles (138). Inspection of Equation 
indicates that the maximum flux of a solute through the stratum corneum can be enhanced 
by three mechanisms; (a) increasing the diffusivity of the solute in the stratum corneum; (b) 
affecting the partitioning between the stratum corneum lipids and other stratum corneum 
components; (c) increasing its solubility in the stratum corneum lipids (141). Accordingly, 
skin absorption depends upon the physiochemical properties of the solutes (69), so that 
lipophilic compounds penetrate more easily than hydrophilic compounds and lower MW 
more easily than high MW (69). As well, the vehicle is a key factor in determining the efficacy 
of transdermal drug delivery systems. Two main mechanisms are thought to govern the 
effect of vehicles on the skin permeability of solutes; firstly, the force driving the drug into 
the skin is due to thermodynamic activity of the solute in the vehicle (142) and secondly, the 
skin barrier properties may be modified by interaction with the skin’s lipid and keratin 
components (142). 
Several technological advances have been made in the recent decades to overcome the 
stratum corneum barrier and thereby deliver therapeutic substances accurately to their skin 
target sites in sufficient quantities (82). One approach is to use chemical penetration 
enhancers (27). These can act by various mechanisms, such as promoting supersaturation 
in the vehicle, leading to an enhanced partitioning into stratum corneum (75), interaction 
with intercellular lipids causing organisation disruption and thereby raising their fluidity, 
extraction of stratum corneum lipids (143) or interaction with intercellular protein and 
denaturation of keratin (64, 82). While it is well recognised that appropriately chosen 
vehicles can enhance skin penetration (144), there appear to be limited studies examining 
the effect of vehicles on the maximum flux of solutes across the skin.  
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In this study, we sought to explore the impact of various solution compositions on the skin 
permeation of some model drugs. We compared in vitro maximum penetration fluxes (Jmax) 
and solubilities in the vehicles (Sv) and in the stratum corneum (SSC) of four drugs (caffeine, 
minoxidil, lidocaine and naproxen) having a range of lipophilicities (log P -0.07, 1.24, 2.44, 
and 3.18, respectively). We used a range of solvent vehicles that were hypothesised to affect 
the skin to differing degrees to evaluate vehicle effects on permeability parameters. 
 
3.2.1 The solubility parameters concept 
An understanding the interaction of between topically applied formulations and the skin 
barrier is crucial for tailoring effective skin delivery. The equilibrium between solute solubility 
in the vehicles, and in the skin and the complex interaction that may occur between different 
components of the system will determine the targeting of topical solutes to the stratum 
corneum, epidermis and deeper tissues (98, 104). Solubility parameters have been used as 
tools to predict the adhesive and cohesive properties of materials and in particular have 
been used to model and predict the permeation of topically applied substances (145). The 
solubility parameter concept was developed by Hildebrand (146, 147), who assumed that 
the solubility of the compounds rely on the cohesive energy, the square root of  cohesive 
pressure is Hildebrand’s solubility parameter, δ:  
 δ = √C =  √∆Hv − RT ÷ Vm                  (1) 
Where ∆𝐻𝑣 Is the heat of vaporisation, R is the gas constant, T is absolute temperature, 
and Vm is the molar volume of the solvent. Frequently, the RT term is ignored because it 
accounts for only 5-10% of the evaporation heat (145). If the solubility parameter of the 
vehicle and the drug are similar, it is likely that the drug is soluble in the vehicle. This model 
is an experimental  development of the rule of “like dissolve like” (145). Hansen proposed a 
model to extend Hildebrand’s model to polar and hydrogen binding systems and defined the 
solubility parameter as: 
δt2 = δd2 + δp2 + δh2                                   (2) 
Where δt is the total or three dimensional solubility parameter, δd the dispersive, δp the polar 
term and δh the hydrogen binding (115, 116, 148). The Hansen model describes solvents 
as points in three dimensional space and the solute as a sphere of solubility (Fig 1). If the 
solvent point is within the solute volume space, the solute is dissolved by the solvent and if 
the solvent points are located outside the space volume, the solvent does not dissolve the 
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solute (148). Furthermore, Hansen (116) developed the solubility parameter equation to 
express the distance (Ra), between two materials: 
(Ra) 2 = 4 (δD2 - δD2)2 + (δP2 – δP2)2 + (δH2 – δH2)2           (3) 
Equation 3 was improved from plots of experimental values where the constant “4” more 
accurately represented the solubility data by encompassing the “good” solvents (148). 
Various approaches to quantify solvent-solute and solvent-skin interaction using the 
solubility parameter have been suggested (δ). The first attempt to characterise human skin 
with the HSP was made visually using psoriasis scales of swelling when immersed for 
prolonged time in different solvents (114). An extensive study has been done on permeation 
through viable human skin that allowed placement of the solvents into groups according to 
actual permeation rates (115). In the second part of this study (B: pretreatment) we explored 
the use of HSPs in the particular solute-vehicle, solute-skin and vehicle skin interaction. We 
used a hydrophilic model solute (caffeine) and a range of vehicles with differing HSPs. Heat 
separated epidermal membrane was pretreated for 2 h with the chosen vehicle and an 
aqueous solution of caffeine was applied for 8 h. Flux and drug retained in the epidermis 
after the experiment was measured to determine the effect of the vehicle on the skin 
parameters. 
 
Figure 3.1 Hansen sphere in schematic form (145) (Copyright ©2011; Steven Abbott, 
Charles Hansen and Hiroshi Yamamoto) 
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3.3 Materials and methods 
3.3.1 Chemicals 
Caffeine, naproxen, minoxidil, lidocaine, ethanol, OA, EU, polyethylene glycol 400 
(PEG400) and polyethylene glycol 6000 (PEG6000) were purchased from Sigma-Aldrich 
Pty. Ltd. (Sydney, Australia). MO was purchased from Galtex (Australia, Ltd), Glycerol from 
Ajax (a division of Naplex industries, Australia Pty. Ltd), Polyoxyl-20 Oleyl ether (Volpo-N20) 
was purchased from CRODA (Croda Europe Ltd, United Kingdom) and Polyoxyl 10 Oleyl 
ether (Volpo-N10, also known as Brij96v) from UNIQEMA (Wilton, United Kingdom). All 
chromatography reagents were analytical reagent grade. 
The physicochemical properties of the model compounds are shown in Table 3.1. 
Table 3.1. Physicochemical properties of model compounds [Molecular weight (MW g/mol); 
Lipophilicity (Log P); Melting point (MP °C); Molar volume (MV), Solubility in aqueous 
solution (Saq mg/L); Dissociation constant (pKa)]  
Compound MWa  Log Pa MPa MVb Saq pKaa 
Caffeine 194.19 -0.07 238 151.8 21600 14 
Minoxidil 209.25 1.24 248 214.6 2200 4.61 
Lidocaine 234.34 2.44 68.5 89.7 4100 7.9 
Naproxen 230.26 3.18 153 142.6 15.9 4.2 
aChemIDplus advanced-chemical information with searchable synonyms, structure, 
formulas http://chem.sis.nlm.nih.gov/chemidplus/   
bHSPiP program (Steven Abbott of Steven Abbott TCNF Ltd; ©2011 Steven Abbott and 
Johann Wiechers) 
 
3.3.2 Sample analysis 
All samples were analysed using a High Performance Liquid Chromatography (HPLC) 
system consisting of Shimadzu SIL-20 a HT, CBM-20A system controller, a SPD-20A 
detector, LC-20AD a pump and an auto injector. Samples were separated isocratically on a 
Phenomenex Luna 5µm, C18 (150 x 4.6 mm) column using aqueous buffers containing 
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acetonitrile. Caffeine, minoxidil, lidocaine and naproxen were detected at 273, 281, 210 and 
230 nm respectively. 
 
3.3 3 Determination of Solubility in the vehicles (SV) 
SV was determined in saturated solutions of the compounds in each vehicle (see Table 3 A-
D). An excess amount of the compound was added to 5 ml of the vehicle and the samples 
were incubated in a water bath at 32°C for 24 h, with continuous magnetic stirring. The 
samples were then centrifuged at 4000 rpm for 15 min and the supernatants were analysed 
by validated HPLC methods, after appropriate dilution where necessary. 
 
3.3.4 Human skin preparation 
Human epidermal membranes were prepared from abdominal full-thickness skin using heat 
separation (149 ). The skin was provided by a female donor (aged 57) following an elective 
surgical procedure, with ethical approval granted by the University of Queensland Human 
Research Ethics Committee (Approval No. 2008001342). The epidermal membranes were 
stored at -20°C until use. 
 
3.3.5 Determination of Solubility in the stratum corneum (SSC) 
The stratum corneum was prepared from epidermal sheets by trypsin digestion (149). The 
full-thickness skin was immersed in water at 60°C for 1 min, allowing the epidermis to be 
teased off the dermis. The epidermis was floated overnight on a solution of 0.01% trypsin in 
phosphate buffer saline at 37°C. The viable epidermis was scraped off using cotton buds 
and the remaining stratum corneum membrane was rinsed several times with distilled water. 
The isolated stratum corneum sheets were placed flat on aluminium foil and stored at -20°c 
until use.  
Discs of stratum corneum (4 replicates for each sample) were weighed before using. They 
were then equilibrated in a saturated solution 1mL of each solute at 32°C for 24 h, according 
to established methods (150). At the end of incubation period, the stratum corneum was 
removed and blotted dry. It was extracted with 1 mL 70% ethanol/water for another 24 h, at 
the same temperature used for equilibrium (32°C). The SSC was determined from the amount 
of recovered model compound in the extraction fluid, measured by HPLC.  
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3.3.6 Solvent uptake in the stratum corneum 
The total solvent uptake into the stratum corneum was determined from the weight 
difference of a piece of the dry stratum corneum (about 0.6mg) soaked in individual solvents 
(1 mL) for 24 h at 35°C. The stratum corneum pieces were wiped three times with Kimwipe 
tissues before being weighed again. 
 
3.3 7 In vitro permeation study 
The epidermis has cut into discs and mounted stratum corneum side uppermost in horizontal 
glass Franz type static diffusion cells, with 4 replicates for each vehicle. The cells had an 
exposed surface area of 1.33 cm² and a receptor volume of approximately 3.4mL. To assess 
the integrity of the epidermis, the donor and receptor chambers were filled with PBS 
(phosphate buffered saline pH 7.4) and the cells equilibrated for 30 min before measuring 
transepidermal electrical resistance with a standard multimeter. Skin samples with 
resistance less than 20 kΩ were considered damaged and were discarded (151). Donor and 
receptor chambers were then emptied and the receptor refilled with PBS. The diffusion cells 
were placed in a Perspex holder in a water bath, to maintain the receptor phase temperature 
at 35°C, and the receptors were constantly stirred with magnetic fleas (152). 
The formulations (see Table 3.2) were applied to the skin at an infinite dose of 1 mL and the 
donor chamber was covered with a glass cover slip to minimise evaporation from the donor 
phase. Samples of receptor phase (200 µL) were removed at regular time points over the 
next 8 h and replaced with same amount of fresh PBS. All samples were analysed using 
HPLC.  
 
3.3.8 In vitro pretreatment permeation study 
The epidermis was cut into discs and mounted in horizontal glass Franz type static diffusion 
cells, with 4 replicates for each vehicle. Receptor compartment was filled with phosphate-
buffered saline (pH7.4), maintained at 35°C in water bath. The donor doses (1 mL) of the 
vehicles were added to the skin and left for 2 h., covered with glass cover slip to minimise 
evaporation. Before application of caffeine, the excess vehicles were removed and the skin 
surface washed three times with water before applying 1 mL of water containing 3% caffeine. 
Samples of receptor phase (200 µL) were removed at regular time points over the next 8 h 
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and replaced with same amount of fresh PBS. All samples were analysed using a HPLC 
system. 
 
3.3.9 Prediction of maximum flux 
The method used the software package HSPiP generously supplied by Stephen Abbott 
(153) based on melting point and molar volume of the solute. The experimental temperature 
and the HSPs of the solute and the stratum corneum was used to predict Jmax. The HSP 
distance (Ra) can be related to the mutual solubility of two substances and is given by: 
Ra = [4(δD1 – δD2)2 + (δP1 – δP2)2 + (δH1 – δH2)2]1/2      (4) 
Where δD, δP and δH are the dispersion, polar and hydrogen-bonding HSPs of the interacting 
substances. 
This method relies solely on the properties of the solute and the interaction between it and 
the skin. No account is taken for the effect of the vehicle on the skin. 
 
3.3.10 Data analysis  
The cumulative amount penetrating per skin surface area (Q, µg/cm²) was plotted against 
time (h). The steady state flux JSS (µg/cm²/h) was derived from the slope of the linear portion 
of the cumulative amount (Q) versus time (t) plot.  
Jmax, applicable to saturated solutions, is derived from the experimental steady state flux by 
correcting for the actual solubility in the vehicle (106). (Equation 5) 
Jmax= JSS. Sv / CV          (5) 
Where Sv is the solubility in the vehicle and CV is the experimental vehicle concentration 
used. 
The diffusivity of solutes in the skin divided by path length (D*) was calculated from equation 
6: 
D*=Jmax / SSC          (6) 
The Partitioning of solute in the stratum corneum (KSC) was calculated from equation 7: 
KSC= SC density * SSC/CV                                                                             (7) 
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The permeability coefficient (KP) of caffeine was calculated from equation 8 
KP = JSS / CV                                                                                                                                                   (8) 
Total solubility parameters (3D) for each of the solvents were estimated by formulating 
efficacy software (JW solution B.V., The Netherlands). The solubility parameter for human 
skin was taken from the Hanson Handbook (148). 
Data were analysed by one-way analysis of variance (ANOVA) with post-hoc comparisons 
(Tukey in Graph pad); P<0.05 was considered to be significant. 
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Table 3.2. Composition of vehicles used.  
Caffeinea Minoxidilb Lidocainec Naproxend 
  mineral oil   
100% water  100% water *  
25% PEG 6000 /water  35% PEG6000/water  25% PEG6000/water    40% PEG6000/water 
35% PEG 6000/water  50% PEG6000/water  50% PEG6000/water 50% PEG6000/water 
50% PEG 6000/water  75% PEG6000/water  75% PEG6000/water  75% PEG6000/water 
90% PEG 6000/water     
20% glycerol/water * 20% glycerol/water *   
3% V20/water * 3% V20/water *  5% V20/water * 
25% PEG400/water *  30% PEG400/water * 5% V20/30% PEG400/water* 
20% ethanol/water     
40% ethanol/water    
60% ethanol/water  60% ethanol/water  60% ethanol/ water   60% ethanol/water  
60% ethanol/water/5% V20   60% ethanol/water/5% V20 
   25% ethanol/water/25% V10/ 
60% ethanol/water/ 5% EU  60% ethanol/water/5% EU 60% ethanol/water/5% EU  60% ethanol/water/5% EU 
60% ethanol/water/3% OA  60% ethanol/water/3% OA 60% ethanol/ water /3% OA  60% ethanol/ water /3% OA 
60% ethanol/water/1%SLS  60% ethanol/water/1%SLS 60% ethanol/water/1%SLS  60% ethanol/water/1%SLS 
 
Concentrations (w/v) of caffeine, minoxidil, lidocaine and naproxen were a3%, b2%, c2.5%, d2%, respectively, except those marked by *, 
where the solutions are saturated. Vehicles containing ethanol are shaded, with those also containing penetration enhancers in a darker 
shading. 
 
3.4 Results  
3.4.1 In vitro permeation of solutes across epidermal membranes  
Figure 3.2 shows drug permeation through human epidermal membranes generally 
reaching a steady state by 2-4 h. The estimated steady state and maximum fluxes (Jmax, 
determined from Equation 5) for all solutes are summarised in Table 3.3 (A-D). Vehicles 
containing EU, OA and SLS, all generally regarded as skin penetration enhancers, affected 
permeation fluxes to varying extents. EU and OE significantly increased the flux of caffeine, 
minoxidil and naproxen compared to all vehicles lacking penetration enhancers. There were 
no significant differences in the presence of SLS (P>0.05, n=4). On the other hand, the 
highest Jmax for lidocaine came from EU and SLS.  
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Figure 3.2 In vitro percutaneous permeation through epidermal human skin: A1- caffeine 
with penetration enhancer vehicles, A2- caffeine with controls; B1-minoxidil with penetration 
enhancer vehicles, B2- minoxidil with controls; C1- lidocaine with penetration enhancer 
vehicles, C2- lidocaine with controls; and D1- naproxen with penetration enhancer vehicles, 
D2- naproxen with controls (Mean± SEM, n=4).  
Symbols: Black, inert controls; Red, oleic acid (OA); Green, eucalyptol (EU); Blue, sodium 
lauryl sulphate (SLS); Yellow, ethanol vehicles; Orange, glycerol; Grey, 5% volpo in 30% 
PEG400/water. 
Table 3.3. 
A: Caffeine 
Vehicle 
% Active Sv   
(mg/cm3) 
JSS 
(µg/cm²/h) 
Jmax   
(µg/cm²/h) 
SSC 
(mg/cm3) 
D* (x104 
cm/h) 
H2O 100% 3 31.3±1 2.1±.16 2.2±06 21.6±2.6 1.0 
H2O / 25% PEG6000  3 98.5±8.2 2±2.0 6.5±3.7 98.2±0.3 0.7 
H2O / 35% PEG6000  3 85.2±5.2 3.5±1.8 6.7±3.7 68.2±0.3 0.2 
H2O / 50% PEG6000  3 57.4±9.5 1.1±.16 2.1±0.9 49.5±0.3 0.3 
H2O / 90% PEG6000  3 17.9±0.4 2.1±1.6 1.2±0.7 60.2±0.3 0.2 
H2O / 20% glycerol Sat’d 48.1±4.5 10.5±4.0 35.0±11.6 22.9±16.2 15.3 
H2O / 3% V10 Sat’d 69.4±7.8 1.6±1.4 5.3±5.0 51.9±25.7 1.0 
H2O / 25% PEG400  Sat’d 72.8±6.7 4.7±3.0 15.5±13.0 17.5±8.3 8.8 
ethanol 20% / H2O 3 48.0±1.0 2.4±0.5 3.8±1.4 39.5±9.0 1.0 
ethanol 40% / H2O 3 71.9±1.7 11.8±3.0 28.3±8.0 54.5±24.5 5.2 
60% ethanol/H2O/5% V10  3 54.6±0.6 33.9±3.5 61.8±6.5 105.5±9.9 5.9 
60% ethanol/ H2O 3 81.5±1.1 9.4±.48 25.6±2.5 151.9±34.4 1.7 
60% ethanol/ H2O /1%SLS 3 74.8±1 18.1±8.8 45.2±6.0 100.9±23.5 4.5 
60% ethanol/ H2O / 5% EU  3 98.3±7.3 310.0±10.4 1015.8±28.9* 254.5±66.0 39.9 
60% ethanol/ H2O /3% OA 3 56.0±2.5 368.2±17.0 692.6±24.0* 155.9±44.7 44.4 
(Mean ± 95% confidence intervals, n=4)  
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B: Minoxidil  
Vehicles 
% 
Active 
Sv 
(mg/cm3) 
JSS 
(µg/cm²/h) 
Jmax 
(µg/cm²/h) 
SSC 
(mg/cm3) 
D* (x104 
cm/h) 
35% PEG6000/water  2 15.5±2.3 0.4±0.1 0.3±0.1 13.2±0.4 0.2 
50% PEG6000/water  2 39.0±0.9 0.3±0.1 0.3±0.1 12.3±4.2 0.5 
75% PEG6000/water 2 73.0±1.2 0.3±0.0 0.3±0.1 15.5±0.4 0.2 
20%glycerol/water Sat’d 5.9±0.1 0.1±0.1 0.1±0.1 4.6±1.0 0.3 
3%Volpo+water  Sat’d 21.6±1.2 0.1±0.1 0.1±0.1 5.3±0.6 0.2 
60% ethanol/water 2 34.7±2.7 2.2±1.4 3.7±1.5 44.0±5.3 0.5 
60% ethanol/water/1%SLS 2 51.4±0.7 7.8±4.7 20.0±12.2 62.6±10.4 3.2 
60% ethanol/water/5% EU 2 56.0±0.6 4.3±2.2 101.6±6.2* 68.7±4.7 14.8 
60% ethanol/water/3% OA 2 71.4±8.7 9.3±26.4 332.96±54.2* 133.8±8.6 24.9 
(Mean ± 95% confidence intervals, n=4) 
C: Lidocaine  
Vehicles 
% 
Active 
Sv 
(mg/cm3) 
JSS 
(µg/cm²/h) 
Jmax 
(µg/cm²/h) 
SSC  
(mg/cm3) 
D* (x104 
cm/h) 
mineral oil  2.5 44.9±2.3 7.6±0.4 7.6±0.4 29.9±4.7 2.5 
100% water  sat’d 7.2±0.7 21.5±12.0 6.1±2.9 11.6±2.7 5.3 
25% PEG6000/water    2.5 23.3±0.2 33.0±9.3 15.4±11.1 69.3±3.8 2.2 
50% PEG6000/water 2.5 47.7±3.0 14.9±3.2 14.2±12.7 49.2±2.7 2.9 
75% PEG6000/water  2.5 94.9±4.2 26.3±14.0 11.4±18.7 48.7±2.8 2.3 
30% PEG400/water  sat’d 67.1±10.7 5.6±2.7 8.2±2.8 19.0±0.4 4.3 
60% ethanol/ water   2.5 47.9±0.4 38.4±8.5 73.5±16.3 97.1±12.4 7.6 
60% ethanol/water/1%SLS  2.5 97.4±21.0 71.9±11.4 280.3±39.4 114.1±22.5 21.7 
60% ethanol/ water /5% EU  2.5 64.0±6.8 185.8±17.2 475.7±41.3 133.7±27.6 33.4 
60% ethanol/ water /3% OA  2.5 62.8±13.0 72.2±28.7 181.4±64.2 107.4±11.6 15.0 
(Mean ± 95% confidence intervals, n=4)  
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D: Naproxen  
Vehicles 
% 
Active 
Sv 
(mg/cm3) 
JSS 
(µg/cm²/h) 
Jmax 
(µg/cm²/h) 
SSC 
(mg/cm3) 
D* (x104 
cm/h) 
40% PEG6000/ H2O 2 45.5±11.7 3.4±1.4 3.5±0.8 9.6±3.5 3.7 
50% PEG6000/ H2O 2 66.8±5.6 2.0±0.1. 5.6±0.7 12.0±4.0 4.6 
75% PEG6000/ H2O 2 84.2±11.4 2.0±0.1. 5.1±2.8 16.6±7.0 3.1 
5% volpo/ H2O Sat’d 15.1±11.9 2.3±1.3 2.3±2.0 3.5±0.2 6.2 
5%volpo/30%PEG400/H2O Sat’d 76.6±8.0 13.4±7.0 13.7±6.6 26.0±0.9 5.2 
Ethanol/V10/H2O (1/1/2) 2 25.9±6.9 4.1±0.9 5.3±1.4 9.5±1.6 5.6 
60% ethanol/ H2O /5% V10  2 51.9±0.7 14.5±1.2 37.7±3.2 37.8±2.4 9.9 
60% ethanol/ H2O 2 50.9±1.1 9.2±1.5 23.4±3.9 18.3±5.0 12.8 
60% ethanol/ H2O / 1%SLS 2 55.3±16.0 14.8±2.4 41.0±6.6 23.9±90 17.1 
60% ethanol/ H2O / 5% EU 2 20.7±14.6 72.5±7.0 74.9±12.3 38.7±1.2 11.7 
60% ethanol/ H2O /3% OA 2 23.9±12.0 373.3±20.5 446.3±37.9 55.6±1.8 80.2 
  
(Mean ± 95% confidence intervals, n=4) 
 
3.4.2 Impact of formulation on active solubility in the stratum corneum, maximum flux 
and derived diffusivity 
To investigate some of the determinants of increased flux in these vehicles, we examined 
the relationships between some of the parameters in Table 3.3 (A-D). As shown in Figure 
3.3 (A-D), although there were considerable differences in vehicle solubility (Sv), Jmax was 
independent of Sv, for all control vehicles. Particularly those containing ethanol and may 
alter the properties of the skin barrier those Figure 3.3E shows Jmax enhancement for 
vehicles containing ethanol, EU, OA and SLS, expressed as a ratio:  
Jmax / Jmax (50% PEG6000 control).  
The greatest enhancement was seen with EU and OA, predominantly with the more 
hydrophilic solutes, caffeine and minoxidil. 
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Figure 3.3. A-D, Jmax versus solubility in the vehicles (Sv). A, Caffeine; B, Minoxidil; C, 
Lidocaine; D, Naproxen.  
The dashed lines represent the mean of the control values. E: Jmax enhancement ratio 
compared to control (50%PEG6000/water) for selected vehicles. (Mean ± 95% confidence 
intervals, n=4) 
Symbols: Black, inert controls; Red, oleic acid (OA); Green, eucalyptol (EU); Blue, sodium 
lauryl sulphate (SLS); Yellow, ethanol vehicles; Orange, glycerol; Grey, 5% volpo in 30% 
PEG400/water. 
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As expected for vehicles that do not alter the properties of the skin, there was little variation 
in diffusivity (D*) amongst the control solutions for all four solutes (see Fig. 3.4A-D). Figure 
3.4E shows D* enhancement for vehicles containing ethanol, EU, OA and SLS, expressed 
as a ratio: D* / D* (50% PEG6000 control). The greatest enhancement in diffusivity was 
again seen with caffeine and minoxidil, applied in the EU and OA vehicles. Smaller effects 
were seen with SLS on caffeine diffusivity and with OA on naproxen. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4. A-D, Effective diffusivity, D* (= D/h) versus solubility in the vehicles (Sv). A, 
Caffeine; B, Minoxidil; C, Lidocaine; D, Naproxen.  
The dashed lines represent the mean of the control values.  E: D* enhancement ratio 
compared to control (50%PEG6000/water) for selected vehicles. (Mean± SEM, n=4) 
Symbols: Black, inert controls; Red, oleic acid (OA); Green, eucalyptol (EU); Blue, sodium 
lauryl sulphate (SLS); Yellow, ethanol vehicles; Orange, glycerol; Grey, 5% volpo in 30% 
PEG400/water.  
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We next explored the relationships between maximum flux and solubility in the stratum 
corneum. Rearranging Equation 6, we obtain Jmax = SSC. D*, indicating that if D* is constant, 
there should be a linear relationship between Jmax and SSC (with a slope of D*, or D/h). We 
have already seen that for our control vehicles, there was a minimal variation in D*. Figure 
3.5 illustrates the observed linear relationships between Jmax and SSC for each solute and 
the control vehicle, with R2 values ranging from 0.67 to 0.88. Vehicles containing ethanol 
and penetration enhancers show elevated Jmax values that do not fit the relationships seen 
with the control vehicles, reflecting the effects on diffusivity seen in Figure 3.5.  
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Figure 3.5 Jmax versus solubility in the stratum corneum, SSC for A, Caffeine; B, Minoxidil; 
C, Lidocaine; D, Naproxen (Mean ± SEM, n=4).  
Symbols: Black, inert controls; Red, oleic acid (OA); Green, eucalyptol (EU); Blue, sodium 
lauryl sulphate (SLS); Yellow, ethanol vehicles; Orange, glycerol; Grey, 5% volpo in 30% 
PEG400/water. 
 
3.4.3 Mechanism underpinning the differential enhanced uptake of actives into the 
epidermis 
We investigated the hypothesis that stratum corneum solubility was related to the amount 
of vehicle taken up by the membrane, carrying with it an amount of solute determined by its 
solubility in the vehicle. Vehicle uptake into the stratum corneum was determined by 
measuring the weight of pieces of stratum corneum before and after incubation in the various 
vehicles. Solute uptake was then estimated from this and the measured solubility of the 
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solutes in each vehicle (Sv). The relationships between solute solubility in the stratum 
corneum from each vehicle (SSC) and the vehicle uptake or solute uptake are shown in 
Figures 3.6 and 3.7, respectively. There was a good correlation for both parameters with all 
compounds, with the exception of naproxen uptake, where the values for the EU and OA 
vehicles were seen as outliers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6 Solubility in the stratum corneum (SSC) versus predicted solvent uptake values 
from a range of vehicles (Mean, n=4) for A, Caffeine; B, Minoxidil; C, Lidocaine; D, 
Naproxen.  
Symbols: Black, inert controls; Red, oleic acid (OA); Green, eucalyptol (EU); Blue, sodium 
lauryl sulphate (SLS); Yellow, ethanol vehicle; Orange, glycerol; Grey, 5% volpo in 30% 
PEG400/water.  
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Figure 3.7. Solubility in the stratum corneum (SSC) versus predicted solute uptake values 
from range of vehicles for A, Caffeine; B, Minoxidil; C, Lidocaine; D, Naproxen (Mean, n=4). 
Symbols: Black, inert controls; Red, oleic acid (OA); Green, eucalyptol (EU); Blue, sodium 
lauryl sulphate (SLS); Yellow, ethanol vehicle; Orange, glycerol; Grey, 5% volpo in 30% 
PEG400/water. 
To predict stratum corneum solubility of the solutes, an optimal regression was found when 
it was assumed that all the dissolved solute in the vehicle was taken up into the stratum 
corneum as defined by: 
SSC (predicted) = SSC (skin, control) + Sv * Vup/VSC      (9) 
Where Vup is the volume of vehicle taken up, VSC is the measured volume of the stratum 
corneum used, and  
SSC (skin, control) = SSC (control, observed) - Sv (control) * Vup (control) /VSC  (10) 
Predicted versus experimental SSC plots are shown in Figure 3.8. Good correlations were 
seen for caffeine, minoxodil and lidocaine, with R2 values of 0.81, 0.80 and 0.84 respectively, 
and 0.69 for the combined dataset of all actives. The correlation for naproxen was poor (R2 
= 0.02). Equation 9 under predicted SSC in each case, as shown by most of the points falling 
below the line of identity. The underproduction is also indicated by values of Lin’s 
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concordance correlation coefficients of 0.65, 0.86, 0.72, 0.42 and 0.73 for caffeine, minoxidil, 
lidocaine, naproxen and the combined dataset, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8. Predicted versus experimental solubility in the stratum corneum (SSC) from a 
range of vehicles for A, Caffeine; B, Minoxidil; C, Lidocaine; D, Naproxen; E, the combined 
dataset (Mean, n=4). 
Symbols: Black, inert controls; Red, oleic acid (OA); Green, eucalyptol (EU); Blue, sodium 
lauryl sulphate (SLS); Yellow, ethanol vehicles; Orange, glycerol; Grey, 5% volpo in 30% 
PEG400/water. The red dotted line is the line of identity. 
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3.4.4 Can the permeation fluxes of actives from various vehicles be predicted by a 
solubility parameter approach? 
We used a method based on physicochemical properties of the solutes and the HSP 
interaction between the solute and the skin to predict Jmax. This method takes no account of 
the properties of the vehicle or its effect on the skin. For the inert control vehicle (50% PEG-
6000/water) there was a good correlation (R2=0.9439) between predicted and observed log 
Jmax for the four solutes (Fig. 3.9, white symbols). The regression line approximated the line 
of identity, with a Lin’s concordance correlation coefficient of 0.9007. Minoxidil applied in the 
control vehicle 50% PEG-6000/water (white circle) appears to be an outlier, with a smaller 
observed flux than predicted. 
Figure 3.9 also shows a comparison between the control vehicle and the vehicles containing 
60% ethanol and the penetration enhancers EU, OA and SLS. The increased fluxes 
observed with these enhancing vehicles were not matched by the predicted values, 
supporting the view that the vehicles have modified the epidermal barrier. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9. Log Jmax (predicted using Hansen solubility parameters by method of Abbott) vs 
log Jmax (observed) for caffeine (triangles), minoxidil (circles), lidocaine (diamonds) and 
naproxen (squares) applied to human epidermal membranes in different vehicles. 
Vehicles are 50% PEG6000/water (control, white symbols), 60% ethanol/water (yellow), 
60% ethanol/water/1% SLS (blue), 60% ethanol/water/3% OA (red), 60% ethanol/water/5% 
Eucalyptol (green). 
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3.4.5 Caffeine vehicle solubility  
The solubility of caffeine in a range of solvents (Sv) (16.6-47.8) is shown in Table 3.4. Figure 
3.10 shows that with the particular solvents chosen for this study, a better relationship 
between solubility and δv was seen when the Sv increased as the solubility parameter for the 
vehicle approached that of caffeine. (δtotal=25). This study agrees with a study done by Cross 
in 2001 on silicone membrane with hydrocortisone (104) when they claimed that the best 
relationship between solubility and δtotal may not be linear. 
 
 
 
 
 
 
 
 
 
 
Figure 3.10. Relationship between experimentally determined caffeine solubility in each 
solvent (S
v
) and solvent solubility parameter (δ
V
). (The dashed line is the total solubility 
parameter area for caffeine.) 
 
3.4 6 Penetration and solubility data 
In vitro permeability of caffeine through excised human skin was examined after 
pretreatment with different vehicles for 2 h. Fig 3.11 shows that drug permeation generally 
reaches a steady state in 1-2 h, allowing a steady state flux to be established. 
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Figure 3.11 Permeation profiles of caffeine through epidermal human skin after pre-
treating skin for 2 h with a range of vehicles (Mean ± sd, n=3).  
OA (oleic acid in 60%ethanol/water); EU (eucalyptol in 60%ethanol/water); SLS (sodium 
lauryl sulphate in 60%ethanol/water); MO (mineral oil); SO (silicone oil), MEU 
(Eucalyptol/Volpo-N10/water/ethanol). 
 
The estimated permeation parameters for all solutes are summarised in Table 3.4. OA and 
EU formulations and SLS significantly increased the flux of caffeine through the epidermal 
human skin compared to the other vehicles. In fact, these reported the highest Jmax for 
caffeine. There were no significant differences in the presence of 60% ethanol (P<0.05, 
mean ± SD, n=4). Generally, the effect of the Eucalyptol/Volpo-N10/water/ethanol (MEU) 
vehicle on the diffusivity (D*, determined from Equation 6), of caffeine seems to be larger 
than those on D* with other vehicles (Table 3.4). The effect of the penetration enhancer 
vehicles (EU, OA, SLS and 60% ethanol/water) on the partitioning (KSC determined from 
Equation 8), of caffeine seems to be larger than those on KSC for other vehicles (Table 3.4) 
The effect of pretreatment vehicles on caffeine flux is summarised in the Table 3.4. 
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Table 3.4 Vehicle solubility parameters and skin parameters 
Formula 
code 
Vehicles δV SV 
(mg/mL) 
Jmax 
(µg/cm²/h) 
SSC 
(mg/cm
3
) 
D* 
(cm/h) 
KSC 
 
Water 100% water 47.8 31.3 1.2 21.6 0.6 0.7 
50%PEG6000 50% PEG6000/water 33.5 57.4 2.0 49.5 0.4 1.6 
75%PEG6000 75%PEG6000/water 27.4 41.0 1.3 54.4 0.2 1.8 
20% ethanol 20%ethanol/water 43.4 48.0 1.8 39.5 0.5 1.3 
40% ethanol 40%ethanol/water 39.0 71.9 10.7 54.5 1.9 1.8 
60% ethanol 60%ethanol/water 34.7 81.5 18.3 151.0 1.2 5.0 
OA 60%ethanol/water + 5%OA 34.0 56.0 40.3 156. 2.6 5.2 
EU 60%ethanol/water + 5% EU 33.5 98.3 38.9 254.6 1.5 8.5 
SLS 60%ethanol/water + 1% 
SLS 
34.6 74.8 
20.1 
100.9 
2.0 3.4 
MO Mineral oil 16.6 0.4 0.002 0.4 - - 
SO 50% 
Silicone/volpo/water/ethanol 
21.0 33.7 2.1 47.7 
0.4 1.6 
MEU Eucalyptol/Volpo-
N10/water/ethanol 
27.4 110.0 37.2 35.5 
10.2 1.2 
 
Enhancement ratio of the flux was greatest after pretreatment with the penetration enhancer 
vehicles. However, the flux was not enhanced to the same extent (Fig 3.12). Also, the 
enhancement partitioning ratio of caffeine into the stratum corneum is generally higher for 
OA and EU solutions (Fig 3.12).  
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Figure 3.12 Mean plot summarising the effect of Hansen solubility parameter of vehicle on 
enhancement of Jmax, partition and diffusion.  
MEU (eucalyptol, Volpo-N10, ethanol and water). 
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Figure 3.13 Composite of the effects of vehicle pretreatment on diffusion and partition of 
caffeine. (The red line is the identity line). 
MEU (eucalyptol, Volpo-N10, ethanol and water). 
Figure 3.13 is the composite plot for caffeine with all vehicles. The line of identity suggests 
that the enhancement mechanism is an increase into the partition of the epidermis.  
The Jmax and SSC of caffeine from each vehicle in the δV range (16-48) are shown in Figure 
3.14. A linear relationship, found between Jmax and SSC R2=0.80, can be seen when all points 
are considered. Also a linear relationship was found between the caffeine permeability 
coefficient (KP) and SSC R2=0.80 (Fig 3.14B).  
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     A 
 
     B 
 
Figure 3.14 Relationship between (A) Jmax and SSC and (B) caffeine permeability 
coefficient (KP) and SSC. 
MEU (eucalyptol, Volpo-N10, ethanol and water). 
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3.5 Discussion 
This work has revealed marked differences in the epidermal permeation of solutes using 
different solution vehicles, some of which contained excipients that were hypothesised to 
alter the properties of skin. This was demonstrated by differences in solute uptake into the 
stratum corneum, permeation maximum flux and derived diffusivity. Interpretation of our 
results adds to our mechanistic understanding on how vehicles effect the penetration of 
different solutes. Our findings of selective permeation enhancement can be understood in 
terms of three mechanisms: i) alterations in the solubility of the drug in the applied vehicle, 
ii) uptake of the vehicle carrying the active compounds into the stratum corneum, and iii) 
changes in the properties of the stratum corneum membrane, such as fluidisation of the lipid 
bilayers. 
In this work, we estimated the solute maximum (or saturated) fluxes (Jmax) as a measure of 
skin permeation rates. It has long been recognised that maximum flux is independent of the 
vehicle and dependent solely on the thermodynamic activity of the solute in the vehicle, 
provided the vehicle or solute does not alter the properties of the membrane (154). This 
concept was initially highlighted in the work of Twist and Zatz (155), who showed the same 
flux for methyl paraben across synthetic membranes, regardless of its solubility in a range 
of different vehicles. More recently, we published similar findings on the epidermal 
permeation of a group of phenols with similar molecular weights but different log P values 
(106-108). Our results for the control solutions here are consistent with these findings in that 
similar low values for Jmax were found for each control solutions not affecting skin 
permeability across a range of vehicle solubilities. In contrast, the Jmax values seen with the 
enhancer solutions and to some extent, ethanol/water, are much higher than the controls, 
indicating that these vehicles have altered the properties of the stratum corneum.  
An interesting result from this work was the predominant effect on Jmax and D* seen with the 
more hydrophilic solutes, caffeine and minoxidil, compared to lidocaine and naproxen. This 
suggests that flux increases in these compounds are driven by increased diffusivity. It is well 
recognised that diffusivity is independent of solute lipophilicity when the vehicle does not 
alter the properties of the stratum corneum (107, 141). However, this may not be the case 
when the vehicle does affect the stratum corneum. For example, we (107) recently showed 
enhanced diffusivity for the more hydrophilic phenols applied to epidermal membranes in 
isopropyl myristate (IPM), a vehicle that has a high affinity for the skin and can disrupt 
stratum corneum lipid arrangements (156). The diffusivity-driven increases in caffeine 
permeation seen here, particularly with the EU vehicle, were consistent with previous work 
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showing increased diffusivity of the polar compound 5-FU with EU enhancers, which was 
explained in terms of disruption of stratum corneum lipids (157). Skin permeation of the 
lipophilic compound tamoxifen has also been shown to be enhanced by terpenes, due to 
enhanced partitioning into the stratum corneum (158). Williams and Barry (159) suggested 
that generally, partitioning plays a greater role in enhancement of more lipophilic 
substances. 
The relationship between stratum corneum solubility and solute maximum flux and the 
recognition that the stratum corneum solubility depends upon both solvent and solute uptake 
into the stratum corneum were key findings in this work. Firstly, our results, showing good 
linear relationships between Jmax and solubility in the stratum corneum for the control 
vehicles but not for the vehicles that affected the skin, are consistent with our previous 
findings (106-108). This supports the concept that dual mechanisms for permeation 
enhancement, stratum corneum solubility and diffusion, may be acting in varying degrees in 
these systems. The observed correlations between stratum corneum solubility and solute or 
solvent uptake prompted us to hypothesise that the solvent acts as a carrier to draw solute 
into the stratum corneum. Interestingly, the points for the penetration enhancer vehicles 
generally follow the same linear regression lines as those for the controls in Figures 3.6 and 
3.7, whereas they do not in Figure 3.5. This suggests that enhanced fluxes for these 
compounds may be mainly driven by diffusivity rather than stratum corneum solubility. 
Polyethylene glycols (PEGs) are used in a great variety of cosmetic applications because of 
their solubility and viscosity properties and because of their low toxicity (160). Based on 
available data, the PEGs with a wide molecular weight range (200 to 10000) are safe for 
use in cosmetic products (160). It was clear from our results that PEG6000 vehicles were 
inert and did not penetrate skin, as would be expected for a compound of such a high 
molecular weight. The vehicles containing EU, OA and SLS also contained 60% ethanol, 
while some of the other vehicles had 20%, 40% and 60% ethanol/water. Generally, the 
responses with ethanol/water solutions alone were less than those with the enhancers. The 
influence of ethanol in aqueous solutions in the transport of hydrophilic and lipophilic drugs 
has been investigated and it has been suggested that ethanol has no or little effect in 
penetration at low levels. However, at higher concentrations, it can cause extraction of lipids 
(57, 161-163), which is consistent with our results. Pershing et al. found that ethanol 
enhances the flux of oestradiol across human skin without affecting diffusion, while 
increasing the solubility of drug in the membrane (164). This work also found that 60% 
ethanol/water with caffeine, minoxidil and lidocaine had little effect on diffusivity but 
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increased the solubility of these solutes in the stratum corneum. Ethanol is a volatile solvent 
and evaporation can lead to increased drug concentration and a greater driving force for 
permeation (45, 57, 165), although this is unlikely to have occurred in our infinite dose 
experiments here. 
We attempted to use solubility parameters to predict solute maximum fluxes and from this 
to distinguish between vehicles that do or do not affect the skin. The prediction depends 
entirely on the properties of the solute (molar volume, melting point), the HSPs of the solute 
and the skin and the experimental temperature. It therefore applies only to inert vehicles that 
have no effect on the skin. Deviations of observed fluxes from the predicted values could be 
attributed, in part, to skin effects. The plot of predicted versus observed Jmax values for a 
typical inert vehicle that was used for all solutes (50% PEG-6000/water) showed excellent 
correlation and concordance. It was noted that Jmax for minoxidil was over-predicted by the 
solubility parameter method. The pKa of minoxidil is 4.61 and we believe that at the pH at 
which the experiment was performed, the compound was substantially ionised, leading to a 
lower than expected experimental flux. A better fit to the predicted correlation line would be 
obtained if the minoxidil point was adjusted to account for the degree of ionisation. As 
expected, given that the HSP prediction of Jmax takes no account of vehicle effects on the 
skin, there were significant deviations from predicted values seen for the four vehicles shown 
in Figure 3.9. The 60% ethanol/water and the ethanol/water/SLS vehicles showed the least 
deviation, as seen above. We also applied a published regression based on a large literature 
database (89) to predict Jmax (data not shown). This used solute properties (log P, molecular 
weight and melting point) and once again, took no account of vehicle-skin interactions. The 
resulting correlation between predicted and observed Jmax values was almost identical to 
that obtained with the HSP prediction, but with a poorer correlation coefficient (0.7344). 
Recently, Riviere reported a quantitative structure permeability model to predict in vitro 
permeation of some ectoparaciticides through porcine and canine skin that accounted for 
both the physicochemical properties of the penetrant and the formulation components (166).  
For the pretreatment study, the principal gaols were to find the relationship between total 
solubility parameters, solute, solvents and skin. The important finding in this work is the 
parabolic relationship between enhancement ratio for Jmax, KSC, SV and δV for the vehicles 
which interacted with skin and straight line in vehicles which did not interact with skin (inert) 
such as water and PEG6000 vehicles. The treatment result with the caffeine showed a linear 
relationship between Jmax, and SSC; the same finding has been shown with pretreatment 
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results. The effect of vehicles on flux is summarised in mean effect plot (Fig 3.12 and Table 
3.4). Enhancement is generally higher for OA, EU and eucalyptol vehicle MEU. It is noted 
that Hansen 2007 (148) considered the stratum corneum to have 30 (total solubility δV) 
implying that vehicles with a value close to this should mix easily with the skin and have 
maximal enhancement properties. This is seen in the present study, which shows that any 
vehicle in the range close to 30 will penetrate the barrier effectively. This hypothesis is in 
accordance with the similarity in enhancement values for most vehicles. After recognising 
that Jmax was increased by vehicle pretreatment, we proceeded to separate it into its partition 
and diffusion components. Vehicles can strongly effect permeation through the stratum 
corneum barrier by altering the partitioning coefficient between the vehicles and the 
membrane (KSC) and or solute diffusion (D*) within the membrane (167). The KSC is a kinetic 
effect that could be related to structural effects such as alterations to the stratum corneum 
cells structure. As mentioned earlier, if the vehicle has no effect on the skin, the Jmax of a 
given solute appears to be independent of vehicles for saturated solutions. This has been 
noted experimentally (168), (107) for many vehicles. However, the ones known as 
penetration enhancers are either entering the skin to change partitioning and diffusion or 
removing the skin components. The partitioning coefficient KSC was determined 
experimentally as described, so the apparent diffusivity D* could be found indirectly from 
JSS/KSC. The main effects plots for KSC and D* are shown in Figure 3.12. Generally the effects 
of a vehicle on KSC seem to be similar to those on D*, but trend with respect to δv can be 
seen. Water, MO, PEG6000 vehicles, silicone oil and 20% ethanol/water as expected have 
no effect on any of the three factors Jmax, KSC and D*. 
Figure 3.13 is a line of identity, so it is apparent that the effect of vehicles on partitioning is 
more than on diffusion, suggesting that the enhancement mechanism includes a high 
increase in the thermodynamic (partition). These results agree with Rosado et al’s (167) 
finding that the enhancement mechanism includes a greater increase in the thermodynamic 
(partition) than in the kinetic (diffusion). The maximum flux of compounds was increased by 
increasing the solubility of these compounds in the stratum corneum lipids (Table 3.4). A 
linear relationship found between Jmax and SSC, r2=0.80, could be seen when all points were 
considered (Fig 3.14A). A linear relationship was found between caffeine permeability 
coefficient (KP) and SSC r2=0.80 (Fig 3.14B). In future, expansion of the HSP or other 
approaches to account for vehicle-skin interactions would be valuable to provide more 
realistic predictions that can be generally applied. 
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3.6 Conclusions 
This study has shown that the permeation of caffeine, minoxidil, lidocaine and naproxen 
were selectively enhanced by vehicles containing specific excipients that were hypothesised 
to alter the properties of skin (OA, EU, SLS and ethanol). The greatest effects were seen on 
flux and diffusivity by the EU and OA vehicles on the more hydrophilic compounds, caffeine 
and minoxidil. Enhancements in stratum corneum solubility were predicted by 
experimentally determined uptake of solvent and solute. We conclude that enhanced solute 
fluxes are mainly driven by increased diffusivity in the stratum corneum, likely to be due to 
greater lipid fluidisation caused by the enhancers. In the pretreatment study, there was 
enhancement of caffeine flux following penetration enhancer vehicles pretreatment of heat 
separated epidermis. Enhancement could be related to HSPs of the vehicle. Calibration of 
the solute flux and its solubility in the stratum corneum data is a simple novel plotting 
procedure that separated and quantified the effects of the vehicle on solute partition and 
diffusion. The treatment and pretreatment results indicate that mainly, enhancement is 
related to an increase in partition into skin with an increase in diffusivity. The diffusivity was 
obtained for all compounds and was unaffected by the inert control vehicles (controls) 
supporting the notion that Jmax is determined by stratum corneum solubilities and not 
diffusivity.  
68 
 
Chapter 4 
 
Synergistic skin penetration enhancer and nanoemulsion formulations promote the 
human epidermal permeation of caffeine and naproxen 
 
4.1 Abstract 
Targeted delivery of topically applied drugs to various skin compartments, including hair 
follicles, can be achieved by designing an optimised drug delivery system. One of the many 
ways of enhancing delivery through the skin is by formulation optimisation. They are 
considered as novel alternatives to conventional transdermal delivery systems and the main 
reasons include simplicity of the formulation process, stability of the system and a high 
potential in pharmaceutical applications. Nanoemulsions, a formulation, act as efficient 
vehicles for topical drug delivery mainly due to their potential of providing enhanced solubility 
and improved bioavailability. The aim of this study is to assess delivery of caffeine, a model 
hydrophilic compound and Naproxen, a model lipophilic compound across human epidermal 
and full-thickness skin, utilising nanoemulsion formulations containing oleic acid (OA) and 
eucalyptol (EU) as oil phases. Evaluations were also undertaken to prove that the maximum 
flux of the compounds may be enhanced by either increasing their solubility in the stratum 
corneum lipid component or by increasing the diffusivity of the solutes in the stratum 
corneum. Two oil-in-water (O/W) nanoemulsion formulations containing caffeine and 
naproxen (3% and 2% w/w, respectively) with OA or EU as oil phases were prepared. The 
proportion of the surfactant, co-surfactant and aqueous phase was selected through the 
construction of a pseudo-ternary phase diagram. The formed systems were characterised 
using particle size, measurement of electrical conductivity, viscosity and refractive index. 
Nanoemulsions and controls consisting of 3% w/w caffeine in water (C1), 60% ethanol/water 
(C2), or 50% PEG6000/water (C3); 2% naproxen in 60% ethanol/water (C2) or 25% ethanol, 
25% volpo-N10 and 50% water (C4) were applied to epidermal and excised full-thickness 
human abdominal skin in Franz diffusion cells (n=4) for 8 h. The stratum corneum distribution 
of the chosen model drugs was studied using the tape-stripping technique. The amount of 
caffeine and naproxen in receptor fluid, extracts of tape strips (20 times) and skin was 
quantified using HPLC. The effect of the nanoemulsion formulation on the skin and the 
delivery route was determined using Multiphoton microscopy (MPM). The results depicted 
that both O/W nanoemulsions significantly enhanced the delivery of caffeine that permeated 
across as well as was retained in the skin as compared to the controls. The rate of 
penetration of naproxen through the skin (epidermis and full-thickness skin) (flux) as well as 
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the amount retained in the skin were significantly greater than for all the controls (p<0.005) 
for both O/W nanoemulsions, whereas no significant differences in flux and skin retention 
between the EU and OA nanoemulsions was observed. For Naproxen, it was found that the 
maximum flux was related to the stratum corneum solubility of the nanoemulsion formulation 
and the amount of vehicle absorbed into the stratum corneum, as well as the amount of 
naproxen dissolved in that absorbed vehicle. Caffeine maximum flux enhancement was 
found to be associated with increased skin diffusivity. These relationships were reflected in 
the uptake of active compound into the stratum corneum, carried with the vehicle being 
taken up. Also, estimated diffusivity appeared to be vehicle independent. Images of 
nanoemulsion treated skin showed altered stratum corneum barrier structure. In the case of 
caffeine, the transdermal flux from EU formulations was higher than OA nanoemulsions but 
the amount retained in the stratum corneum and skin were not significantly different for these 
formulations. In conclusion, both the nanoemulsion systems in this study significantly 
enhanced penetration of caffeine and naproxen. The possible cause of enhancement may 
be due to alterations in the stratum corneum barrier structure due to the presence of EU and 
OA as penetration enhancers in the formulation. Further work is needed, directed at applying 
theoretical principles based on HSPs to design formulations for improved targeting of 
specific skin layers. 
 
4.2 Introduction 
Percutaneous absorption offers an attractive non-invasive route of administration for local 
topical or systemic effects of substances but is limited by the skin's inherent barrier to 
penetration of any exogenous material. It is well established that the uppermost layer of the 
skin, the stratum corneum, is the main barrier to such penetration but can be overcome to 
meet therapeutic and cosmetic goals by prudent considerations of the active’s potency, 
physicochemical properties, formulation and delivery systems (169). Formulation 
approaches include optimisation, use of pro-drugs and incorporation of chemical or 
biological modifiers to transiently reduce stratum corneum barrier function. The range of 
delivery systems in current use include: topical products, transdermal patches, physical 
methods such as microneedles and heat as well as other technologies, including 
iontophoresis, sonophoresis, radiofrequency and laser ablation(169).  
Microemulsions, defined as single phase and thermodynamically stable isotropic systems 
composed of water, oil and amphiphilic molecules (170), are attractive systems for 
enhancing drug delivery to the skin because of their ease of formulation, thermodynamic 
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stability and solubilisation(171). They are capable of incorporating and enhancing the skin 
delivery of both hydrophilic and lipophilic drugs (172, 173) and are considered to be more 
stable than conventional emulsions because of their small droplet sizes preventing phase 
separation. Moreover, small droplet size provides better adherence to membranes, leading 
to more efficient transport of drug molecules in a controlled fashion (174, 175).  
Micro- and nanoemulsions may be categorised into three main types: water in oil (W/O), 
bicontinuous and O/W though a mixture of oil, water and surfactants will be able to generate 
a variety of structures and phases (173, 176, 177). When similar amounts of oil and water 
are used, the structures formed are not well characterised and are assumed to be 
continuous (178). While micro- and nanoemulsion formation depends on the capacity of the 
surfactant system to decrease the surface tension, in practice almost all surfactants require 
the presence of additional co-surfactants. Excipients such as short- or long-chain alcohols 
or polyglycerol derivatives have been used to achieve low surface tension. Addition of a co-
surfactant reduces the interfacial tension as well as the critical micelle concentration. The 
correct selection of components is the main factor to be considered when formulating 
microemulsions for topical or transdermal delivery (179). Micro- and nanoemulsions may 
enhance topical and transdermal delivery mainly by increasing the solubilisation capacity for 
hydrophilic and lipophilic compounds, maintaining constant supply of the drug from the 
internal to the external phase and thus keeping the external phase saturated and promoting 
skin absorption. The formulation ingredients such as the oil, surfactants, co-surfactants and 
penetration enhancers may increase drug diffusion by enhancing partitioning through the 
skin. Also, the low interfacial tension required for micro- and nanoemulsion formations may 
be responsible for the excellent wetting properties, which ensures surface contact between 
the membrane and the vehicle (180). In addition to their favourable permeation 
enhancement properties, micro- and nanoemulsions may also reduce skin irritancy of certain 
excipients. For example, an aqueous solution containing 20% propylene glycol was shown 
to cause irritation, but the same concentration of propylene glycol used as a co-surfactant 
in microemulsion formulations did not (181). 
The components of the oil phase in a microemulsion may include penetration enhancers 
such as lecithin, hydrophilic terpenes such as EU or unsaturated fatty acids such as OA to 
enhance the permeation of the active through the skin without causing local irritation (182, 
183). Studies suggest that these penetration enhancers may cause disruption of the stratum 
corneum lipid organisation thus increasing the fluidity and decreasing diffusion resistance to 
solutes (182, 184). In this study OA and EU were selected as the penetration enhancers. 
71 
 
The objective of this study was to investigate the synergy of using skin penetration 
enhancers in nanoemulsions on human epidermal permeation for a model hydrophilic 
compound (caffeine; log P, -0.07) and a lipophilic compound (naproxen; log P, 3.18). OA 
and EU were the penetration enhancers studied. Each formulation was characterised in 
terms of its physical and chemical properties, including deriving their apparent solubility 
parameters. We then carried out in vitro human epidermal permeability studies in Franz 
diffusion cells and evaluated the permeation of caffeine and naproxen from nanoemulsions, 
formulated with skin penetration enhancers as the oil phase, and various control solutions. 
As described in our previous work (108, 185), we also estimated for each active ingredient 
its saturated flux, solubility in the stratum corneum and diffusivity as well as quantifying the 
extent of formulation uptake into the stratum corneum. These were then used to investigate 
the mechanism by which the nanoemulsions facilitated an enhanced permeation of the 
active ingredient across the human epidermis. We also examined the effects of these 
microemulsions on the full-thickness skin.  
 
4.3. Materials and Methods 
Caffeine, naproxen, ethanol, oleic acid (OA), eucalyptol (EU), were purchased from Sigma-
Aldrich Pty. Ltd. (Sydney, Australia). Volpo-N10 was obtained from Umiqema (Witton 
Centre, Witton Redcar TS10 4RF, UK). All chromatography reagents were analytical grade. 
 
4.3.1 Preparation of Emulsions 
Volpo-N10 (surfactant) was dissolved in ethanol (co-surfactant) in a 1:1 ratio. The resulting 
mixture was then mixed with the oil phase, OA or EU (oil) in a 0.6:1:1 ratio followed by gentle 
mixing with phosphate buffered saline (PBS). The resulting nanoemulsions were clear at 
room temperature. Caffeine and naproxen were dissolved in the nanoemulsions and control 
solutions at 3% w/w and 2% w/w, respectively. A pseudo-ternary phase diagram was 
constructed using the water titration method. At the weight ratio of 1:1 the highest amount 
of water was solubilised in the system. The O/(S/Co-S) mixture was diluted drop wise with 
PBS under moderate agitation. The samples were classified as nanoemulsions when they 
appeared as clear liquids.  The compositions of emulsions and control solutions made are 
shown in Table 4.1.  
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Table 4.1 Compositions (% w/w) of nanoemulsions formulations (C3 and C4), with 
penetration enhancers eucalyptol (E1 and E2) and oleic acid (O1 and O2), and control 
mixtures (C1 – C2). The concentration of caffeine (marked as C) dissolved in aqueous 
controls and nanoemulsions was 3% w/w, whereas a concentration of 2% w/w was used for 
naproxen (marked as N). 
 Water Ethanol PEG-6000 Volpo-N10 Eucalyptol Oleic Acid 
C1C 100 - - - - - 
C2C,N 40 60 - - - - 
C3C 75 - 25 - - - 
C4N 50 25 - 25 - - 
E1C,N 30.97 26.55 - 26.55 15.93 - 
E2C,N 36.59 24.39 - 24.39 14.63 - 
O1C,N 30.97 26.55 - 26.55 - 15.93 
O2 C,N 36.59 24.39 - 24.39 - 14.63 
 
4.3.2 Characterisation of emulsions 
The droplet size distributions, refractive indices and electrical conductivities of the emulsions 
were determined at ambient temperature using dynamic light scattering (Zetasizer Nano ZS, 
Malvern Instruments, Ltd, Malvern, UK), on a RFM34 refractometer (Bellingham & Stanley, 
UK) and a Digitor multimeter (DSE, Australia), respectively. Electrical conductivity 
measurement enables identification of the continuous phase of the emulsion, with O/W 
emulsions being conductive, while W/O emulsions are not. The viscosity of the emulsion 
formulations was measured using a U-tube viscometer at 25°C. All determinations were 
done with three replicates.  
 
4.3.3 Human skin preparation 
Skin samples were obtained with informed consent from female patients undergoing elective 
abdominoplasty, and approval from The University of Queensland Human Research Ethics 
Committee (HREC Approval no. 2008001342). The procedures were conducted in 
compliance with guidelines of the National Health and Medical Research Council of 
Australia. Full-thickness skin was prepared by removal of subcutaneous fat by blunt 
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dissection. Heat separation was used to separate epidermal membranes from full-thickness 
skin, by immersing it in water at 60°C for 1 min, to allow the epidermis to be teased away 
from the dermis (186). Stratum corneum was prepared from the epidermal membranes by 
trypsin digestion (187). The epidermis was floated overnight on a solution of 0.01% trypsin 
in PBS at 37°C. The digested viable epidermis was gently scraped off with cotton buds and 
the remaining stratum corneum membrane was rinsed several times with distilled water. The 
isolated stratum corneum membranes were dried with absorbent paper and placed flat 
between parafilm sheets covered with aluminium foil. All skin membranes were stored frozen 
at -20°C until use. 
 
4.3.4 Determination of the solubility of actives in the various formulations (SV) 
The solubility of caffeine and naproxen in each formulation (SV) was determined by adding 
caffeine or naproxen to 5 mL of each nanoemulsion or control solution until an excess 
amount remained. The samples were then incubated in a water bath at 32°C for 24 h with 
continuous agitation and centrifuged at 4700 rpm for 10 minutes. The supernatant was 
withdrawn and diluted to accurately quantify the amount of each compound by HPLC. 
 
4.3.5 Determination of solubility in the stratum corneum (SSC) and solvent uptake 
To determine the stratum corneum solubilities of caffeine and naproxen from the various 
vehicles, pre-weighed discs of stratum corneum (4 replicates for each compound) were 
incubated in 1 mL saturated solutions of each compound in the various vehicles at 32°C for 
24 h (187). At the end of the incubation period, the stratum corneum discs were removed 
and blotted dry and further incubated with 1 mL of 70% ethanol/water for 24 h at 32°C to 
enable complete extraction of the solutes. SSC was determined from the amount recovered 
in the extraction fluid measured by HPLC divided by the thickness and area of the stratum 
corneum (185). The total solvent uptake into the stratum corneum was determined from the 
weight differences of the dry pieces of the stratum corneum (about 0.7mg) soaked in each 
formulation (1mL) for 24 h at 32°C. The stratum corneum pieces were wiped three times 
with Kimwipe tissues before being weighed again. 
 
4.3.6 In vitro skin penetration and distribution study 
In vitro skin permeation studies were performed with epidermal skin in Franz diffusion cells 
with an effective diffusion area of 1.33cm² and an approximate receptor chamber capacity 
of 3.4 mL. The skin was cut into discs and mounted between the donor and receptor 
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compartment of the Franz cell with the stratum corneum side facing the donor chamber. The 
receptor compartment containing PBS (pH 7.4) was immersed in a water bath at 35±0.5°C. 
The donor solution consisted of 1mL of the nanoemulsions or control formulations, 
containing either 3% w/w caffeine or 2% w/w naproxen. The donor compartment was 
covered with parafilm to prevent evaporation. At pre-determined time points, 200 µL of the 
receptor phase was withdrawn and replaced with an equal volume of fresh PBS.  
In vitro skin absorption studies were performed with full-thickness human abdominal skin in 
Franz diffusion cells as described previously. The skin was cut into discs and mounted in 
between the donor and receptor compartment of the Franz cell with the stratum corneum 
side facing the donor chamber. The receptor compartment containing PBS (pH 7.4) was 
immersed in a water bath at 35±0.5°C. The donor solution consisted of 1mL of nanoemulsion 
formulations (with 3% and 2% w/w of caffeine and naproxen, respectively) or control 
formulations. The donor compartment was covered with parafilm to prevent evaporation. At 
pre-determined time points, 200 µL of the receptor phase was withdrawn and replaced with 
an equal volume of fresh PBS over the duration of the study. The caffeine and naproxen 
content in the samples was determined using HPLC. On completion of the diffusion studies, 
the donor remaining at the end was withdrawn and the skin in each cell was wiped with a 
cotton bud to remove any formulation. This was followed by tape stripping (20 tape strips) 
to separate the stratum corneum from the epidermis by application of adhesive tape (D-
Squame tapes, CuDerm Corp., TX) to the exposed skin surface for about 5 seconds. Tapes 
were placed in separate scintillation vials, soaked overnight with 2 mL methanol with 
constant shaking. The amount of absorbed material in the stratum corneum was determined 
by HPLC. The amounts in the first tape were not included, as this represents surface 
material. Subsequent to tape stripping, the remaining skin was sliced into small sections; 
homogenised and soaked overnight with 2 mL methanol under constant shaking. The 
caffeine and naproxen content in these samples was then determined by HPLC. 
 
4.3.7 Multiphoton microscopy (MPM)  
Multiphoton microscopy (MPM) was used to assess the effect of these formulations in the 
stratum corneum. A DermaInspect system (JenLab GmbH, Jena, Germany), coupled to an 
ultra-short-pulsed, mode-locked, 80-MHz Titanium Sapphire laser (Mai Tai, Spectra 
Physics, Mountain View, California, USA) was used to image the skin. Full-thickness 
abdominal skin was mounted in Franz diffusion cells and an infinite dose of formulation 2 of 
EU and OA was applied. Samples of untreated skin were used as controls. After 8 h, the 
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Franz diffusion cells were dismantled and the skin was rinsed gently with water and blotted 
dry with a tissue. It was then placed on a microscope slide and protected with a cover slip 
(108). Images were captured by two photon excitation at 740 nm.  The skin was imaged at 
four depths, from the superficial surface, corresponding to the stratum corneum (~5-10 µm), 
stratum granulosum (SG; ~15-20 µm), stratum spinosum (SS; 25-30 µm) and stratum basale 
(SB; 35-40 µm). Keratinocyte morphology was used to confirm each of these layers. 
 
4.3.8 HPLC analysis of caffeine and naproxen 
Caffeine and naproxen in solution and extracts from various matrices were analysed by a 
sensitive and rapid HPLC. The HPLC system consisted of a Shimadzu SIL-20 a HT, CBM-
20A system controller, a SPD-20A detector, LC-20AD a pump and an auto injector. Isocratic 
separation of both caffeine and naproxen was achieved on a Phenomenex Luna 5µm, C18 
(150 x 4.6 mm) column. For caffeine analysis, elution was performed at ambient temperature 
with a mobile phase of 95% water, 2% acetonitrile, 2% tetrahydrofuran and 0.5% acetic acid 
at a flow rate of 1mL/min. Detection wavelength was 273nm. For naproxen the mobile phase 
consisted of 35% water, 45% acetonitrile, 20% methanol and 0.3% acetic acid at a flow rate 
of 0.7 mL/min. The detection wavelength was 230 nm. 
 
4.3.9 Data analysis 
The cumulative amount (Q, µg/cm²) of caffeine and naproxen penetrating through an area 
of 1.3 cm2 was plotted against time (t). The steady state flux JSS (µg /cm²/h) was determined 
from the slope of the linear portion of the cumulative amount (Q) versus time t plot.  
The maximum flux (Jmax) that would be applicable to saturated solutions can be estimated 
from the experimental steady state flux corrected for the known solubility in the formulation 
by Equation 2 (185)  
Jmax= JSS. Sv / CV          (1) 
Where SV is the solubility of the formulation and CV is the experimental concentration used. 
The diffusivity of solute in the skin divided by path length (D*) was calculated from the 
maximum flux and the solubility of the active compound in the stratum corneum according 
to Equation 2 (185). 
D* = Jmax / SSC          (2) 
Where SSC is the experimentally determined solubility of the solute in the stratum corneum.  
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HSPs (D, P, H) for formulation excipients, solvents and active compounds were obtained 
from the software package HSPiP (JW solutions B.V, the Netherlands). The total solubility 
parameters were also obtained from HSPiP, according to the formula: 
total2 = D2 + P2 + H2          (3) 
Values of the solubility parameters for human skin (D=17, P =8 and H=8) were taken from 
Hansen Solubility Parameters: A User’s Handbook (148) and used with the reported 
solubility parameters for caffeine (D=19.5, P =10.1 and H=13.0) and naproxen (D=18.9, 
P =4.3 and H=9.9) to estimate the HSP distance (Ra), a measure of the similarity between 
two materials: 
Ra = [4(D1 - D2)2 + (P1 -+ P2)2 + (H1 - H2)2]1/2     (4) 
 
4.3.10 Statistics 
All experiments were analysed by one-way analysis of variance (ANOVA) with post-hoc 
comparisons (Tukey) using GraphPad Prism 6 (GraphPad Software Inc. La Jolla, CA92037, 
USA); p<0.05 was considered to be significant.  
Comparisons were made between the nanoemulsion formulations, with and without 
enhancers, and controls as well as between the different nanoemulsion formulations for the 
cumulative amount permeated at different time points and the amount of caffeine and 
naproxen recovered following skin extraction. A result was considered significant when p < 
0.05.  
Table 4.2 Physical and chemical characterisation of the various of nanoemulsion formulations and control mixtures defined in Table 1. 
Physical and Chemical 
Properties 
 Formulations 
 Control mixtures Nanoemulsion 
formulations 
Nanoemulsion 
formulations with 
eucalyptol 
Nanoemulsion 
formulations with oleic 
acid 
 C1C C2C,N C3C C4N E1C,N E2C,N O1C,N O2 C,N 
Appearance  Clear Clear Clear  Clear Clear Clear Clear Clear 
Viscosity (cp)  0.96 2.65 22.20 25.40 13.7±4.5 15.1±4.0 23.0±4.7 28.3±4.5 
Conductivity (µS)  0.21 1.15 0.12 1.05 87.5±2.2 91.3±3.9 80.8±8.2 84.5±10.1 
Refractive Index  1.33 1.36 1.32 1.34 1.38 1.37 1.38 1.37 
Emulsion droplet size 
(nm) 
 - - - - 
29.6±3.1 19.5±1.3 8.0±0.5 12.4±0.1 
Hansen Solubility 
Parameters (MPa)1/2 
D 15.5 15.4 16.7 15 15.3 15.3 15.3 15.3 
P 16 11.9 13.6 11.9 9.4 9.3 9.4 10 
H 42.3 28.7 25.7 28.4 20.7 22.5 21.2 22.9 
Total 47.8 34.7 33.5 34.3 27.4 28.8 27.8 29.3 
(HSP dist)a  43.2 26.3 29.1 20.7 15.8 17.3 14.8 16.8 
Molar volume (MV)  18 30.8 35.9 30.9 43.3 38.9 44.2 39.5 
aHSP distances (Ra) of mixtures calculated from Equation 4 below, using software package HSPiP. 
 
4.4 Results  
4.4.1 Physical and chemical characterisation of the formulations used 
Table 4.2 summarises the physical and chemical properties of the various formulations used 
in this study. In general, all formulations were clear and had a low viscosity. As one example, 
shown in Figure 4.1, the nanoemulsions area in the pseudo-ternary phase diagram with a 
1:1 w/w ratio of Volpo-N10 to ethanol is in a region with a surfactant concentration between 
80% and 40%. In this region, a high amount of water can be solubilised without causing 
phase separation and is characterised by transparency and higher viscosity. In contrast, in 
other regions of the phase diagram, a turbid emulsion is seen. Figure 4.1 also shows that 
the proportion of the ternary diagram existing as the nanoemulsion increases as the amount 
of water increases and the concentration of surfactant / co-surfactant mixture decreases.  
 
Figure 4.1. Ternary phase diagram of the oil, surfactant/co-surfactant mixture and water at 
ambient temperature. The dotted line in the diagram represents the nanoemulsion. 
 
Table 4.2 also shows the viscosity, conductivity, refractive index and, where appropriate, 
nanoemulsion droplet size. However, it is apparent that, consistent with OA’s surface active 
properties, the droplets from the nanoemulsions containing OA are smaller than those of 
EU.  Further, all nanoemulsions had mean droplet sizes < 100 nm, indicating that they 
should be regarded as being nanoemulsions, and high conductivities, consistent with them 
being oil in water (O/W) nanoemulsions. Also, included in Table 4.2 are the estimated 
solubility parameters and “average” molar volume for each of the formulations studied. It 
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evident that the various solubility parameters are in the general order: 
water>nanoemulsions>nanoemulsions containing penetration enhancers. 
 
4.4.2 In vitro permeation of caffeine and naproxen across epidermal membranes  
Figure 4.2A shows the cumulative amount (g/cm2) of caffeine that penetrated across 
epidermal membranes versus time for nanoemulsions and controls for this study. 
Penetration from nanoemulsions containing skin penetration enhancers was greater than 
from control vehicles. The corresponding cumulative amount versus time profiles for 
naproxen are shown in Figure 4.2B, where similar but greater penetration occurs from 
nanoemulsions compared to controls. For both caffeine and naproxen, the ethanol/water 
solution promoted a greater epidermal penetration than the other control solutions. 
 
 
 
 
 
 
 
 
 
 
Figure 4.2. In vitro percutaneous permeation through epidermal human skin A-caffeine; B-
naproxen (E1, green solid lines; E2, green dashed lines; O1, red solid lines; O2, red dashed 
lines; C1 (water), crosses; C2 (60% EtOH/water), yellow squares; C3 (50% 
PEG6000/water), diamonds and C4 (Volpo-N10/EtOH/water), circles. 
 
4.4.3 Impact of formulation on active solubility in formulation, solubility in stratum 
corneum, maximum flux and derived diffusivity 
Table 4.3 shows the estimated active solubility in formulation, solubility in stratum corneum, 
maximum flux calculated from steady state flux using Equation 1 and diffusivity per path 
length D*  derived from the maximum flux and stratum corneum solubility using equation 2. 
It is apparent that both caffeine and naproxen have a much higher solubility in nanoemulsion 
formulations containing enhancers than in controls.  Indeed, the solubility of caffeine in water 
was much less than the corresponding values with the other controls and with the emulsions; 
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naproxen had a higher solubility in the nanoemulsions than in the controls. Pronounced 
enhancements in caffeine and naproxen maximum fluxes were evident for the aqueous 
ethanolic solution and the various emulsion formulations containing enhancers, the 
enhancement being between one and two orders of magnitude greater than the controls 
(Figure 4.3).  It is apparent that the solubility of caffeine in the stratum corneum after 
application of various emulsion formulations containing enhancers is modest, whereas the 
derived D* for these formulations increases by one or two orders of magnitude. It is thus 
apparent that the marked formulation enhancement in caffeine penetration arises from the 
enhancers reducing the diffusion resistance for caffeine permeation.  In contrast, the 
solubility of naproxen in the stratum corneum after application of various emulsion 
formulations containing enhancers is about one order of magnitude greater than the 
controls, whereas the derived D* is not greatly different from the slight enhanced D* seen 
for an aqueous ethanolic formulation. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Estimated maximum fluxes for caffeine and naproxen for each of the 
formulations plotted against the solubility of these actives in the formulations. Circles, 
caffeine; Triangles, naproxen. Black symbols - controls (solutions in water and 25% 
PEG6000/water for caffeine, 25% PEG6000/water and Volpo-N10/EtOH/water for 
naproxen); Yellow symbols - 60% EtOH/water; Red symbols - nanoemulsions containing 
oleic acid; Green symbols - nanoemulsions containing eucalyptol 
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Table 4.3 Experimental data for caffeine and naproxen in different nanoemulsions without and with penetration enhancers and control 
vehicles. (Mean ± SD).  
 Active 
 Caffeine Naproxen 
Formulation SV 
(mg/mL) 
Jmax 
(g/cm2/h) 
SSC (µg/mL) D* 
(cm/h *1E4) 
SV 
(mg/mL) 
Jmax 
(g/cm2/h) 
SSC (µg/mL) D* 
(x104 cm/h) 
C1 31.3±1.2 2.2±0.8 21.6±2.2 1.0±0.4 - - - - 
C2 81.5±13.4 25.6±3.1 151.0±37.7 1.7±0.2 50.9±1.4 23.4±4.8 18.3±6.1 12.8±2.6 
C3 57.4±10.1 2.5±0.7 49.4±14.2 0.5±0.1 66.8±1.9 6.2±0.3 16.0±1.8 3.9±0.2 
C4 - - - - 25.9±1.5 7.3±2.7 9.5±1.7 7.7±2.9 
EU1 112.3±8.5 263.6±1.2 38.2±15.3 69.1±0.3 174.9±8.3 122.4±27.1 101.8±22.4 12.0±2.7 
EU2 110.8±9.5 267.7±24.0 36.5±4.1 73.3±6.6 148.1±5.1 86.6±8.9 114.0±35.1 7.6±0.8 
OA1 101.8±2.2 118.8±57.3 52.4±3.9 22.7±11.0 198.5±0.4 101.2±41.7 113.8±66.7 8.9±3.7 
OA2 90.2±8.1 136.4±95.2 64.4±20.6 21.2±14.8 170.6±3.3 74.0±2.3 95.9±58.2 7.7±0.2 
The formulations are defined in Table 1 and are nanoemulsion formulations (C3 and C4), with penetration enhancers eucalyptol (EU1 and 
EU2) and oleic acid (OA1 and OA2), and control mixtures (C1 – C2). 
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The different mechanisms of enhancement for the nanoemulsions with enhancers for 
caffeine and naproxen are more clearly shown in Figure 4.4. In Figure 4.4A it is evident that 
the Jmax for naproxen is correlated with its solubility in the stratum corneum Ssc whereas, as 
shown in Figure 4.4B, caffeine is better related to its altered diffusivity D* associated with 
the various formulations. 
 
 
 
 
 
 
 
Figure 4.4 Impact of stratum corneum solubility and apparent diffusivity D* on the maximum 
flux Jmax for caffeine and naproxen. A. Jmax versus stratum corneum; B. Jmax versus D*. 
Circles, caffeine; Triangles, naproxen. Black symbols - controls (solutions in water and 25% 
PEG6000/water for caffeine, 25% PEG6000/water and Volpo-N10/EtOH/water for 
naproxen); Yellow symbols - 60% EtOH/water; Red symbols - nanoemulsions containing 
oleic acid; Green symbols - nanoemulsions containing eucalyptol. The trend line for 
naproxen is shown. It is evident from Figure A that Jmax is more dependent on stratum 
corneum solubility for naproxen, whereas in Figure B Jmax is better related to D* for caffeine. 
 
4.4.4 Mechanism underpinning the differential enhanced uptake of caffeine and 
naproxen into the epidermis 
Figure 4.5 shows that the enhanced solubility in the stratum corneum from the various 
formulations could be related to the uptake of both caffeine and vehicle into the stratum 
corneum. An optimal regression was found when it was assumed that all the dissolved solute 
in the vehicle was taken up into the stratum corneum as defined by: 
SSC (predicted) = SSC (skin, control) + SV (vehicle) * Vup / VSC 
Where Vup is solvent uptake and VSC is the volume of the stratum corneum. SSC (skin, 
control) represents the solute in the stratum corneum, derived from the experimental data 
for a control solution: 
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SSC (skin, control) = SSC (exp, control) - Sf (exp, control) * Vup (control) / VSC  
An excellent SSC (predicted) versus SSC (experimental) is evident for naproxen (R2=0.84) but 
not for caffeine (R2=0.48). 
 
 
 
 
 
 
 
 
 
Figure 4.5. Stratum corneum solubility predicted from solvent uptake for caffeine (A) and 
naproxen (B). (Lin’s concordance correlation coefficient for caffeine is 0.58 and for naproxen 
is 0.93.) Black symbols, control solutions in water and 25% PEG6000/water for caffeine, 
25% PEG6000/water and Volpo-N10/EtOH/water for naproxen); Yellow symbols, 60% 
EtOH/water; Red symbols - nanoemulsions containing oleic acid; Green symbols - 
nanoemulsions containing eucalyptol. 
 
Can the solubility of the actives in various formulations and the uptake of 
formulations into stratum corneum be predicted by the solubility parameter 
approach? 
Figure 4.6 shows the relationships between the solubility of solutes in formulations, uptake 
of formulations into stratum corneum and stratum corneum solubility as a function of the 
HSP distance (Ra). Figure 4.6A shows that the experimental solubilities of caffeine and 
naproxen in the various vehicles were highest when Ra was lowest and when the solutes 
and nanoemulsions were most similar in their various solubility parameters. Figure 4.6B 
shows that solvent uptake into the stratum corneum is also greatest for these formulations 
when Ra is lowest, i.e. formulations which are most similar to the stratum corneum in their 
various solubility parameters.    
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Figure 4.6. Solute solubility in vehicle and formulation uptake into stratum corneum as a 
function of their estimated HSP distance (Ra). A & B. Vehicle solubility (SV) for caffeine 
(circles) and naproxen (triangles) respectively versus the Ra between the nanoemulsion 
formulations and controls; C & D: Formulation uptake into the stratum corneum for caffeine 
(circles) and naproxen (triangles) respectively versus the Ra between the nanoemulsion 
formulations and the skin. Black symbols - controls (solutions in water and 25% 
PEG6000/water for caffeine, 25% PEG6000/water and Volpo-N10/EtOH/water for 
naproxen); Yellow symbols - 60% EtOH/water; Green symbols - nanoemulsions containing 
eucalyptol; Red symbols - nanoemulsions containing oleic acid. 
 
4.4.5 In vitro permeation of caffeine and naproxen across full-thickness human skin 
The cumulative amount of caffeine and naproxen penetrated through full-thickness human 
skin (µg/cm²) was plotted as a function of time (h) and the slope yielded the pseudo steady-
state flux JSS (µg/cm2/h). The permeability coefficient KP (cm/h) was calculated from 
equation 1. After 8 h exposure, the amount of caffeine delivered into the receptor from the 
microemulsion formulations was significantly higher than controls (P<0.05), Fig 4.7. 
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Figure 4.7. In vitro percutaneous permeation through full-thickness human skin; A-caffeine; 
B-naproxen (E1 (Eucalyptol 1 - green solid lines);  E2 (Eucalyptol 2 - green dashed lines; 
O1 Oleic acid 1 - red solid lines; O2 (Oleic acid - red dashed lines; C1 (water -, crosses; C2 
(60% EtOH/water - yellow squares; C3 (50% PEG6000/water - diamonds and C4 (Volpo-
N10/EtOH/water - circles. 
The calculated flux and permeability coefficient from O/W microemulsions for both systems 
(OA and EU) was 10-fold higher (36.8 and 56 µg/cm2/h, respectively) than controls (C1, C2 
and C3) (1.7, 4.6 and 1.2 µg/cm2/h, respectively) in the case of caffeine; and 2- to 3- fold 
(11.9 and 11.3 µg/cm2/h OA and EU, respectively) higher than controls (C2, C4) (4.7 and 
5.5 µg/cm2/h, respectively) for naproxen.  
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Table 4.4. Caffeine and naproxen permeation parameters for different vehicles though full-
thickness skin (Mean ± SD, n=4) 
 KP (cm/h *1E4) Jmax (g/cm2/h) D* 
(x104 cm/h) 
Formulation Caffeine Naproxen Caffeine Naproxen Caffeine Naproxen 
C1 0.5±0.1 - 1.5±0.3 - 0.7±0.7 - 
C2 1.2±0.3 1.4±0.3 10.0±3.0 7.3±2.8 0.7±0.2 4.0±1.5 
C3 0.3±0.1 - 1.8±0.7 - 0.4±0.1 - 
C4 - 1.6±0.1  4.2±1.5  4.5±1.6 
E1 11.4±2.8 5.2±0.5 127.9±31.4 90.8±8.9 33.5±8.2 8.9±0.8 
E2 12.0±2.1 4.8±1.0 132.5±26.5 71.1±8.8 36.3±7.2 6.2±1.4 
O1 6.9±4.3 2.4±0.4 69.8±21.8 47.0±8.3 13.3±4.0 4.1±0.7 
O2 9.6±1.6 3.3±1.0 86.9±15.0 55.7±18.2 13.5±2.0 5.8±2.2 
 
C1 is 100% water, C2 is 60% ethanol/water, C3 is 25% PEG6000/water, and C4 is 25% 
Volpo-N10 25% ethanol/50% water 
EU nanoemulsions containing eucalyptol as oil phase, OA nanoemulsions containing Oleic 
Acid as oil phase 
 
Figure 4.8 shows that more caffeine was promoted from nanoemulsion formulations into 
skin and stratum corneum than from the controls and that the amount permeating from these 
formulations was greater for caffeine than for naproxen. However, the same pattern not seen 
for lipophilic drug naproxen. Also, a significant difference (P<0.05) was found in the amount 
of caffeine retained in the stratum corneum when compared between nanoemulsions and 
controls (C1 & C3). No differences were found between nanoemulsion formulations for 
caffeine and naproxen. Unexpectedly, high naproxen levels were retained in the stratum 
corneum from control C2 (60% ethanol/water) solution. We are not sure why this occurred 
but it could be due to enhanced partitioning of actives into the stratum corneum caused by 
ethanol. 
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A- 
 
 
 
 
 
 
B- 
 
 
 
 
 
 
 
Fig 4.8 A-Caffeine; B-naproxen retained in the stratum corneum (SC) and skin from 
nanoemulsion formulations and controls after 8 h permeation in full-thickness human skin 
(Mean ± SEM, n=4) 
Table 4.5 shows the lag time for full-thickness skin is higher than for epidermal membrane 
for both caffeine and naproxen and from all nanoemulsion formulations and controls. It also 
shows that the caffeine flux of nanoemulsion formulations from epidermal membranes was 
significantly higher than the flux from full-thickness skin (P<0.05).The naproxen epidermal 
flux was slightly higher than full-thickness skin but was not significant. 
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Table 4.5 Estimated lag times and steady state flux for caffeine and naproxen in epidermal 
membrane and full-thickness skin. 
Formulation  Lag time (h) JSS (g/cm2/h) 
Caffeine  FTS Epi FTS Epi 
C1 4 2.5 1.4±0.3 2.1±0.6 
C2 3 2 3.7±1.1 9.4±0.9 
C3 4 3 0.9±0.1 1.3±0.4 
E1 2.5 1 34.2±8.6 70.4±0.3 
E2 2.5 1 35.9±6.3 72.5±6.2 
O1 2.5 1 20.6±2.0 35.0±19.6 
O2 2.5 1 28.9±5.8 454±10.5 
Naproxen     
C2 3 1.5 2.9±0.8 9.2±1.5 
C3 - 2 - 1.9±0.1 
C4 4 2 3.3±1.2 5.7±1.7 
E1 3 0.5 10.4±1.0 14.0±3.6 
E2 3 0.5 9.6±2.3 11.7±1.1 
O1 3 0.5 4.7±0.8 10.2±4.8 
O2 3 0.5 6.5±2.0 8.7±0.3 
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4.4.6 Multiphoton microscopy of full-thickness human skin after exposure to 
nanoemulsion formulations 
MPM images of human full-thickness skin exposed to the formulations and corresponding 
control samples (untreated) are shown in Figure 4.9. The pseudo-coloured images (40X) 
have been recreated from normalised average endogenous autofluorescence lifetime of 
NADPH and FAD. The images are coloured from shorter lifetime (blue) to longer lifetimes 
(red). An area (2cm2) of skin pre-treated with the formulations for 8 h was imaged using the 
Derma Inspect multiphoton tomography system. We observed a change in stratum corneum 
morphology compared to the control skin. The hollowing of the cellular regions (Figure 4.9-
white arrow) can be attributed to the action of nanoemulsion on the stratum corneum lipids. 
In addition, an increase in the thickness of the viable epidermis was observed. The visible 
layers could be observed for a greater depth. In the case of the oleic acid formulation the 
total depth of the epidermis was 100 µm; this is nearly twice the generally observed 
thickness of epidermis. However, when metabolic analysis of the NADPH and FAD lifetimes 
was conducted on the viable layers, no change was observed. The treated skin and the 
control skin were both found to have a comparable average lifetime (tm). (188, 189) 
 
 
 
 
 
 
 
 
 
 
 
Fig 4.9 Structural and viability study of excised skin following the topical application of 
nanoemulsion formulations-. SC = stratum corneum; SG = stratum granulosum; OA = 
nanoemulsions with oleic acid; EU = nanoemulsions with eucalyptol  
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4.5 Discussion 
This work has demonstrated that the skin permeation of caffeine and naproxen is markedly 
enhanced using nanoemulsion formulations containing the penetration enhancers, OA and 
EU, in comparison to the controls. These results are consistent with those previously 
reported for skin permeation of hydrophilic and lipophilic drugs using microemulsion 
formulations (190). A key question we also addressed was how the nanoemulsions with the 
penetration enhancers promoted skin penetration. It is evident that the nanoemulsions made 
in this study worked by three mechanisms, which may or may not be working in concert to 
give a synergistic effect: i) an enhanced solubility of the drug in the applied vehicle, ii) uptake 
of the vehicle carrying the drug into the stratum corneum, and iii) alteration of the properties 
of the stratum corneum membrane, for example by fluidisation of the stratum corneum lipids.  
The combinations of surfactants and oils used in our emulsions enabled the vehicle solubility 
of both caffeine and naproxen to be increased more than any single solvent solution or 
solvent mixture used in this study as controls (Table 4.3). The 3- to 4-fold increase in 
solubility of the water soluble compound caffeine in the nanoemulsions compared to the 
aqueous solution is most likely reflecting the process of micellar solubilisation (191). The 
nanoemulsion induced enhanced solubility was even more evident with the lipophilic 
naproxen, with a 6- to 8-fold solubility enhancement seen when compared to the complex 
co-solvent mixture containing Volpo-N10 and ethanol (25.9 mg/mL). The findings are 
consistent with the general view that solubilisation is even more pronounced for lipophilic 
compounds (192). The nanoemulsions were also associated with excellent stratum corneum 
solubility, particularly in the case of the more lipophilic naproxen (Table 4.3). Further, both 
EU and OA are known to disrupt the stratum corneum by multiple mechanisms, including 
dissolution of stratum corneum lipids (193).  
To clarify that there had been a nanoemulsion induced permeation enhancement for caffeine 
and naproxen, we estimated the solute maximum (or saturated) fluxes (Jmax). The use of 
maximum flux enables the potential enhancement caused by the nanoemulsions to be 
defined as it is now well recognised that maximum flux is independent of the vehicle and 
dependent solely on the thermodynamic activity of the solute in the vehicle, provided the 
vehicle or solute does not alter the properties of the membrane (106, 154). This concept 
was initially highlighted by the work of Twist and Zatz (155), who showed the same flux for 
methyl paraben across synthetic membranes, regardless of its solubility in a range of 
different vehicles. Our results for the control solutions are consistent with these findings in 
that a similar low value for Jmax for both caffeine and naproxen was found for each control 
91 
solution not affecting skin permeability across a range of vehicle solubilities. In contrast, the 
Jmax values seen with nanoemulsions and to some extent, ethanol/water, are much higher 
than the controls (Figure 4.3), consistent with their enhancement of skin permeability and 
suggesting that these vehicles have altered the properties of the stratum corneum. The 
penetration enhancer, EU, had a much greater effect on Jmax than OA for the hydrophilic 
drug caffeine; a differentiation not seen with the lipophilic naproxen.  
In order to understand the mechanisms by which the solutions and nanoemulsions had 
acted as permeation enhancers, we also estimated the underlying Jmax determinants of 
stratum corneum solubility and stratum corneum diffusivity. Ethanol, used as a co-surfactant 
in these nanoemulsions, has been shown to extract stratum corneum lipids and perturb 
barrier function by improving the permeation of more hydrophilic drugs such as caffeine 
through skin by partitioning between the vehicle and stratum corneum. Peltola et al also 
reported enhanced transdermal delivery of the lipophilic steroid oestradiol from 
microemulsions containing ethanol as a co-surfactant (194), with which our findings are 
consistent. Interestingly, ethanol has been reported to act synergistically with terpenes to 
enhance penetration of both hydrophilic and lipophilic drugs (195, 196). The increased 
ethanol content in the 60% ethanol/water mixture however, was likely to have a greater 
effect on the skin, particularly on the extraction of skin lipids. This would have a larger impact 
on the partitioning of the hydrophilic caffeine, compared to the lipophilic naproxen, 
accounting for the much greater enhancement of SSC seen with caffeine. 
Table 4.3 showed that the stratum corneum solubility of naproxen was enhanced by the 
nanoemulsions much more than that for caffeine (range, 96-114 mg/mL compared to 36-64 
mg/mL) and that this increased stratum corneum solubility was, in turn, associated with an 
enhanced flux (Figure 4.4). In contrast, there was no such clear relationship seen with 
caffeine (Figure 4.4). On the other hand, the apparent linear relationship between effective 
diffusivity in the epidermal membrane and Jmax for caffeine (Figure 4.4) suggests that the 
nanoemulsion formulations may have modified the stratum corneum lipids (157). In contrast, 
the Jmax for naproxen appears to not have been increased by alterations in the stratum 
corneum diffusivity. In general, diffusivity will be independent of solute lipophilicity for those 
vehicles that do not affect the stratum corneum (107, 197). However, when the vehicle does 
affect the stratum corneum, there may be varying impacts for different types of solutes. We 
have found, for instance, an increased diffusivity for the more hydrophilic phenol compounds 
such as isopropyl myristate (IPM) relative to more lipophilic phenols. IPM has a high affinity 
for skin and can disrupt the lipid bilayer regions of the stratum corneum intercellular matrix. 
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Its stratum corneum diffusivity enhancement was most pronounced for moderately 
hydrophilic compounds like methyl paraben (log P 1.95) and 4-propoxyphenol (log P 2.34) 
and so may be anticipated to also affect caffeine (log P -0.07), consistent with the 
nanoemulsion enhancement of its diffusivity seen in this work. Interestingly, we also 
observed a reduced diffusivity for the more lipophilic phenols (above log P of about 3.0) from 
IPM (107), consistent with our findings with naproxen. Our findings of diffusivity-mediated 
caffeine flux increases, that were particularly evident in the nanoemulsions containing EU, 
are consistent with previous work showing increased diffusivity of the polar compound 5-FU 
with terpene enhancers, including EU (157). In that work, the terpenes were not considered 
to act by increasing stratum corneum solubility but by disruption of the stratum corneum 
lipids to enhance diffusivity. On the other hand, in other work, OA had only a moderate 
diffusion-enhancing effect compared to the terpene d-limonene for solutes with a range of 
lipophilicities (198), analogous to our findings. Terpenes have also been shown to enhance 
the permeation of a lipophilic compound, tamoxifen, by enhancing its partitioning into the 
stratum corneum (199). Williams and Barry (159) observed that in general, partitioning may 
play a greater role in enhancement of more lipophilic substances. Another contribution to 
enhanced flux seen with the nanoemulsions could come from an increase in surface area 
coverage, due to distribution of the drug in the nanoemulsion droplets to aid in the transfer 
of the active compounds from the formulation to the stratum corneum (184, 194). 
A key finding in this work is that the nanoemulsion enhanced stratum corneum solubility is 
due to the uptake of solute dissolved in the formulation and this, in turn, depends on the 
solubilities of the solutes in the formulations and formulation uptake into the stratum 
corneum. We did explore for any the relationships between the solubilities of the active 
compounds in the various formulations and in the stratum corneum after application of the 
formulations with the HSP distance for the nanoemulsions and actives (Figure 4.6). Our 
conclusion is that the data are consistent with the adage of “like dissolves like” in that the 
highest solubility in the formulations and the uptake of formulations into the stratum corneum 
corresponded to the lowest HSP distance. The findings appear to be consistent with the 
general principles enunciated by Abbott et al (153). Further studies using an expanded 
range of vehicles and actives may allow predictive algorithms to be generated. 
The caffeine and naproxen permeation of full-thickness skin and epidermis layers was 
measured. Epidermal membrane had, as expected, higher permeability of caffeine and 
naproxen as flux than the full-thickness skin. However, fluxes of caffeine and naproxen 
absorbed into the receptor from full-thickness skin compared with epidermis were similar. A 
study by Cross et al found that the ratio of fluxes of salicylate into the receptor from their 
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formulations remained constant in full-thickness skin and epidermis and they suggested that 
the dermis constitutes a similar barrier to the diffusion of active ingredients from their 
formulations (200). Therefore, the presence of dermis and hypodermis did not affect the 
permeation amount of caffeine and the stratum corneum was just limiting the rate of barrier 
against penetration. These results are similar to other results obtained from a study done in 
2008 on caffeine (201).  
The amount of caffeine and naproxen retained in the stratum corneum was measured by 
tape stripping to correlate solubility of solute in the formulations to that in the stratum 
corneum. We found that the solubility of nanoemulsion formulations containing caffeine and 
naproxen in the stratum corneum followed the same trend as that obtained from tape 
stripping (amount of caffeine and naproxen retained in the stratum corneum). It was seen 
(Table 4.4) that the highest permeability of naproxen was obtained from OA and EU 
nanoemulsion formulations, which may be due to high solubility of naproxen in the stratum 
corneum from these formulations compared with controls. Naoui et al found significant 
differences in the amount of caffeine stored in the stratum corneum (202). It was previously 
claimed that diffusional resistance in the dermal matrix could significantly decrease the 
permeability of lipophilic solutes (203). As shown in Table 4.5, this effect is evident for both 
caffeine and naproxen in this study with the greatest reduction in flux and diffusion seen for 
caffeine. 
Our microscopic evaluation of the skin concurs with the lipid dissolution hypothesis. As 
described in the results, the dissolution of stratum corneum lipids was evident after 8 h of 
treatment with the emulsions. Walker and Hadgraft found that the use of oleic acid as a 
penetration enhancer disrupted the intercellular lipid arrangement of the stratum corneum 
(188). A study using a EU nanoemulsion with curcumin (log P 3.2) as a model penetrant 
showed similar changes to those observed in our work (189). Their histological images 
comparing a PBS control and the terpene nanoemulsion showed keratin fragmentation and 
disruption of the lipid bilayers after 24 h microemulsion treatment of full-thickness pig ear 
skin.  
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4.6 Conclusions 
In conclusion, the nanoemulsion systems in this study significantly enhanced the human 
epidermal permeation of caffeine and naproxen. Both a nanoemulsion increase in stratum 
corneum solubility and in diffusivity could be shown as the key mechanisms for this increase 
with the enhanced solubility arising from solute being carried into the stratum corneum with 
the formulation. Analysis of these data using solubility parameters suggests that “like 
dissolves like” is the key adage determining solute solubility in the formulations, uptake of 
the formulations into the stratum corneum and then the stratum corneum solubility. Our 
results comparing the responses in epidermal membrane full-thickness skin highlight the 
additional behavior provided by the dermis in the permeation of both hydrophilic and 
lipophilic solutes. 
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Chapter 5 
Appendageal delivery 
A. Potential of nanoemulsion formulations for delivery of Minoxidil through skin 
appendages, stratum corneum and permeation through human skin. 
B. Investigation of the effects of nanoemulsions containing penetration enhancers on 
follicular penetration of the hydrophilic model compound caffeine. 
 
5.1 Abstract 
Hair follicles are pertinent and efficient penetration pathways and reservoirs for topically 
applied chemicals/drugs. Penetration enhancers can also be incorporated as the oil phase 
of microemulsions to further enhance drug delivery. Penetration enhancers are used to 
reduce the skin barrier by physically and chemically altering its properties. Enhanced 
minoxidil delivery, targeted to receptors localised within hair follicles, aims to promote hair 
growth. We aimed to compare the permeation of minoxidil into and through excised human 
skin using different nanoemulsion formulations, compared to a simple solution control. A 
further aim was to prove that maximum flux of solutes can be enhanced by increasing its 
solubility in stratum corneum lipid components and increasing the diffusivity of the solute in 
the stratum corneum. Oil in water (O/W) nanoemulsions containing 2% minoxidil and either 
oleic acid (OA) or eucalyptol (EU) as oil phase were prepared and characterised. 
Nanoemulsions and control (C - 2% minoxidil in 60% ethanol/water) were applied to full-
thickness excised human abdominal skin in Franz diffusion cells (n=4) for 24 h. Minoxidil 
concentrations in receptor fluid (through the skin), tape strip extracts (stratum corneum 
retention), follicular casts (hair follicle retention) and homogenised skin extracts (deeper skin 
retention) were analysed by high performance liquid chromatography (HPLC). Minoxidil 
penetration through and into skin was greater for all nanoemulsions compared to the control. 
The OA formulation was the best at promoting minoxidil retention into the superficial skin 
compartments (stratum corneum and hair follicles). The EU formulation was best for deeper 
penetration into and through the skin. We also found that maximum flux was related to 
formulations and was dependent on stratum corneum solubilities for minoxidil. These 
solubilities, in turn, depended on the amount of vehicle absorbed into the stratum corneum 
and the amount of minoxidil dissolved in that absorbed formulation. 
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The second aim of this study was to investigate the effectiveness of our nanoemulsion 
formulations for follicular delivery of caffeine. In excised human full-thickness skin, hair 
follicles were opened by tape stripping, blocked with a microdrop of super glue and 
acriflavine (for visualisation), or left untreated. Caffeine in nanoemulsion formulations 
containing OA or EU and in controls was topically applied. Caffeine retention in the stratum 
corneum, hair follicles and the skin, as well as penetration through the skin after 24 h was 
determined. Separately, acriflavine was applied to the skin and imaged in the follicles and 
surrounding area by multiphoton microscopy 
Nanoemulsions caused significant increases in caffeine permeation through untreated skin, 
compared to controls (16- and 25-fold for OA and EU, respectively), with the follicular route 
contributing 18% of caffeine permeation for the OA nanoemulsion and 24% for EU. When 
follicles were opened, the respective contributions rose to 32% and 43%. The 
nanoemulsions also promoted caffeine retention in the follicles, with 11- and 15-fold 
increases with OA and EU, respectively. Imaging showed cellular uptake of acriflavine 
around the opened follicle, but not in the untreated follicle with OA, suggested that OA was 
unable to penetrate the sebum barrier around the follicle. This study demonstrated effective 
delivery of a hydrophilic model drug into and through hair follicles and showed that the 
follicles and surrounding regions may be targeted by optimised formulations for specific 
treatment. 
O/W nanoemulsions containing OA or EU enhanced transdermal delivery of minoxidil. OA 
appeared to promote stratum corneum and follicular delivery more than EU. This study has 
also suggested that OA and EU nanoemulsions containing caffeine as a hydrophilic model 
drug appeared to be convenient to be used in the transfollicular penetration. Improved 
follicular targeting has implications for acne treatment and vaccine delivery to adjacent 
antigen-presenting cells. 
 
5.2 Introduction 
The knowledge of the permeation process is essential for improving and optimising skin 
transport solutes and cosmetics. Even though the stratum corneum is commonly known as 
the most important barrier to transdermal absorption, it is also regarded as the main route 
for penetration. Recently, researchers have suggested, in addition to percutaneous 
absorption, hair follicles and sebaceous glands may contribute significantly to topical or 
transdermal delivery (204). Previously, the actual importance of the transfollicular route had 
been overlooked based on the fact that the hair follicle orifices occupy only approximately 
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0.1% of the total skin surface area (205). Nonetheless, hair follicles are a pocket within the 
epidermis extending deep into the dermis, providing a much greater area for absorption 
below the surface of skin. Follicular density has major effects on penetration. Shelley and 
Melton observed the appearance of tiny multiperifollicular wheals on hairy human skin after 
topical administration of epinephrine and histamine phosphate in propylene glycol. There 
was no response in areas with less hair density, thus, suggesting follicular contribution (206). 
Also, studies by a number of researchers have shown higher absorption rates in skin areas 
with higher follicle density (207), (208). Previous studies of the transfollicular route were 
mostly qualitative and histological studies depended on stain and dye localisation within the 
hair follicle. For instance, Mackee et al (209) were amongst the first to study the role of the 
hair follicles in topical drug delivery. There have been substantial studies on the effect of 
vehicles and drugs on the transfollicular route but it seems the physicochemical features of 
the solute itself may influence the final transport of the solutes within the skin. Many 
theoretical considerations of the follicular route have been suggested. Theoretical 
consideration of the transfollicular or shunt pathway was first considered by Scheuplein 
(210). Shunt-mediated diffusion of charged dye was observed. Transient diffusion depended 
upon conditions, considered to be either transdermal or transfollicular (210). These 
examples of transient percutaneous absorption apply only to solution dosage forms, and 
can not necessarily be extended to other topical vehicles (204). Particle size may greatly 
influence targeted delivery into hair follicles (205), (211) and different particle sizes may be 
used to aim at various depths in the follicular duct. It has been suggested that 750 nm and 
1500 nm polystyrene particles can penetrate to the end of a hair follicle (44). However, it 
has been also reported that 750 and 1500 nm particles were not able to enter the cells after 
topical administration, although 40 nm particles did enter (212). Lademann et al (15) 
identified body-region-dependent hair follicle features varying in follicular size and follicular 
distribution. Furthermore, it has been reported that solutes enter from active hair follicles 
only and that inactive or closed hair follicles produce sebum and prevent the growth of hair. 
Consequently, open orifices are obtained by mechanical peeling before applying the 
substances (213). The variation in the stratum corneum thickness in different body areas 
has been the most important reason for the varying rates of absorption.  
Nanoemulsions are a modern approach to carrying drugs acting as new delivery system due 
to their high solubilisation and the possibility of managing delivery rates of drugs. Mostly, 
these advanced formulations have been used topically. It is believed that drug permeation 
rates from nanoemulsions are significantly higher than from other formulations such as 
conventional emulsions and vehicles because the nanoemulsions combine several 
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enhancing components (202). Nanoemulsions are a dispersed system of oil, water, 
surfactant and co-surfactant. The mixture of oil, water and surfactant could form a wide 
range of phases or structures, which can be discerned microscopically. The 
physicochemical properties of nanoemulsions influence the delivery of a drug to the skin 
and many hypotheses have been put forward. One of these theories claimed that contact of 
the drug with the skin could be improved by low interfacial tension between oil and water 
(176). The bioavailability of the drug increases due to the low interfacial tension and the 
fluctuating oil-water interface, which enhances material movement between lipophilic and 
hydrophilic domains of the nanoemulsion and the stratum corneum (202).  
The aim of this study was to determine the influence of an oil-in-water droplets nanoemulsion 
on the permeation of minoxidil as a moderate lipophilic drug (log P 1.24) in hair follicles, 
stratum corneum, other skin layers and in receptor samples after 24 h. Minoxidil was the 
drug to be loaded into the nanoemulsions that contained EU and OA (oil), Volpo-N10 (non-
ionic surfactant) and ethanol (co-surfactant). The second aim of the present study was to 
investigate the transfollicular delivery enhancement of caffeine using the same 
nanoemulsion formulations. Differential tape stripping was performed followed by 
cyanoacrylate skin surface biopsies to determine the amount of caffeine in the hair follicles. 
Follicular closing and opening technique in human skin was also performed to determine 
the penetration of caffeine through hair follicles. Skin was also imaged using a LaVision 
multiphoton microscope to see permeation into hair follicles and the area around the hair 
follicles. 
 
5.3. Materials and Methods 
5.3.1 Chemicals  
Caffeine, minoxidil, ethanol, OA and EU, were purchased from Sigma-Aldrich Pty. Ltd. 
(Sydney, Australia). Volpo-N10 was obtained from Umiqema (Witton Centre, Witton Redcar 
TS10 4RF, UK). All chromatography reagents were analytical grade. 
 
5.3.2 Nanoemulsion formulation preparation and Characterisation 
Volpo-N10 (surfactant) was dissolved in ethanol (co-surfactant) in a 1:1 ratio. The resulting 
mixture was then mixed with the oil phase, OA or EU (oil) in a 0.6:1:1 ratio followed by gentle 
mixing with phosphate buffered saline (PBS). The resulting nanoemulsion was clear at room 
temperature. Minoxidil and caffeine were dissolved in selected nanoemulsions at 2% and 
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3% w/w, respectively. The characterisation methods are described in Chapter 5. The 
compositions of emulsions and control solutions are shown in Table 5.1 and 5.2. 
 
Table 5.1 Compositions and solubilities of minoxidil in selected nanoemulsion formulations 
and control (%w/w) 
Formulation Compositions 
C 2% minoxidil in 60% ethanol 
M1E 2% minoxidil + 15.93% EU+53.10% Volpo-N10/ethanol+30.97% water 
M2E 2% minoxidil + 14.63% EU+ 48.78% Volpo-N10/ethanol+ 36.59% water 
M3O 2% minoxidil + 15.93% OA+53.10% Volpo-N10/ethanol+30.97% water 
M4O 2% minoxidil + 14.63% OA+ 48.78% Volpo-N10/ethanol+ 36.59% water 
 
Table 5.2 Compositions of selected nanoemulsion formulations and controls (%w/w) 
Formulation Compositions 
C1 3% caffeine in water 
C2 3% caffeine in 25% PEG6000/water 
MO 3% caffeine + 14.63% OA+ 48.78% Volpo-N10/ethanol+ 36.59% water 
ME 3% caffeine + 14.63% EU+ 48.78% Volpo-N10/ethanol+ 36.59% water 
 
5.3.3 Determination of SV and the solubility in the stratum corneum SSC 
Solubility in the formulation (SV) was determined by adding minoxidil to 5 mL of each 
nanoemulsion or control solution until an excess amount remained. The samples were then 
incubated in a water bath at 32°C for 24 h with continuous agitation and centrifuged at 4700 
rpm for 10 minutes. The supernatant was withdrawn and diluted to accurately quantify the 
amount of each compound by HPLC.  
The stratum corneum was prepared from epidermal sheets by trypsin digestion (149), then 
stored frozen at -20°C until use. Circles of stratum corneum (4 replicates for each 
formulation) were weighed before use. They were then equilibrated in a saturated solution 
1mL of each formulation at 32°C for 24 h, according to established methods (150). At the 
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end of the incubation period, the stratum corneum was removed and blotted dry. Then it was 
extracted using 1 mL 70% ethanol/water for another 24 h, at the same temperature used for 
equilibrium (32°C). The solubility in the stratum corneum (SSC) was determined from the 
amount of recovered model compound in the extraction fluid, measured by HPLC, divided 
by the area (1.33cm) and the thickness (0.02cm) of the stratum corneum. 
 
5.3.4 Solvent uptake in the stratum corneum 
The total solvent uptake into the stratum corneum was determined from the weight 
difference of piece of the dry stratum corneum (about 0.7mg) soaked in individual 
formulations (1mL) for 24 h at 32°C. The stratum corneum pieces wiped three times with 
Kimwipe tissues before weighing again. 
 
5.3.5 Open hair follicles technique 
A cyanoacrylate skin surface biopsy was used to open the hair follicles; a drop of ethyl 
cyanoacrylate, (Loctite Super glue) was placed on the skin and covered with a glass slide 
under slight pressure as described by Lademann 2000 (214). After 5 min, the cyanoacrylate 
polymerised and the slide was removed with one quick movement to open the hair follicles. 
 
5.3.6 Blocked hair follicle technique 
Our group has developed a method to plug the hair follicles on excised skin to evaluate their 
contribution in permeability across the skin. Accordingly, all hair follicles in a marked region 
were carefully identified under the ZEISS microscope (Stemi 2000-C). The plugging 
procedure involved applying 0.1μL acriflavine solution (dissolved in milliQ water) to form a 
globule around the follicle and subsequently 0.1μL of ethyl cyanoacrylate, (Loctite Super 
glue) (Henkel, Ohio, USA) was added on top of it. The polar monomers of cyanoacrylate 
polymerise when they come in contact with the water molecules in the presence of 
acriflavine dye. This dye-sensitised polymerisation forms long and strong chains, thus 
plugging the skin and hair follicle.  
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5.3.7 In vitro skin penetration study 
In the first part, 2% minoxidil was totally solubilised in formulations that have high 
concentrations of water (e.g., O/W) Therefore, two concentrations of nanoemulsion 
formulations were chosen for OA and EU and control in minoxidil (Table 5.1). In vitro skin 
absorption studies were performed on a Franz diffusion cell with an effective diffusion area 
of 1.33 cm² and 3.4 mL receptor chamber capacity using full-thickness human abdominal 
skin. The skin was cut into circlular pieces and mounted in a Franz diffusion cell between 
donor and receptor compartment, the stratum corneum side was facing the donor chamber 
and the dermal side was facing the receptor chamber. The receptor contained PBS buffer 
(pH 7.4) at 35°C. 1 mL of nanoemulsion formulation or control formulation was added to the 
donor. The donor was wrapped with parafilm after addition of the nanoemulsions to prevent 
water evaporation. After 30min, 60min, 90min, 2h, 3h, 4h, 6h, 8h and 24h, 200 µL of the 
receptor was withdrawn and replaced with the same amount of fresh PBS buffer. The 
samples were analysed by HPLC. After Franz diffusion studies were completed, skin in each 
cell was wiped with cotton buds to remove any remaining formulation and then subjected to 
tape stripping (20 times) which involved by application of adhesive tape (D-Squame tapes, 
CuDerm Corp., TX) to the exposed skin surface for about 5 second, and then the tape was 
carefully removed. The tapes were placed into separate vials and soaked overnight with 2 
mL methanol before analysis by HPLC. The amount of absorbed material in the tapes was 
determined, representing material deposited within the stratum corneum. 
Follicular casting followed tape stripping; one drop of superglue was placed on a microscope 
slide. Then, the slide was pressed onto the surface of the stripped skin with light pressure 
for 15 min. After that, the slide was peeled carefully from the skin. The superglue was 
dissolved by rubbing with acetone–soaked cotton buds (four times), the cotton buds were 
soaked overnight in 2 mL methanol and then were analysed by HPLC. 
After follicular casting, the skin was chopped into small pieces, homogenised and soaked 
overnight in 2 mL methanol under constant shaking and at room temperature before being 
analysed by HPLC. 
 
Part 2 of study, the full-thickness skin (FTS) was cut into discs and divided into three groups 
(open hair follicles, plugged hair follicles and normal skin), then mounted in horizontal glass 
Franz type static diffusion cells, stratum corneum side uppermost, with 3 replicates for each 
formulation. The Franz diffusion cells had an exposed surface area of 1.33 cm² and a 
receptor volume of approximately 3.4 mL. The formulations (see Table 5.2) were applied to 
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the skin at an infinite dose of 1mL and the donor chamber was covered with a glass cover 
slip to minimise evaporation from the donor phase. Samples of receptor phase (200 µL) 
were removed at regular time points over the next 24 h and replaced with the same amount 
of fresh PBS. All samples were analysed using HPLC.  
After Franz diffusion studies were completed, the skin in each cell was wiped with cotton 
buds to remove any remaining formulation and then subjected to tape stripping (20 times) 
which involved application of adhesive tape (D-Squame tapes, CuDerm Corp., TX), to the 
exposed skin surface for about 5 second, and then carefully removed. The tapes were 
placed into separate vials and soaked overnight with 2 mL methanol before being analysed 
by HPLC. Results for the first tape are discarded, as this represents surface deposited 
material only. 
Follicular casting followed tape stripping. One drop of superglue was placed on a 
microscope slide. Then, the slide was pressed onto the surface of the stripped skin with light 
pressure for 15 min. After that, the slide was peeled carefully from the skin. The superglue 
was then dissolved by rubbing with acetone–soaked cotton buds (four times). The cotton 
buds were soaked overnight in 2 mL methanol and then analysed by HPLC. 
After follicular casting, skin was chopped into small pieces, homogenised and soaked 
overnight with 2 mL methanol under constant shaking before being analysed by HPLC.  
 
5.3.8 Sample analysis 
Minoxidil and caffeine in the receptor fluid, stratum corneum, hair follicles and skin layers 
were analysed and validated by sensitive and rapid HPLC. The HPLC system consisted of 
a Shimadzu SIL-20 a HT, CBM-20A system controller, a SPD-20A detector, LC-20AD a 
pump and an auto injector. Isocratic separation was performed on a Phenomenex Luna C18 
5μ (150×4.6 mm) column. The mobile phase of minoxidil (60% of 0.01M sodium dihydrogen 
phosphate [Na2H2PO4] buffer, 40% acetonitrile v/v containing 2.5 mM sodium dodecyl 
sulphate [SDS] (adjusted to pH 3) was pumped across the system at 1mL/min flow rate. 
Minoxidil and its internal standard (propyl paraben) were detected at 281 nm. The caffeine 
in the skin and receiver compartments were assayed by HPLC using the same conditions 
as described in Chapters 3 and 4. 
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5.3.9 Visualisation of follicles and follicular delivery  
The LaVision Microscope (LaVision BioTec GmbH, Germany) was used to assess the effect 
of these formulations in hair follicles and the area around hair follicles. The Multiphoton 
system coupled to an ultra-short-pulsed Titanium Sapphire laser (Mai Tai, Spectra Physics, 
Mountain View, California, USA) was used to image the skin. Full-thickness abdominal skin 
(3 replicates) were mounted in Franz diffusion cells and a finite dose of acriflavine in the 
formulations containing EU, OA and control (water) was applied. Samples of untreated skin 
were used as controls. After 24 h, the cells were dismantled and the skin was rinsed gently 
with water and blotted dry with a tissue. It was then placed directly on a microscope slide. 
Images were captured by two photon excitation at 740 nm. A 100 µm Z- stack was captured 
with a 5 µm step size totalling 20 images. The skin was imaged through to capture different 
depths, from the superficial surface, corresponding to the stratum corneum (SC; ~5-10 µm), 
stratum granulosum (SG; ~15-20 µm), stratum spinosum (SS; 25-30 µm) and stratum basale 
(SB; 35-40 µm). Keratinocyte morphology was used to confirm each of these layers. Image 
analysis was done using Image J (Wayne Rasband, National Institutes of Health, USA). 
 
5.3.10 Data analysis 
The cumulative amount (Q, µg/cm²) of minoxidil and caffeine penetrating through an area of 
1.3 cm2 was plotted against time (h). The steady state flux, JSS (µg/cm²/h), was determined 
from the slope of the linear portion of the cumulative amount (Q) versus time plot.  
The maximum flux (Jmax) that would be applicable to saturated solutions can be estimated 
from the experimental steady state flux corrected for the known solubility in the formulation 
by Equation 1 (185)  
Jmax= JSS. SV / CV         Equation (1) 
Where SV is the solubility in the formulation and CV is the experimental concentration used. 
The permeability coefficient KP (cmhˉ¹) was calculated by Equation 2 below which is derived 
from Fick’s 1st law of diffusion (215). 
KP = JSS / CV                                                                                                   Equation (2) 
Where CV is the initial concentration of the model compound in the donor. 
The apparent diffusivity of solute in the skin divided by path length (D*) was calculated from 
the maximum flux and the solubility of the active compound in the stratum corneum 
according to Equation 3 (185). 
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D* = Jmax / SSC         Equation (3) 
Where SSC is the experimentally determined solubility of the solute in the stratum corneum.  
Hansen solubility parameters (HSPs) (D, P, H) for formulation excipients, solvents and 
active compounds were obtained from the software package HSPiP (JW solutions B.V., The 
Netherlands). The total solubility parameters were also obtained from HSPiP, according to 
the formula: 
total2 = D2 + P2 + H2         Equation (4) 
The cumulative amount, fluxes and transfollicular penetration per one hair follicle in the 
receiving solutions were calculated by the following equations which have been mentioned 
below: 
Cumulative amounts (µg/cm2) = 
𝑭𝑨 𝒐𝒑𝒆𝒏−𝑭𝑨 𝒃𝒍𝒐𝒄𝒌
𝟏.𝟑𝟑
 
Transfollicular penetration per one HF (µg/one HF) = 
(𝑭𝑨 𝒐𝒑𝒆𝒏−𝑭𝑨 𝒃𝒍𝒐𝒄𝒌)
𝒏𝒖𝒎𝒃𝒆𝒓 𝒐𝒇 𝑯𝑭
 
Where FA open was the caffeine amount in the open system, FA block was the caffeine 
amount in the block system and HF was the hair follicle. 
 
5.3.11 Statistics 
All experiments were analysed by one-way analysis of variance (ANOVA) with post-hoc 
comparisons (Tukey) using GraphPad Prism 6 (GraphPad Software Inc. La Jolla, CA92037, 
USA); P<0.05 was considered to be significant.  
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5.4 Results  
5.4.1 Cumulative amount of minoxidil in the receptor after 24h 
The cumulative amount of minoxidil penetrating the full-thickness human skin from 
formulations and controls are shown in Figure 5.1. The cumulative amount of minoxidil 
penetrating through human skin (µg/cm²) was plotted as a function of time (h) and the slope 
yielded the pseudo steady-state flux, JSS (µg/cm2/h) (Table 5.3). The permeability coefficient 
KP (cm/h) was calculated (Table 5.3). After 24 h exposure, the permeation of minoxidil 
delivered into the receptor from the nanoemulsion was significantly higher than the control 
(P<0.05). The highest permeation was seen with the formulation containing EU as the oil 
phase. However, all formulations were significantly higher than controls and there were no 
significant differences between OA and EU nanoemulsion formulations in the amount of 
minoxidil permeation after 24 h. 
 
Figure 5.1 Permeation profiles of minoxidil through excised human skin from nanoemulsions 
and controls (Mean ± SD, n=4) 
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Table 5.3 Transdermal permeation parameters and pH of the minoxidil from formulations 
and control (Mean ± SD, n=4) 
Formulation J
SS 
(µg/cm
2
/h) 
Kp X1E4 
(cm²/h) 
J
max 
(µg/cm²/h) 
D*  
(x104 cm/h) 
S
V 
(mg/mL) S
SC
 (mg/mL) pH 
C 1.9±0.1 0.9±0.0 3.3±0.2 0.8±0.0 34.7±2.7 44.3±4.6 7.2 
M1E 18.1±2.3 9.1±1.1 188.4±23.4 13.8±0.1 207.8±1.6 136.1±16.9 7.1 
M2E 12.7±1.9 6.3±0.1 179.9±27.1 12.5±1.8 283.4±2.3 143.9±13.4 7.2 
M3O 6.2±1.9 3.1±1.3 42.6±12.9 5.7±2.4 137.3±1.1 74.2±8.0 5.4 
M4O 6.9±1.2 3.5±0.5 52.8±9.0 7.0±1.2 152.1±1.3 75.1±5.7 5.9 
 
 
5.4.2 Amount of minoxidil in the stratum corneum and hair follicles 
The effect of nanoemulsion formulations on minoxidil penetration into the stratum corneum 
was assessed by tape stripping, is shown in Figure 5.2. Application of M1E M2E, M3O, 
resulted in more minoxidil being recovered in the stratum corneum than from control and 
M4O. The minoxidil recovered from follicular casting is also shown in Figure 5.2; more 
minoxidil was retained from the appendages after application of the formulation containing 
OA than EU, although both were higher than the control which contained 60% ethanol. 
However, the differences between these formulations (OA, EU) failed to reach statistical 
significance.  
 
 
 
 
 
 
Figure 5.2 Minoxidil retained in stratum corneum, hair follicles and skin layers (Mean ± SD, 
n=4) 
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5.4.3 Amount of minoxidil retained in the skin layers (viable epidermis and dermis) 
after 24h 
The amount of minoxidil retained in the skin after 24 h from nanoemulsion formulations and 
control is showed in Figure 5.2. Minoxidil retained in the skin from nanoemulsion 
formulations were significantly higher than control and were in this order M1E>M2E> M3O> 
M4O, the same pattern as receptor.  
 
5.4.4 Jmax estimated, solubility in the stratum corneum SSC and diffusivity (D*) and SV 
Maximum flux (calculated from steady state flux using Equation 1), permeability coefficient 
KP (calculated from Equation 2) and the apparent diffusivity D* (diffusivity divided by path 
length, from Equation 3) are shown in Table 5.3 (caffeine). Significantly enhanced fluxes 
were observed for minoxidil with the nanoemulsions compared to the control. Apparent 
diffusivity was also enhanced with the nanoemulsions 
To elucidate the mechanisms by which maximum flux was enhanced in these formulations, 
we examined the relationships between Jmax and some determinants of this parameter. As 
seen in Figure 5.3A, the stratum corneum solubility of minoxidil was enhanced by the 
nanoemulsions much more than that of the control (range, 34.7-283 mg/mL). Moreover, 
minoxidil increased stratum corneum solubility, which was associated with an enhanced flux. 
Figure 5.3B shows a clear relationship between effective diffusivity in the membrane and 
Jmax, indicating that the nanoemulsion formulations have affected the epidermis so that 
diffusivity also has become a major determinant for Jmax for this drug.  
In addition, minoxidil has shown no relationship between SSC and solubility in formulations 
(SV) for all nanoemulsion formulations (Fig 5.3C).  
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Figure 5.3 Minoxidil A - J
max 
values for all formulations versus solubility in the stratum 
corneum (S
SC
) (R
2
=0.77); B- J
max 
values for all formulations versus Diffusivity (D*) (R
2
= 
0.89); C- Solubility in the stratum corneum versus S
V; D- Solute uptake  versus total solubility 
parameters (yellow circle is control (60% ethanol/water), red is OA formulations and green 
is EU formulations). 
 
5.4.5 Minoxidil solubility in the vehicles 
The solubility of minoxidil in the formulations is also shown in Table 5.3. The solubility of 
minoxidil in the control (60% ethanol/water) was much less than in the corresponding values 
of the nanoemulsions. EU tended to enhance the stratum corneum solubility of minoxidil 
more than OA did. 
 
5.4.6 Solubility in the stratum corneum and solvent uptake.  
The solubility of caffeine in the stratum corneum for each of the different vehicles is shown 
in Table 5.3. There were significant differences between the stratum corneum solubilities of 
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minoxidil in the nanoemulsion vehicles compared to the control solution. We investigated 
the possibility that the stratum corneum solubility was determined by the uptake of the 
vehicle into the membrane, carrying solute with it. We explored whether vehicle uptake into 
the stratum corneum was related to the properties of the vehicle. Figure 5.3D shows solute 
uptake into the stratum corneum plotted against the total solubility parameter of the vehicle 
(total); we found that solvent uptake into the stratum corneum is greatest for those 
formulations where the total solubility parameter is lowest (Fig 5.3D).  
 
 
Figure 5.4 S
SC 
(predicted) versus S
SC 
(measured) (yellow circle is control (60% 
ethanol/water), red is OA nanoemulsion and green is EU nanoemulsion) 
We also attempted to predict solubility in the stratum corneum from solvent uptake (Fig 6.4), 
by assuming the solute was taken up by the stratum corneum partitions into a skin 
compartment from the vehicle, using the equation: 
SSC (predicted) = SSC (skin, control) + SV (vehicle) * Vup / VSC 
Where Vup is solvent uptake and VSC is the volume of the stratum corneum. SSC (skin, 
control) represents the solute in the skin compartment, derived from the experimental data 
for a control solution: 
SSC (skin, control) = SSC (exp, control) – SV (exp, control) * Vup (control) / VSC  
Where SSC (predicted) was plotted against SSC (experimental) versus experiment stratum 
corneum (Figure 5.4); a good relationship was found with minoxidil (R2=0.82). 
 
5.4.7 Cumulative amount of caffeine in the receptor after 24 h 
Two nanoemulsion formulations containing OA and EU as the oil phase and as penetration 
enhancers have been characterised and tested in a previous study and have been used in 
R² = 0.828
0
50
100
150
200
250
0 50 100 150
P
re
d
ic
te
d
 (
S S
C
)
SSC ( mg/mL) (experimental)
110 
the present study (Table 5.2). The cumulative amount of caffeine penetrating the full-
thickness human skin from open, normal and block hair follicles from these formulations and 
controls are shown in Figure 5.5A-C. The cumulative amount of caffeine penetrating through 
human skin (µg/cm²) was plotted as a function of time (h) and the slope yielded the pseudo 
steady-state flux JSS (µg/cm2/h) (Table 5.4). After 24 h exposure, the permeation of caffeine 
delivered into the receptor from the nanoemulsions was significantly higher than the controls 
(P<0.05).The highest permeation was seen from the open hair follicles Fig 5.5B. However, 
there were no significant differences between open and normal hair follicles in the amount 
of caffeine permeating after 24 h (Fig 5.5A&B). 
The caffeine flux from nanoemulsion formulation systems was higher than the controls. The 
caffeine flux from open hair follicles (OHF) was higher than from normal hair follicles (NHF) 
and block hair follicles (BHF) from ME formulation systems. The transfollicular penetration 
of caffeine from nanoemulsion formulations was also calculated and found to be higher than 
controls (Fig 5.6A&B) (Table 5.4). Also, the transfollicular flux was higher for nanoemulsions 
relative to controls (Table 5.4).  
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Table 5.4 The cumulative amounts (µg/cm2), fluxes (µg/cm2/h) and follicular penetration 
(µg/one hair follicle) by follicular closing technique and open hair follicle technique using 
Franz diffusion cells for 24 h from nanoemulsion formulations and controls.) 
Formulations C1 C2 MO ME 
Cumulative amount (µg/cm2) (NHF) 28.2±7 27.3±2.8 441.4±21.5 672.5±23.8 
Cumulative amount (µg/cm2) (OHF) 67.5±10 20.6±2.6 845.9±105 884.2±98 
Cumulative amount (µg/cm2) (BHF) 21.3±1.4 16.6±3.4 362.7±27 510.2±9.4 
Cumulative amount (µg/cm2) (N-BHF) 12.2 14.9 168.7 288.9 
Cumulative amount (µg/cm2) (O-BHF) 51.5 8.3 573.2 500.6 
Transfollicular per one HF (N-BHF) 1.7 2.1 24.1 41.3 
Transfollicular per one HF (O-BHF) 7.4 1.6 81.9 71.5 
Flux (NHF) 0.6±1 1.3±0.1 21.4±1 32.6±1 
Flux (OHF) 2.5 ±0.1 0.1±0.01 40.1±4.5 41.2±5 
Flux (BHF) 1.1±0.02 0.9±0.1 17.6±1.3 24.7±0.4 
Flux (N-BHF) 0.6 0.7 8.7 15 
Flux (O-BHF) 1.1 0.3 27.9 22.7 
Flux- Transfollicular per one HF (N-BHF) 0.1 0.9 1.2 2.1 
Flux- Transfollicular per one HF (O-BHF) 0.2 0.04 4 3.2 
 
HF = hair follicle; NHF = normal hair follicle, OHF = open hair follicle, BHF = blocked hair 
follicle (Mean±SEM, n=3); N-BHF = Contribution to permeation by all the hair follicles; 
O-BHF = Contribution to permeation by the open hair follicles. 
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A- 
 
B- 
 
C- 
 
Figure 5.5 Permeation profiles of caffeine through: A- normal excised human skin; B- 
Excised human skin (after opening the hair follicles); C- Excised human skin (after plugging 
the hair follicles) from nanoemulsion formulations and controls (Mean±SEM, n=3). 
MO (Nanoemulsion with oleic acid); ME (Nanoemulsion with eucalyptol); B (Blocked hair 
follicles). 
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A- 
 
B- 
 
Figure 5.6 Permeation profiles of caffeine through excised human skin: A- Contribution to 
permeation by all the hair follicles; B- Contribution to permeation by the open hair follicles 
from nanoemulsion formulations and controls (Mean±SEM, n=3). 
MO (Nanoemulsion with oleic acid); ME (Nanoemulsion with eucalyptol); N (Normal hair 
follicles). 
 
5.4.8 Amount of caffeine in the stratum corneum and in the hair follicles 
The effect of nanoemulsion formulations and controls from different techniques on caffeine 
penetration into the stratum corneum, which has been assessed by tape stripping, is shown 
in Figure 5.7 and Table 5.5. More caffeine has been recovered from the stratum corneum 
from nanoemulsions than from controls and similar pattern for both controls and 
nanoemulsions from all techniques.  
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Recovery of caffeine from follicular casting is shown in Figure 5.8 and Table 5.5; the amount 
of caffeine recovered from skin layers after application of formulations containing OA and 
EU was slightly higher than for controls. However, the amount of caffeine recovered from 
appendages after application of formulations containing EU and OA and controls from 
blocked hair follicles was lower than for other tests (open and normal hair follicles). 
5.4.9 Amount of caffeine retained in the skin layers (viable epidermis and dermis) after 
24 h 
The amount of caffeine retained in the skin after 24 h from nanoemulsion formulations and 
control and from open, normal and blocked hair follicles are shown in Figure 5.9 and Table 
5.5. The amount of caffeine retained in the skin from nanoemulsion formulations was 
significantly higher than controls and almost same for all tests (NHF, OHF, and BHF).  
Table 5.5 Amount of caffeine (µg/cm
2
) in different skin compartments for controls and 
nanoemulsion formulations.  
Formulations Retention in the stratum 
corneum 
Retention in the HF Retention in the Skin   
 NHF BHF OHF NHF BHF OHF NHF BHF OHF 
C1 52.4±5 49.6±5 52.8±3 7.7±2 4.5±1 4.8±1 63.1±12 39.4±6 30.9±4 
C2 39.5±3 35.8±6 30.7±2 1.5±0 3.8±1 4.2±1 58.8±13 25.9±6 41.0±11 
MO 113.2±15 128.2±18 115.0±30 12.5±1 12.1±1 15.6±3 623.5±49 713.3±83 724.2±50 
ME 108.7±24 111.3±10 95.2±15 14.0±2 8.5±2 14.1±1 874.0±58 868.1±48 886.0±150 
HF = hair follicle; NHF = normal hair follicle, OHF = open hair follicle, BHF = blocked hair 
follicle (Mean±SEM, n=3).  
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Figure 5.7 Caffeine retained in the stratum corneum from nanoemulsion formulations and 
controls after 24 h (Mean ± SEM, n=3) 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8 Caffeine retained in the hair follicles after topical administration of nanoemulsion 
formulations & controls up to 24 h (Mean ± SEM, n=3) 
N = normal hair follicle, O = open hair follicle, B = blocked hair follicle 
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Figure 5.9 Caffeine retained in the viable epidermis and dermis from nanoemulsion 
formulations and controls after 24 h (Mean ± SEM, n=3) 
N = normal hair follicle, O = open hair follicle, B = blocked hair follicle 
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5.4.10 Multiphoton microscopy imaging to evaluate follicular blocking technique and 
assess the penetration of model fluorescent dye (Acriflavine) 
Figure 5.10 illustrates representative images of normal, open and blocked follicles. When 
the area around the follicle was imaged, both open hair follicles and normal hair follicles 
showed cellular uptake of acriflavine in the viable layers. The EU nanoemulsion showed 
uptake of acriflavine when follicles were unmodified while the OA nanoemulsion showed 
acriflavine uptake into the viable cells with the follicles being opened. However, when the 
follicles were blocked no visible uptake of acriflavine was seen in the viable cells from either 
of the emulsions or the control.  
 
5.5. Discussion 
Nanoemulsions are composed of non-ionic surfactant (Volpo-N10) which is nontoxic and 
two types of oil (OA and EU) which are themselves penetration enhancers (188, 216-218). 
In order to assess the effect of these nanoemulsion formulations of minoxidil on the 
accumulation and permeation through the skin, an in vitro study was carried out using full-
thickness human skin and Franz diffusion cells. The results of this study were similar to a 
study done by Grice et al in 2010, in which they found that the minoxidil recovery from 
appendages was of the same order as the cumulative amount of minoxidil penetrating 
through the skin (45). In the current work, it was found that at early on in the experiments 
the effect of formulations were similar to that of the control, but a change occurred after 4 h 
similar to the Grice et al finding, and also similar to another study by Patois et al in 2011, 
which showed that minoxidil penetrated excised pig skin after 6 h, suggesting that the dermis 
has a longer lag time for penetration in the receiver (219). Our results showed that after 24 
h only a small amount of minoxidil reached the receptor fluid. In 2011, Mura et al also found 
that only small amount of minoxidil reached the epidermis after 8 h (220). The pH value of 
skin is between 4.2 – 6.1, applied formulations outside of these pH values may lead to skin 
damage (219). For the nanoemulsion formulations having EU as oil phase, the pH was 
around 7.2 and the ionisation of minoxidil may have contributed to a high skin accumulative 
profile from this formulation as the skin has a positive charge. However, the pH of 
nanoemulsions with OA are at skin range (~5.4); these results are similar to Padois et al 
findings (219). This study used ethanol as a co-surfactant and also the control contained 
60% ethanol, therefore evaporation of the solvent could increase the viscosity of the vehicles 
and reduce the solubility of minoxidil in the skin and thermodynamic activity of the drug in 
the vehicles, (especially the control) and permeation (221) (222). Incorporation of minoxidil 
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in O/W nanoemulsion formulations increased the penetration drug flux significantly (3- to 9-
fold), compared with the control (Table 5.3), and these results are consistent with other 
results that have been done to evaluate the transdermal delivery of several hydrophilic and 
lipophilic drugs from nanoemulsion formulations (223). The mechanism for this increase is 
due to increased solubility of these solutes in the stratum corneum (SSC) and also by 
increased D* across the skin (Table 5.3). Our study also focused on the relationship between 
Jmax and SSC, D*. A unique finding in this work is the linear relationship between Jmax and SSC 
and D* from all formulations (Figure 5.3A&B). Similarly, Zhang et al showed a linear 
relationship between Jmax and SSC for phenolic compounds (108). OA and EU are well known 
penetration enhancers. It is believed that OA provides high permeation due to its cis double 
bond at C9 which causes a kink in the alkyl chain and disrupts the skin lipid (224). Although 
skin lipid is also disrupted by the nanoemulsion and shows enhanced penetration, it acts as 
a solution (224). This could be contributed to a low percentage of enhancing chemicals 
compared to the percentage in other formulations. So, the compounds of the vehicle are as 
important as the structure of the vehicle (225). EU is believed to act by changing intercellular 
lipid, disrupting the lipid structure organisation and increasing fluidisation which leads to 
increased diffusivity of the drug (159). A study done by Obata et al in 1991 (226) suggested 
that ethanol combined with relatively hydrophilic terpenes such as EU have a much greater 
enhancing effect than lipophilic terpenes. It is also claimed that polar terpenes such as EU 
could provide better enhancement for hydrophilic drugs than hydrocarbon terpenes such as 
R-(+)-limonene (227, 228). In our study nanoemulsion formulations with EU gave the highest 
permeation of minoxidil: these results are consistent with the microemulsion results 
conducted with curcumin by Liu et al (2010). They reported that terpenes have a different 
mechanism to enhance transdermal drug delivery: the first possibility proposed was that EU 
enters the skin as a monomer to increase the solubility of drug in the skin, increases the 
partitioning of drug in the skin and creates high drug concentration in the upper layers of the 
skin (189). Our study agrees with this mechanism as the solubility of minoxidil from EU 
nanoemulsions has a higher solubility in the stratum corneum than that of OA formulations. 
Another mechanism depended on the direct drug transfer from nanoemulsion droplets to the 
stratum corneum (189).  
We showed in Figure 5.3D that the solute uptake into the stratum corneum was associated 
with the HSPs of the vehicles. This suggests that the vehicle acts as a carrier for the solute 
into the stratum corneum.  
We also examined whether the uptake solvent of solutes into the stratum corneum may be 
related to the solubility of the solutes in the stratum corneum. Figure 5.4 suggests that our 
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solubility model has good correlation between the predicted SSC and measured SSC for 
minoxidil, as it provides a linear shape with (r2= 0.82). This supports the hypothesis that the 
enhanced minoxidil permeation in this study is mainly due to an increased solubility of the 
compounds in the skin (modified stratum corneum solubility). The model here is to induce 
the idea that the solubility of a solute in the skin can be correlated to its solubility in the 
formulations and the amount of vehicle absorbed by the stratum corneum: our finding is 
supported by Zhang et al (108). 
In the second part of the study, the penetration of substances into the skin occurred by two 
main ways; the transfollicular and transepidermal (transcellular and intercellular) penetration 
routes (229). This study used the normal hair follicles, opened hair follicles and blocked hair 
follicles skin system. The penetration across open hair follicles presented two methods of 
penetration, the transfollicular and transepidermal, while, the blocked hair follicles presented 
only the transepidermal route. The different flux between open, and blocked hair follicles 
skin was determined as the transfollicular penetration flux. 
The caffeine loaded nanoemulsions were investigated for penetration in stratum corneum 
and in hair follicles of human skin. A study by Ogiso et al in 2002 suggested that hair follicles 
play an important role in penetration and reservoir processes (230). Cyanoacrylate skin 
surface biopsy was performed to investigate the transfollicular drug delivery (Fig 5.5) as this 
method provides selective qualitative and quantitative penetration of topically applied drugs 
into the hair follicles (15). The amount of caffeine permeating the stratum corneum was 
removed using tape stripping. Then, the follicular contents were removed by cyanoacrylate 
skin surface biopsy. The caffeine permeating the rest of the skin was measured by mincing 
and extracting the stripped skin. The transfollicular flux from nanoemulsion formulations was 
higher than from controls. A study by Bhatia et al in 2013 on adapalene penetration in 
porcine ear skin suggested that increased water content in the nanoemulsions, increased 
the amount of drug in the stratum corneum and in the hair follicle (231). As the nanoemulsion 
formulations in the study are O/W nanoemulsions, the finding of this study was consistent 
with Bhatia et al’s findings. The mechanism of permeation enhancement with ME 
formulations may be because of increase partitioning and diffusion of caffeine into the 
stratum corneum. Hair follicles provide an attractive site in dermatology and can act as long 
term reservoirs for topical application (232), whereas, drugs located in the uppermost cell 
layers of the stratum corneum, are continuously depleted because of the physiological 
process of desquamation (231), which suggest, that the stratum corneum provides only a 
short term reservoir function. Drug depletion in hair follicles occurs primarily through the 
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slow process of sebum production and hair growth (14), (233). Colloidal systems such as 
microemulsions have demonstrated good potential for targeting hair follicles. The present 
study indicates that nanoemulsions with penetration enhancers (OA and EU), not only 
increase the permeation through the stratum corneum, but also demonstrate optimal 
penetration into the hair follicles. The flux of caffeine in the stratum corneum increased from 
2.5 (µg/cm2) ± 0.1 in control (C1) to 40 (µg/cm2) ± 4.5 with OA and 41 (µg/cm2) ± 5 in EU 
nanoemulsions and the penetration in the hair follicles also increased from 0.2 (µg/cm2) in 
control (C1) to 4 and 3.2 (µg/cm2) with MO and ME, respectively. Therefore, nanoemulsions 
were able to penetrate the hair follicle and increased the transfollicular caffeine penetration. 
Faster absorption of caffeine was detected after 24 h when the hair follicles were open. 
Otberg et al (234) conducted a similar study on caffeine in vivo and found that artificial 
blocking of hair follicles led to passage through the interfollicular epidermis and its lipid 
domain only and possibly through sweat glands. Blocking hair follicles led to prolonged time 
for caffeine to penetrate the skin (234). The same study suggested that hair follicles can be 
an important route for chemical compounds. This study also finds that hair follicles should 
not be ignored in the development and optimisation of topically applied drugs and cosmetics. 
The present study was only with caffeine, which is a model hydrophilic compound. The novel 
follicular plugging method we developed was very effective in visualisation of the blocked 
follicles both under the optical microscope while plugging and also allowed multiphoton 
imaging to evaluate the penetration into and around the hair follicles. The increase in 
observed acriflavine penetration was similar to the increase in caffeine penetration from the 
Franz cell studies. Acriflavine stained the nuclei of the cells consistent with other 
unpublished studies conducted. As with the follicular casting studies where the amount of 
caffeine present in the hair follicle was calculated, we imaged the area of the hair follicle and 
the skin around the hair follicle and observed a large amount of acriflavine (hydrophilic model 
compound) present in the follicle and sweat glands. We also observed that when the follicles 
were blocked off by the cyanoacrylate and acriflavine blocking procedure, the intercellular 
area of viable layer cells seemed to have taken up some of the acriflavine delivered through 
the OA nanoemulsion. However, the staining was unlike the nuclear staining observed 
previously and was more localised around the cells. Further studies will be needed to further 
understand this interesting observation and also to evaluate the effect of hair follicles on 
percutaneous penetration of other compounds with different physicochemical properties.  
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Figure 5.10 Skin images after applying nanoemulsion formulations and controls. 
 
  
τm (0-2000 ps) 
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5.6 Conclusion  
In short, from these results for minoxidil transdermal penetration, we found that O/W 
nanoemulsions containing OA and EU as oil phase and penetration enhancers were highly 
effective in vitro. The transdermal flux of minoxidil increased 3~ 9-fold in contrast to the 
control. Moreover, transport by the appendages can be a valuable route for minoxidil. The 
mechanism of penetration from these formulations is by increasing the partitioning and 
diffusivity of minoxidil in the stratum corneum. The results obtained from the transfollicular 
study demonstrate that nanoemulsion formulations are not only promising vehicles for 
transdermal delivery but also transfollicular delivery of the hydrophilic drug caffeine. The 
imaging results from the skin confirm this finding that the hydrophilic model penetrated the 
hair follicles. Therefore, further study of these advanced formulations and their mechanism 
of action is needed in order to find suitable and safe formulations for transdermal and 
transfollicular delivery of different lipophilicity drugs. 
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Chapter 6 
A comparison of the penetration and permeation of caffeine into and through human 
epidermis after application of various vesicle formulations 
 
6.1 Abstract 
A range of vesicles is now widely used to carry various solutes into and through the 
epidermis. These usually have the active solute encapsulated within and may be modified 
to confer flexibility and skin penetration enhancement. Here, we compared the ability of five 
different vesicle systems to deliver a model hydrophilic drug, caffeine, into and through 
excised human skin. In addition to lipids, the vesicle excipients included eucalyptol (EU) or 
oleic acid (OA) as penetration enhancers, and decyl polyglucoside (DPGluc) as a non-ionic 
surfactant. Vesicle particle sizes ranged between 135 and 158 nm and caffeine 
encapsulation efficiencies were between 46% and 66%. Caffeine penetration and 
permeation was measured using HPLC. We found that niosomes, which are liposomes 
containing a non-ionic surfactant and transferosomes (ultraflexible vesicles) showed 
significantly greater penetration into the skin and permeation across the stratum corneum. 
Significant enhancement of caffeine penetration into hair follicles was found for 
transferosomes and those liposomes containing OA. 
We conclude that targeted delivery of the hydrophilic drug, caffeine, into the skin 
compartments can be modified using optimised vesicular formulations. 
 
6.2 Introduction 
Topical drug delivery offers specific benefits over other administrative routes for local action 
but the barrier nature of the skin presents a major obstacle for many drugs delivered into 
and through it (235). Chemical strategies to reduce the effect of the barrier include the use 
of penetration enhancers, such as OA or octyl salicylate, and the use of more advanced 
colloidal systems such as microemulsions, solid lipid nanoparticles and nanostructured lipid 
carriers. Liposomes are hollow spheres comprising phospholipid and an aqueous phase.  
Hydrophilic drugs may be inserted in the aqueous compartment while lipophilic drugs can 
be sequestered in the phospholipid. Many excipients including lipids, surfactants and 
solvents have been added to improve the stability or other structural features of liposomes 
(236). Cholesterol tends to make the liposome membrane less permeable by filling up holes 
or disruptions (236). Jacobs et al (237) speculated that liposomes may either form a thin 
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lipid film on the surface of the skin, so that water loss is retarded, or combine with 
intercellular skin lipids to form liquid-crystalline matrices in the uppermost skin layers.  
Various forms of liposomes exist. Transferosomes are defined as vesicular particles 
composed of phospholipids and surfactants such that the inner aqueous compartments are 
surrounded by a highly elastic and adaptable lipid bilayer (238). They are metastable, 
making them able to enter pores smaller than their size (239). They present a more flexible 
transport system with improved vesicular stability and the potential to be used with diverse 
active components (240). The flexibility is contributed in part to their relatively high 
membrane hydrophilicity, which gives the membrane the ability to swell more than, for 
example, conventional liposomes. Like liposomes, transferosomes are unilamellar or 
multilamellar structures (241) and contain a surfactant as an edge activator (242, 243). 
Niosomes are uni- or multi-lamellar spheroidal structures containing a mixture of cholesterol 
and non-ionic surfactants such as alkyl ethers, esters or amides (221, 244). They have been 
assessed as an alternative drug delivery system compared to conventional liposomes.  
Niosomes offer higher physical and chemical stability (245) and a great variety of surfactant 
choice (246). It is claimed that for topical applications, niosomes can increase the time of 
drug residence in the stratum corneum and epidermis whilst decreasing drug systemic 
absorption (246). Another study observed structural changes in the lipid interstitial spaces 
of the stratum corneum after exposure of the skin to niosomes and suggested that these 
changes may be responsible for the resultant enhanced penetration (247).  
Skin appendages provide an alternative route for drug penetration through the skin. 
Pertinent to drug penetration via hair follicles, the follicular infundibulum provides an 
increase in the surface area, acting as a reservoir, and represents, at the lower end, an 
interruption of the stratum corneum barrier (248). Some studies have focused on direct 
targeting of hair follicles, such as with compounds for acne and alopecia therapies. Many 
attempts have been made to measure substances retained in the hair follicles after topical 
administration of model compounds such as dyes (249) and nanoparticles (213); however, 
little has been done with therapeutic agents and this subject requires further investigation 
(250).  
This study aimed to investigate the feasibility of vesicle (liposome, transferosome and 
niosome) structure to improve the delivery of the hydrophilic drug caffeine into appendages, 
stratum corneum and through human skin. Differential stripping (40) or tape stripping is a 
useful technique that allows measurement of the amount of solute retained in the stratum 
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corneum and of the amount of follicular retention by follicular casting. In order to target a 
particular skin site after topical application, the formulation of caffeine was manipulated. 
Liposome, transferosome and niosome formulations were prepared by the thin film-
hydration (TFH) method using DLPC and cholesterol (as lipid) and OA, EU, or DPGluc as 
edge activators.  
 
6.3 Materials and Methods 
6.3.1 Materials 
Caffeine, OA, EU, ethanol, cholesterol, dilauroyl L-α-phosphatidylcholine (DLPC, CAS # 
18194-25-7) were obtained from Sigma-Aldrich Pty. Ltd. (Sydney, Australia).  DPGluc (sold 
as Oramix NS 10) was obtained from SEPPIC SA (France). All chemicals and solvents were 
of analytical grade. 
 
6.3.2 Vesicle preparation 
Six different vesicles were prepared, with excipient mixtures as shown in Table 6.1. For all 
vesicles, the excipients were mixed in a rotary flask in the ratios shown, followed by glass 
beads (4 g) and chloroform (3 mL) treatments. Once the lipids were dissolved, the solvent 
was gradually evaporated on a rotary evaporator at 30°C until a lipid film formed on the wall 
of the flask. The flask was set aside for 2 h to eliminate residual chloroform, after which the 
lipid film was stirred with 2 mL caffeine solution (2% in water) for 2 h at 30°C. The liposome 
suspensions were extruded through a polycarbonate membrane with pore size 100 nm using 
the Liposofast extruder (AVESTIN, Inc., Ottawa, Canada). Thirty-one cycles of extrusion 
were performed for each vesicle type. 
 
6.3.3 Vesicle characterisation 
The average particle diameter, polydispersity index  (PDI) and zeta potential of the vesicles 
were measured with a Zetasizer Nano ZS (Malvern Instruments, Ltd, Malvern UK). Each 
sample was measured three times and the mean value was calculated.  
 
6.3.4 Caffeine encapsulation efficiency 
To separate the non-encapsulated drug, the vesicle suspensions were centrifuged at 14000 
rpm for 30 min at room temperature. The amounts of caffeine in the supernatant and also in 
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the clear solution were analysed by high performance chromatography (HPLC). Drug 
encapsulation efficiency (EE%) was calculated as:  EE% = 100* mass of incorporated drug/ 
total mass in vesicle preparation.  
 
6.3.5 Caffeine skin permeation studies 
Permeation studies using full-thickness human abdominal skin were performed in Franz 
diffusion cells with an effective diffusion area of 1.33 cm² and a 3.4 mL receptor chamber 
volume. The skin was provided by a female donor following elective surgery, with ethical 
approval granted by The University of Queensland Human Research Ethics Committee 
(Approval No. 2008001342). The skin was cut into discs and mounted in Franz diffusion 
cells with the stratum corneum side facing upwards. The receptor contained PBS buffer (pH 
7.4) at 35°C. A volume of 160 µL of the vesicle formulations and the control solution was 
applied to the surface of the skin and the donor chamber was covered in parafilm for the 
duration of the experiment to inhibit water evaporation. Several times over a 24 h period, 
200 L of the receptor was withdrawn and replaced with the same amount of fresh PBS 
buffer. After 24 h, the sample was taken, the cells dismantled and the skin in each cell was 
wiped with cotton buds to remove any remaining formulation. Up to 20 tape strips were then 
taken from each skin sample (D-Squame tapes, CuDerm Corp., TX). The tapes were placed 
into separate vials and mixed overnight with 2 mL methanol to extract the caffeine removed 
from the stratum corneum by the tapes. Follicular casting was performed after tape stripping. 
One drop of superglue (LOCTITE®, Henkel Australia) was placed on a microscope slide 
and pressed onto the surface of the stripped skin with light pressure for 15 min. The slide 
was peeled carefully from the skin and the superglue containing caffeine sampled from the 
follicles was dissolved by rubbing four times with acetone–soaked cotton buds. The cotton 
buds were mixed overnight with 2 mL methanol. After follicular casting, the skin was 
chopped into small pieces, homogenised and mixed overnight with 2 mL methanol. Receptor 
fluid and extracts from tapes, casts and skin were analysed by HPLC. 
 
6.3.6 Sample analysis 
Caffeine was analysed by a sensitive and rapid HPLC method. The HPLC system consisted 
of a Shimadzu SIL-20 a HT, CBM-20A system controller, a SPD-20A detector, LC-20AD a 
pump and an auto injector. Isocratic separation was performed on a Phenomenex Luna C18 
5μ (150×4.6 mm) column using 95% water, 2% acetonitrile, 2% tetrahydrofuran and 0.5% 
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acetic acid as the mobile phase, at a flow rate of 1 mL/min. Caffeine was detected at 273 
nm. 
 
6.3.7 Data analysis and Statistics 
The cumulative amount (µg/cm²) penetrating per skin surface area was plotted against time 
(h). The steady state flux JSS (µg/cm²/h) was derived from the slope of the linear portion of 
the cumulative amount versus time (t) plot. 
All data were analysed by one-way analysis of variance (ANOVA) with post-hoc 
comparisons (Tukey) using GraphPad Prism 6 (GraphPad Software Inc. La Jolla, CA92037, 
USA); P<0.05 was considered to be significant.  
 
6.4 Results 
6.4.1 Vesicle characterisation 
Particle size, polydispersity indices (PDI), zeta-potentials and caffeine encapsulation 
efficiencies of all vesicles are presented in Table 6.2. As shown by the low PDI values, all 
vesicles had a narrow size distribution. The high negative zeta potential values for both 
niosomes and the liposomes containing OA indicate that these materials, in particular, would 
be stable in suspension. The encapsulation efficiencies were relatively similar across the 
five vesicle types. 
 
6.4.2 Permeation of caffeine from vesicles and control 
The cumulative amounts of caffeine penetrating full-thickness human skin from each of the 
test formulations over 24 h are shown in Figure 6.1 and overall steady-state fluxes calculated 
from these plots are shown in Table 6.3. Niosomes and transferosomes had significantly 
greater fluxes than other formulations, as indicated. 
Other skin permeation parameters for caffeine from the six applications are illustrated in 
Table 6.3 and Figure 6.2. Penetration of caffeine into the receptor was significantly 
enhanced from the niosomes (N), compared to the aqueous control solution (C) and the 
liposomes (L, LEU, LOA) and from the transferosomes (T), compared to control (C) and the 
basic liposomes (L). In addition, total skin penetration (stratum corneum, hair follicles, 
residual skin and receptor solution) was significantly enhanced by niosomes compared to 
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control (C) and the basic liposomes (L). Caffeine recovered from hair follicles after 
transferosome application was 50% more abundant than with LOA and more than twice that 
seen in all other formulations, although the differences did not reach statistical significance 
(P=0.10, T vs. C). Similarly, stratum corneum and skin retention were enhanced with the 
advanced formulations (niosomes, transferosomes and to a lesser extent, the liposomes 
containing penetration enhancers EU and OA) but differences did not reach statistical 
significance. 
 
6.5 Discussion 
The nano size range of the vesicles used in this study (128-158 nm) makes them suitable 
for topical delivery. We (251) and others (252) have shown that by decreasing the vesicle 
size, the penetration of the encapsulated drug into deeper skin layers can be enhanced. 
Further reductions in vesicle size could be achieved by extrusion through smaller 
membranes, particularly with ultraflexible materials such as transferosomes and 
SECosomes (251). In addition to the narrow range of nano sizes in our series of vesicles, 
the individual vesicles were shown to be homogeneous, as indicated by the low PDI values 
(0.05 to 0.15). However, given this homogeneity in particle size seen across the range of 
vesicle formulations, it is likely that factors other than particle size contributed to the 
observed differences in caffeine flux and retention in skin compartments (Table 6.3, Figs. 
6.1 and 6.2). Regarding the zeta potential, LOA, N possessed a negative surface charge 
(Table 6.2) while LEU, T and L dispersion possessed a neutral charge, indicating that the 
incorporation of edge activators into liposomes had an important influence on their surface 
charge.  
The encapsulation efficiencies seen here (46–66%) compare well with 30% found by Budai 
and coworkers (253) for solid lipid nanocarriers based on soy or egg lecithin. Because 
caffeine log p is -0.07 (KOW =0.85) it is reasonably soluble in both water and lipophilic 
solvents. Therefore, it is able to enter both hydrophilic and lipophilic regions of the vascular 
structure (254). The caffeine encapsulation efficiency was highest in the liposomes 
containing EU. This may be due to the relatively hydrophilic nature of EU which results in 
low permeability of vesicles. 
Optimised vesicular systems can exert different functions upon topical delivery (255). They 
can improve drug deposition in the skin at the site of action, with the additional goal of 
decreasing systemic absorption and thus minimising adverse effects (133). They may also 
provide targeted delivery to skin appendages. In an attempt to find a vesicular formulation 
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for topical delivery of caffeine, vesicular systems were formulated using OA, EU and decyl 
polyglucoside (DPGluc) as edge activators. OA and EU are well known penetration 
enhancers (256). DPGluc is a low irritant, non-ionic surfactant that is commonly used in 
pharmaceutical and cosmetic formulations and can form vesicles including niosomes in 
combination with appropriate amounts of cholesterol (257). 
In this work, all formulations were able to achieve sustained delivery of caffeine into and 
through the skin over 24 h, with no depletion of the donor material. As a percentage of the 
total applied drug dose, total caffeine delivery ranged from 6.6% and 7.4% for the aqueous 
solution and the conventional liposomes, up to 14.9% and 16.0% for the transferosomes 
and niosomes, respectively. The greatest flux was seen for transferosomes and niosomes, 
with apparent flux increases between 12 and 24 h for these formulations. Interestingly, these 
were the vesicles containing DPGluc as edge activators. This hydrophilic surfactant has also 
been shown to act as a penetration enhancer for dermal delivery of tretinoin when 
incorporated into liposomes (258), while other non-ionic surfactants cause similarly 
enhanced permeation fluxes, for example, with lidocaine (259). A relatively constant flux 
after about 8 h was seen with the other formulations, including the liposomes containing EU 
and OA. Given the relatively moderate enhancement of caffeine penetration seen with these 
latter vesicles, it seems likely that their actions as penetration enhancers in those 
formulations were not important factors. The combined functions of surfactant edge activator 
and penetration enhancer would appear to explain the relative enhancement seen with 
DPGluc. While their work relates to the more lipophilic oestradiol, it is interesting to compare 
the findings of El Maghraby et al (260), where greater penetration was seen with surfactant-
containing liposomes than with OA as a penetration enhancer alone. The authors suggested 
that liposomes increased oestradiol permeation by mechanisms that are additional to 
penetration enhancing effects. 
The niosomes and transferosomes also showed greater skin retention than other 
formulations. In particular, penetration into hair follicles from transferosomes appeared to be 
enhanced. The ultradeformable nature of these vesicles may allow them to gain access to 
these appendages more readily. Motwani et al (261) suggested that polar drugs delivered 
from vehicles which are poorly miscible with sebum will have little chance to reach deeper 
parts of the hair follicles. On the other hand, lipophilic vehicles may assist the transport of 
drugs dissolved in the oil phase and into the pilosebaceous units (244). Therefore, 
enhancement of follicular penetration would rely on the solubility of drug in the formulation 
and the compatibility of the formulation with the lipid environment of the sebum (261).  
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One way in which the non-ionic surfactant could enhance solute transfer from vesicles into 
the skin could be to assist in absorption and fusion of the vesicle to the skin surface. This 
could maximise the ability of the vesicle to structurally modify the barrier properties of the 
skin, allowing the solute to pass more readily from its encapsulated environment into the 
intercellular regions of the stratum corneum. Studies (132, 262, 263) conclude that: a) 
absorption and fusion of niosomes and transferosomes into the surface of skin will enhance 
drug permeation; b) the vesicles act as penetration enhancers to reduce the barrier 
properties of the stratum corneum; and c) the lipid bilayers of niosomes act as a rate limiting 
membrane barrier of solutes (264). The possible mechanism for liposome and niosome 
formulations is structural modification of the stratum corneum. For transferosomes, both 
phospholipid (DLPC) and non-ionic surfactant (e.g.,DPGluc) can act as penetration 
enhancers, which are valuable for increasing the penetration of many drugs. These results 
suggest that the mechanism of drug transport across skin depends on the compositions of 
the vesicle formulation and the solute used. 
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 Table 6.1. Liposome formulations showing excipient ratios and aqueous control 
composition. All formulations contained caffeine, 2% w/v. 
 
Table 6.2. Vesicle system characterisation and encapsulation efficiency (mean ± SD) 
 
Name Description Composition 
C Aqueous control solution 100% Water 
L Conventional liposome DLPC:cholesterol 35:7 
LEU Conventional liposome + eucalyptol DLPC:Eucalyptol:cholesterol 35:7:7 
LOA Conventional liposome + oleic acid DLPC:Oleic acid: cholesterol 35:7:7 
T Modified liposome  Transferosome DLPC:DPGluc:cholesterol 35:7:7 
N Modified liposome  Niosome DPGluc:cholesterol 35:735:7 
Formula 
Vesicle size 
(nm) 
PDI Zeta potential Encapsulation 
efficiency % 
L (liposomes) 137.1±1.3 0.06±0.03 2.3±0.7 48 
LEU (liposomes + EU) 142.3±2.3 0.10±0.01 -9.5. ±0.5 66 
LOA (liposomes + OA) 128.4±1.9 0.08±0.02 -51.0±2.7 50 
T (transferosomes) 158.3±4.0 0.14±0.04 -18.3±0.2 47 
N (niosomes) 135.2±2.3 0.15±0.02 -42.6±2.4 46 
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Figure 6.1. Permeation profiles of caffeine through excised human skin from various vesicle 
systems and a control; (Mean ± SEM, n=4).  
 
Table 6.3 Permeation parameters following 24 h application of caffeine from vesicle 
formulations and controls to full-thickness human skin (Mean ± SD, n=4).  
Formula 
JSS 
(µg/cm²/h) 
SC 
retention 
(µg/cm²) 
Hair follicles 
(µg/cm²) 
Skin 
retention 
(µg/cm²) 
Receptor @ 
24h(µg/cm²) 
Total 
(µg/cm2) 
C (Control) 0.7±0.2 17.3±4.2 0.8±0.2 48.4±7.8 14.2±4.1 80.7±12.4 
L (liposomes) 1.4±0.4 24.7±4.1 1.7±0.4 51.7±12.7 28.7±4.3 106.7±20.5 
LEU (liposomes + EU) 1.8±0.7 32.8±5.1 1.6±0.4 95.7±11.0 35.8±15.8 166.0±26.8 
LOA (liposomes + OA) 1.7±0.2 39.4±6.4 3.5±0.7 93.5±7.8 34.9±3.3 147.9±30.7 
T (transferosomes) 4.1±0.8* 66.4±25.9 5.3±3.3 85.7±28.5 85.5±20.3* 242.9±77.6 
N (niosomes) 6.6±0.6** 70.7±28.9 2.2±0.5 103.4±7.8 135.0±13.3** 285.3±50.8* 
The total shown is the sum of retention in the stratum corneum (SC), hair follicles, residual 
skin and receptor penetration. 
Significant differences (1-way ANOVA/Tukey): *versus Control solution (C) and Liposomes 
(L); **versus Control solution (C), Liposomes (L), Liposomes +EU (LEU), Liposomes + OA 
(LOA) 
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Figure 6.2. Caffeine recovery from the stratum corneum (SC), hair follicles, residual skin 
and receptor solution after application of vesicles and control for 24h (Mean ± SEM, n=4).  
aAmount in receptor at 24 h; Transfersomes > Control solution (C] and Liposomes (L);  
bAmount in receptor and total penetration at 24 h; Niosomes > Control solution (C), L = 
Liposomes, LEU = Liposomes +EU, LOA = Liposomes + OA. (1-way ANOVA / Tukey) 
 
6.6 Conclusion  
The in vitro permeation of caffeine from vesicles with different compositions of penetration 
enhancers and non-ionic surfactants have been studied and evaluated. Incorporating the 
non-ionic surfactant DPGluc into liposomes enhanced skin penetration of caffeine more than 
the penetration enhancers OA and EU. The results suggest that fusion of the vesicles with 
the lipid of the stratum corneum and direct transfer of solute from the vesicle formulations to 
the skin may contribute to the mechanism of drug permeation enhancement by 
transferosomes and niosomes. The overall results indicate that the presence of penetration 
enhancers in the vesicle components is not the important operating factor.  
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Chapter 7 
 
Conclusion and Future Directions 
Skin delivery offers many benefits over conventional routes of administration. However, the 
barrier nature of the stratum corneum presents an important issue for many drugs to be 
delivered into and through the skin (2). Hence, many strategies have been used to overcome 
the skin barrier. Penetration enhancers have been claimed to improve drug delivery and can 
be used as oil phase or edge activators in advanced formulations such as microemulsions 
and liposomes. This thesis started with using penetration enhancers with simple solutions 
to explore the relationship between skin penetration maximum flux to the skin solubility for 
different vehicle compositions. Then, I extended this approach by incorporating these 
penetration enhancers into advanced formulations (microemulsions and vesicle systems) to 
investigate their effect on skin permeation of model compounds. The third aim was to 
investigate the effect of these penetration enhancers on follicular penetration of model 
compounds.  
 
7.1 Conclusion 
7.1.1 Effect of Penetration Enhancers; Solution Studies 
This study has shown that the permeation of caffeine, minoxidil, lidocaine and naproxen 
were enhanced by specific vehicles that interacted with the skin (OA, EU, SLS and ethanol). 
The greatest effects were seen on flux and diffusivity by the EU and OA vehicles on the 
more hydrophilic compounds, caffeine and minoxidil. Enhancements in stratum corneum 
solubility were predicted by experimentally determined uptake of solvent and solute. We 
concluded that enhanced solute fluxes were mainly driven by increased diffusivity in the 
stratum corneum, likely to be due to greater lipid fluidisation caused by the enhancers. Much 
evidence in the literature suggests that vehicles can act by promoting partitioning of the skin. 
The solubilities in the stratum corneum depend on the amount of vehicle absorbed in the 
stratum corneum and the amount of solutes dissolved in the vehicles. 
In the pretreatment study, there was enhancement of caffeine flux following pretreatment 
with penetration enhancer vehicles of the heat separated epidermis. Enhancement could be 
related to Hanson solubility parameters of the vehicle. Calibration of the solute flux and its 
solubility in the stratum corneum data is a simple novel plotting procedure that separated 
and quantified the effects of the vehicle on solute partition and diffusion. The treatment and 
pretreatment results indicate that enhancement is related mainly to an increase in partition 
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into the skin with an increase in diffusivity. The diffusivity obtained for all compounds, was 
unaffected by the inert control vehicles (controls) supporting the notion that Jmax is 
determined by stratum corneum solubilities and not diffusivity. More investigations are 
needed to understand the behaviours of different types of actives, and vehicles on the skin 
to design a cosmetic and dermatological product with high strength and fewer side effects. 
 
7.1.2 Synergistic skin penetration enhancer and nanoemulsion formulations promote 
the human epidermal permeation of caffeine and naproxen  
Nanoemulsions can be formed from different aqueous, surfactants, co-surfactants and oil 
components. They are commercially feasible, simple and convenient vehicles to enhance 
delivery of hydrophilic and lipophilic compounds with few side effects. The objective of this 
study was to investigate the effect of nanoemulsions on improving the skin delivery of a 
model hydrophilic (caffeine) and a lipophilic compound (naproxen). The nanoemulsions 
were formulated with oleic acid (OA) and eucalyptol (EU) as penetration enhancers for both 
caffeine and naproxen. Extensive physicochemical characterisation was undertaken to 
evaluate the characteristics of the nanoemulsion systems generated. Evaluations were also 
undertaken to understand the mechanism through which these systems enhance drug 
delivery across skin. Similar to Zhang et al (108), we examined the maximum flux, solubility 
in stratum corneum lipid components and diffusivity of both the model compounds, which 
have different lipophilicity (caffeine -0.07 and naproxen 3.18) from saturated solutions. A 
study was done on full-thickness skin and epidermal membranes. Our nanoemulsions were 
characterised by their transparency, small size and low viscosity. Both the microemulsion 
systems in this study significantly enhanced penetration of caffeine and naproxen. The 
possible cause of enhancement may be due to alterations in the stratum corneum barrier 
structure due in turn to the presence of EU and OA as penetration enhancers in the 
formulation. The mechanism of action of these penetration enhancers depends on the 
lipophilicity of the solute, with effects mediated by changes in diffusion being important for 
the hydrophilic caffeine and effects on stratum corneum solubility being the major 
determinant for the lipophilic dug naproxen. Nanoemulsions are promising vehicles to use 
for systemic delivery, controlled release and improved bioavailability. More investigation will 
allow the elucidation of mechanisms of nanoemulsion delivery into skin.  
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7.1.3 Appendageal delivery 
A series of studies by the Lademann group has emphasised that hair follicles represent a 
highly relevant and efficient penetration pathway and reservoir for topically applied 
substances. The work in Chapter 6 has assessed the transepidermal and transfollicular 
penetration flux and retention in the hair follicles, stratum corneum and in the skin for 
different formulations and two actives. In the first part dealing with minoxidil penetration, we 
found that O/W nanoemulsions containing OA and EU as combined oil phase and 
penetration enhancers were highly effective in vitro with the transdermal flux of minoxidil 
increasing 3 to 9- fold over the control. The mechanism of penetration from these 
formulations is by increasing the partitioning and diffusivity of minoxidil in the stratum 
corneum. In the second part of this work dealing with transfollicular penetration, storage of 
caffeine in the hair follicles as well as retention in the stratum corneum and skin after 24 h 
application of selected nanoemulsions and controls was studied. The results showed that 
the permeation of caffeine delivered into the receptor from nanoemulsions was significantly 
higher than for controls. The highest permeation was seen in the open hair follicles (OHF). 
The caffeine flux from these OHF was higher than from the untreated and blocked hair 
follicles. The transfollicular flux was higher from nanoemulsions relative to controls. Also, 
the amount of caffeine recovered from appendages after application of formulations 
containing EU and OA and controls from blocked hair follicles was lower than that from open 
and normal hair follicles. These results demonstrate that nanoemulsion formulations are 
promising vehicles for transfollicular delivery of the hydrophilic drug caffeine. More 
understanding of the hair follicle structure and function will allow the design of improved 
formulations for follicular delivery. More investigation is required to understand the influence 
of the physicochemical properties of the penetrant and the vehicle on follicular targeting. 
 
7.1.4 A comparison of the penetration and permeation of caffeine into and through 
human epidermis after application of various vesicle formulations 
Vesicle systems are widely applicable for topical administration. They can improve drug 
penetration into the desired skin site, with the aim of reducing systemic absorption and side 
effects. In addition, they are promising candidates for follicular delivery. The aim of this study 
was to investigate the effect of vesicle-encapsulation of a model hydrophilic drug, caffeine 
on its skin delivery. The in vitro permeation of caffeine from vesicles with different 
compositions of penetration enhancers and a non-ionic surfactant was studied. Vehicles that 
incorporated the non-ionic surfactant decyl polyglucoside (DPGluc) caused greater skin 
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penetration of caffeine than those containing either OA or EU as penetration enhancers. The 
results suggest that fusion of the vesicles with the lipid of the stratum corneum and direct 
transfer of solute from the vesicle formulations to the skin may contribute to the mechanism 
of drug permeation enhancement by transferosomes and niosomes. The overall results 
indicate that the presence of penetration enhancers in the vesicle components is not the 
important operating factor. Further investigation will be carried out in ongoing studies with 
fluorescently labelled liposomes. 
 
7.2 Future Direction 
Current Hansen solubility parameter models for predicting solubility and solute maximum 
flux consider only the properties of the solute and either the vehicle or the skin. In future this 
should be extended to take account of solute-vehicle, solute-skin and vehicle-skin 
interaction, analogous to current attempts to develop quality structure–property relationships 
(QSPR) models to account for formulation effects. 
The formulations developed for enhanced permeation of model drugs in this thesis should 
be extended and applied to therapeutic and diagnostic agents, many of which are 
macromolecules, peptides or oligonucleotides. For example, targeted delivery of substances 
for regional treatment or early detection of melanoma or other skin cancers is a promising 
area of application. 
The imaging techniques used to show alteration in stratum corneum morphological 
properties following delivery of nanoemulsions to excised human skin need to be developed 
further to allow quantitation of actual drug delivery to targeted skin sites. 
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Appendix 
Materials and Methods 
This chapter contains general materials and methods used in individual chapters of this 
thesis. Common laboratory techniques have been used in regards to solutes penetration in 
skin such as excised human skin preparation and transdermal delivery using Franz diffusion 
cells. This chapter starts with a list of chemicals that have been used and then experimental 
methods and procedures follow. 
 
Chemicals 
Caffeine, naproxen, minoxidil, lidocaine, ethanol, oleic acid (OA), eucalyptol (EU), 
polyethylene glycol 400 (PEG400) and polyethylene glycol 6000 (PEG6000), cholesterol, 
dilauroyl L-α-phosphatidylcholine (DLPC) were purchased from Sigma-Aldrich Pty. Ltd. 
(Sydney, Australia). Mineral oil (MO) was purchased from Galtex (Australia, Ltd), Glycerol 
from Ajax (a division of Naplex industries, Australia Pty. Ltd), Polyoxyl -20 Oleyl ether (Volpo-
N20) was purchased from CRODA (Croda Europe Ltd, United Kingdom) and Polyoxyl 10 
Oleyl ether (Volpo-N10, also known as Brij96v) from UNIQEMA (Wilton, United Kingdom), 
Decyl polyglucoside (DPGluc, sold as Oramix NS 10) was obtained from SEPPIC SA 
(France). All chromatography reagents were analytical grade. 
 
Drug models 
All drugs have been chosen according to their lipophilicity (log P) and molecular weight (< 
500) that are considered to be the most important physical properties determining 
penetration through human skin. The physicochemical properties of the model compounds 
are shown in Table 1 
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Table 1 Physicochemical properties of model compounds [Molecular weight (MW g/mol); 
Lipophilicity (Log P); Melting point (MP °C); Molar volume (MV), Solubility in aqueous 
solution (Saq mg/L); Dissociation constant (pKa)]  
Compound MWa  Log Pa MPa MVb Saq pKaa 
Caffeine 194.19 -0.07 238 151.8 21600 10.4 
Minoxidil 209.25 1.24 248 214.6 2200 4.61 
Lidocaine 234.34 2.44 68.5 89.7 4100 7.9 
Naproxen 230.26 3.18 153 142.6 15.9 4.2 
aChemIDplus advanced-chemical information with searchable synonyms, structure, 
formulas http://chem.sis.nlm.nih.gov/chemidplus/   
bHSPiP program (Steven Abbott of Steven Abbott TCNF Ltd, ©2011 Steven Abbott and 
Johann Wiechers) 
 
Human skin preparation:  
Skin preparation methods: full-thickness skin 
The skin was provided by female donors undergoing elective surgical procedures. Ethical 
approval was given by The University of Queensland Human Research Ethics Committee 
(HREC Approval no. 2008001342) and donors gave informed consent.  
The skin was placed stratum corneum down in a shallow tray and the fat was surgically 
excised with a scalpel and discarded as pathological waste. In this process, the fat was 
removed as completely as possible, taking care not to cut into the dermis below. The 
remaining full thickness skin was placed flat on 2 sheets of Whatman filter paper, inside a 
labelled manilla folder and sealed in an airtight ziplock plastic bag with air expelled. The full 
thickness skin was frozen and stored flat at -20°C 
Heat separated epidermal membrane 
(Method of Kligman and Christopher 1963) (149) 
The full thickness skin was immersed in hot water (60°C) for up to 60 seconds. After removal 
of skin from the water and draining of excess water, the skin was placed with stratum 
corneum side up on a cork board and secured with pins with slight stretching. Using a blunt 
probe, the epidermis was carefully peeled from the dermis, taking care not to tear it. The 
dermis was discarded, unless required. 
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The separated epidermal membrane (EM) was placed in a shallow tray containing about 
30mm of water, so that the oily outer water resistant layer of the EM was facing up. The EM 
was unrolled and carefully removed from the water on a piece of Whatman 541 filter paper. 
The paper and EM were laid flat to air dry, placed on a cardboard support in a sealed zip-
lock bag and frozen at -20°C until required 
Preparation of the stratum corneum 
The stratum corneum was prepared from epidermal sheets by trypsin digestion (149). The 
full-thickness skin was immersed in water at 60°C for 1 min that allowed the epidermis to be 
teased off the dermis. The epidermis was floated overnight on a solution of 0.01% trypsin in 
phosphate buffer saline (PBS) at 37°C. The viable epidermis was scraped off using cotton 
buds and the remaining stratum corneum membrane was rinsed several times with distilled 
water. The isolated stratum corneum sheets were placed flat on aluminium foil and stored 
at -20°c until use.  
 
Skin integrity: 
To assess the resistance of the epidermis, samples of epidermis were mounted in Franz 
cells: the receptor chamber was filled and 0.5-1 mL of PBS was added to the donor chamber. 
The cells were equilibrated for 30 mins before transdermal electrical resistance 
measurement was performed using a standard Multimeter with silver and silver chloride (Ag 
& AgCl) electrodes one into each chamber.  
Any reading above 20 KΩ is satisfactory (45, 265) a resistance less than 20 KΩ indicates 
that the epidermal integrity may be compromised and the membrane should be replaced. 
PBS was removed from the donor chamber and the surface of the skin gently blotted dry 
with tissue paper before application of the solutions. The receptor chamber was also 
emptied and refilled with new PBS. 
The silver and silver chloride (Ag & AgCl) electrodes were prepared, according to the 
Therapeutics Research Centre SOP (14/07/10), as described below: 
Two silver rods (approx. 6 cm X 2-3 mm diam.) were polished with sandpaper before being 
immersed in 1M KCl solution in a small beaker, not touching each other The rods were 
connected to a constant current power supply (500 µA) for 1h. The AgCl electrode became 
coated with a black AgCl deposit. 
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Skin permeation studies 
Franz Diffusion Cells  
In this thesis, Chapters 3, 4 and 5examined penetration from various formulations using 
excised human epidermal membranes and full-thickness skin. Franz Diffusion Cells are the 
most commonly used method for transdermal penetration studies. The membranes were cut 
into discs (̰2 cm diameter), and mounted stratum corneum side uppermost between the 
glass surfaces of the donor and receptor compartments. Vacuum grease was used as a 
sealant on the edges that were not exposed to the penetrant. The exposed skin surface area 
was 1.33 cm². Clamps were used to hold the cells together. The receptor was filled with an 
appropriate buffer (usually PBS) and the required dose of the test substance was applied to 
the membrane surface. The diffusion cells was placed in a perspex holder in a water bath, 
to maintain the receptor phase temperature at 35°C, over a magnetic 15 point stirring plate. 
Magnetic stirrers in the bottom of each receptor chamber maintained mixing in the receptor 
fluid. Samples of receptor phase (200µl) were removed at regular time points and replaced 
with same amount of fresh PBS buffer (152). Drug concentration in receptor samples was 
determined by HPLC. 
 
3.5.2 High performance liquid chromatography (HPLC) 
3.5.2.1 Standard curve Samples preparation and analysis 
Caffeine samples were dissolved in (PBS) pH 7.4. The internal standard was theophylline 
(5µg/mL) dissolved in the same solvent as the samples. Samples were analysed by HPLC.  
Minoxidil samples were dissolved in methanol then diluted using PBS pH 7.4. The internal 
standard was Propyl paraben (5µg/mL) dissolved in the same solvent. Samples were 
analysed by HPLC. 
 Lidocaine samples were dissolved in PBS pH 7.4. The internal standard was Bupivacaine 
5µg/ml dissolved in the same solvent as the samples. Samples were analysed by HPLC.  
Naproxen samples were dissolved in methanol then diluted using PBS pH 7.4. The internal 
standard was Indomethacin 10µg/ml dissolved in the same solvent. Samples were analysed 
by HPLC 
All samples were analysed using HPLC system consisting of Shimadzu SIL-6B SCL-10 a 
VP system controller, a SPD-10AV UV-VS detector, LC-10AD pump and an auto injector. 
The mobile phase was pumped across the system at 1ml/min flow rate. The column was a 
Phenomenex Luna 5 C18 (150×4.6mm). 
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Chromatographic conditions 
Table 2 Schedule of operating conditions for chromatographic analyses  
 Drug name 
Caffeine Minoxidil Lidocaine Naproxen 
Wavelength 273 nm 281 nm 210 nm 230 nm 
Mobile phase 20mL ACN, 20ml 
THF, 5ml acetic 
acid,950ml H₂O 
0.01M NaH₂PO₃,60% 
H₂O,40%ACN,2.5m
M SDS 
0.05M Na₂HPO₄ 
buffer 73%, 27%ACN 
45% CAN, 20% 
Methanol, 35% 
water and 4mL 
Acetic acid 
Internal standard (IS) Theophylline 
(5 µg/ml) 
Propyl paraben 
(5 µg/ml) 
Bupivacaine 
(10µg/ml) 
Indomethacin 
(10µg/ml) 
Dissolution solvent PBS Methanol PBS Methanol 
HPLC system #4 Shimadzu class 
VP software and 
Excel 2002 
#4 Shimadzu class 
VP software and 
Excel 2002 
#4 Shimadzu class 
VP software and 
Excel 2002 
#4 Shimadzu class 
VP software and 
Excel 2002 
 
Validation method 
Validation of assays includes testing for linearity, range, accuracy, precision, detection limit 
(DL) and quantitation limit (QL) according to FDA guidelines (266). The DL and the QL were 
based on the standard deviation of response (Q) and the slope of calibration curve (S).  
DL=3.3Q / S 
QL=10Q / S 
Stock solutions (1mg/mL) of each compound were prepared by dissolving an accurate 
amount of each compound in the solvents shown in Table 2. The standard curve was then 
concentrated by serial dilutions of the stock dilution to the concentration differences shown 
in Table 3.3. Analysis was based on peak areas. Caffeine, lidocaine and naproxen were 
validated using 3 sets of standard curves plus 3 extra samples of lower limit of quantification 
for caffeine and lidocaine in one day. The minoxidil method was validated using a set of 
standard curves plus 2 extra samples for three days (interday) and one set of calibration 
curves plus 2 extra samples in the morning and afternoon (intraday) (See Table 3). 
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Table 3 Validation results 
 Drug 
 Caffeine Minoxidil Lidocaine Naproxen 
Linearity 0.1-10 
(µg/ml) 
0.05-6 (µg/mL). 0.3-10 
(µg/ml) 
0.15-10 
(µg/ml) 
Accuracy -2.0% Theoretical Conc. 
µg/mL 
Mean of 
d conc 
SD CV% Error 
% 
-0.5% -1.6% 
0.5 0.47 0.01 1.5 -6.81 
1 0.95 0.01 0.9 -5.2 
Precision 2.4% Level Mean SD % cv 3.6% 4% 
0.3µg/mL 0.31 0.01 1.9 
3µg/mL 2.98 0.06 2.1 
Limit of 
quantitation  
0.1 (µg/ml) 1.48 (µg/ml) 0.3215 
(µg/ml) 
0.15 (µg/ml) 
 
Determination of Solubility in the vehicles or formulations (Sv) 
Sv was determined in saturated solutions of the compounds in each vehicle or formulation. 
An excess amount of the compound was added to 5 ml of the vehicle or formulation and the 
samples were incubated in a water bath at 32°C for 24 h, with continuous magnetic stirring. 
The samples were then centrifuged at 4000 rpm for 15 min and the supernatants were 
analysed by validated HPLC methods, after appropriate dilution where necessary (106). The 
Sv was described in Chapters 3, 4 and 5. 
 
Determination of solubility in the stratum corneum (SSC) 
Discs of stratum corneum (4 replicates for each compound) were weighed before using. 
They were then equilibrated in a saturated solution 1mL of each solute at 32°C for 24 h, 
according to established methods (150). At the end of the incubation period, the stratum 
corneum was removed, blotted dry and extracted with 1 mL 70% ethanol/water for another 
24 h, at the same temperature used for equilibrium (32°C). The SSC was determined from 
the amount of recovered model compound in the extraction fluid, measured by HPLC divided 
by the thickness and the area of the stratum corneum. The SSC was examined in Chapters 
3, 4 and 5. 
 
Solvent uptake  
The total solvent uptake into the stratum corneum was determined from the weight 
difference of a piece of the dry stratum corneum (about 0.6 mg) soaked in individual solvents 
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(1 mL) for 24 h at 35°C. The stratum corneum pieces were wiped three times with Kimwipe 
tissues before being weighed again. Solvent uptake was described in Chapters 3 and 4. 
 
Tape stripping 
This technique has been used in Chapters 4, 5 and 6. It is a technique used to remove the 
stratum corneum from skin by applying adhesive tape to the exposed skin surface, followed 
by careful removal. After Franz diffusion studies were completed, skin was washed 3 times 
with an ethanol moistened cotton bud or tissue. These wash samples were saved separately 
for HPLC analysis. After 10 min air drying, the skin was subjected to up to 20 tape strips to 
separate the stratum corneum from the epidermis.  D-Squame tape (CuDerm Corp., USA) 
was applied to the exposed skin surface for about 5 s at a standard pressure and then 
carefully removed. Individual tapes were placed into separate vials and soaked overnight 
with 2 mL methanol before being analysed by HPLC. The amount of absorbed material in 
each tape was then determined. It represented material deposited within the stratum 
corneum. The result of the first tape was discarded, as this represented surface deposited 
material only. 
 
Skin extraction. 
Subsequent to tape stripping, the remaining skin was sliced into small sections; 
homogenised and extracted overnight with 2 mL methanol under constant shaking. Caffeine 
and naproxen concentrations in the extracts were determined by HPLC. 
Extraction of skin was described in Chapters 4, 5 and 6.  
 
Follicular casting 
We used a technique known as the Lademann technique. It allows drugs deposited within 
appendages to be sampled and quantified. The surface and stratum corneum-deposited 
drugs were first removed by tape stripping 20 times. Following tape stripping, one drop of 
superglue was placed on a frosted section of a glass microscope slide, which was then 
pressed onto the surface of the stripped skin and held in place under light pressure for 
several minutes. When the glue was hard, the slide was peeled carefully from the skin, 
taking the contents of the skin appendages with it.  The superglue was dissolved by rubbing 
with acetone-soaked cotton buds (4 times) and the individual cotton buds containing the 
sampled follicular contents were soaked overnight in 2 mL methanol before vortexing and 
quantitation by HPLC. This technique was used in Chapters 5 and 6. 
157 
 
Open and closed hair follicles techniques  
Hair follicle plugging 
Our group developed a method to plug the hair follicles on excised skin to evaluate their 
contribution in permeability across the skin. According to this method we closely identified 
all the hair follicles in a marked region under the microscope (ZEISS, stemi 2000-C, Schott 
(Germany) KL (200LED). The plugging procedure involved applying 0.1 μL acriflavine 
solution (dissolved in milliQ water) to form a globule around the follicle and subsequently 
adding 0.1 μL of ethyl cyanoacrylate, (Loctite Super Glue, Henkel, USA) on top of it. The 
polar monomers of cyanoacrylate polymerised when they came in contact with the water 
molecules in the presence of acriflavine dye. This dye-sensitised polymerisation forms long 
and strong chains, thus plugging the skin and hair follicle. This technique was used in 
Chapters 5  
 
Validation for hair follicle plugging method  
As this is a new method, we wanted to test its efficacy by conducting in vitro skin absorption 
studies. As many of the follicles that could be identified under the microscope were plugged 
by the above technique. Then 1 mL of 3% (w/v) solution of caffeine in water was applied as 
the donor solution, with PBS at pH 7.4 as the receptor solution. The donor chamber was 
wrapped with parafilm after adding of the solution to prevent evaporation. At different times 
over 12 hours, 200 L of the receptor solution was withdrawn and replaced with the same 
amount of fresh PBS. The sample thus withdrawn was analysed for caffeine levels by 
sensitive and rapid HPLC. The sequence of events is shown in Figure 1. 
 
Figure 1 Method of hair follicle plugging (a. hair follicle identification; b. application of 0.1μL 
acriflavine solution dissolved in milliQ water; c. application of 0.1μl of ethyl cyanoacrylate 
(super glue); d. overview of plugged hair follicles in the exposed area.   
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Nanoemulsion formulation preparation 
The formulations were prepared by dissolving Volpo-N10 (surfactant) in ethanol (co-
surfactant). Then, oleic acid or eucalyptol (oil) was dissolved in the surfactant/ co–surfactant 
mixture, followed by gentle mixing with PBS. The surfactant/co-surfactant (S/Co-S) weight 
ratio was 1:1 and the weight ratio of oil: S/Co-S was 0.6:1:1. The resulting nanoemulsion 
was a clear semi-liquid at room temperature. Caffeine, minoxidil and naproxen at 3% w/w, 
2%w/w and 2% w/w, respectively were dissolved in the nanoemulsions and control 
solutions. This preparation method was used Chapters 4 and 5. 
  
Pseudo-ternary phase diagram 
Oleic acid and eucalyptol were used as oil phase (O), Brij 96v was used as the surfactant, 
and ethanol was used as the co-surfactant. The mixture of O with S/Co-S was prepared at 
w/w ratios 0.6:1:1. Then, the O/(S/Co-S) mixture was titrated with water step by step. In 
each step a mixer agitated the mixture to mix it thoroughly and the sample was checked 
visually. If the sample was clear, it has become a nanoemulsion but if it was cloudy, it had 
not become a nanoemulsion. The technique was designed to find the area of nanoemulsion 
existence to be as correct as possible (267). Once the concentration ratio of the 
nanoemulsion was selected, the drug was loaded and physicochemical properties were 
tested at ambient temperature. The preparation was described in Chapter 4. 
 
Vesicle preparation 
Different vesicles were prepared with excipient mixtures. For all vesicles, the excipients were 
mixed in a rotary flask in different ratios, followed by glass beads (4 g) and chloroform (3 
mL). Once the lipids were dissolved, the solvent was gradually evaporated on a rotary 
evaporator at 30 °C until a lipid film formed on the wall of the flask. The flask was set aside 
for 2 hours to eliminate residual chloroform, after which the lipid film was stirred with 2 mL 
caffeine solution (2% in water) for 2 hours at 30 °C. The liposome suspensions were 
extruded through a polycarbonate membrane with pore size 100 nm using the Liposofast 
extruder (AVESTIN, Inc., Ottawa, Canada). Thirty-one cycles of extrusion were performed 
for each vesicle type. The study was described in Chapter 6. 
Encapsulation efficiency 
To separate the non-encapsulated drug, the vesicle suspensions were centrifuged at 14000 
rpm for 30 min at room temperature. The amounts of solute in the supernatant and also in 
the clear solution were analysed by HPLC. Drug encapsulation efficiency (EE%) was 
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calculated as: EE% = 100* mass of incorporated drug/total mass in vesicle preparation. The 
study was described in Chapter 6. 
 
Nanoemulsion and vesicle characterisation (These techniques were used in Chapters 
4 and 6.) 
Nanoemulsions were characterised by transmittance, droplet size, reflection index, 
electrical conductivity and viscosity) 
Vesicles were characterised by droplet size, zeta potential and polydispersity index (PDI).  
Transmittance (Clarity)  
The transmittance (T) of a sample is the ratio between the intensity of light that has passed 
through a sample to the intensity of light when it entered a sample (T=Iincident/Itransmitted). It can 
also be expressed as a percentage (T x 100). Transmittance measured under standard 
conditions can be used as a measure of the clarity of a sample. It is generally accepted that 
nanoemulsions are characterised by transmittance readings >90%. The clarity of 
nanoemulsions in this work was determined by using a spectrophotometer (Hitachi U-1100; 
acrylic cuvettes 10X10X45mm) at a wavelength of 650nm. 
 
Dynamic light scattering (DLS) 
Size (Z-average size) and polydispersity index (PDI (the width of particle size) of 
microemulsions were measured using a Zetasizer Nano ZS (Malvern Instruments, Ltd, 
Malvern, UK). The diameter of a sphere is determined by measuring the speed of the 
random diffusion of molecules in the liquid due to the bombardment by surrounding solvent 
molecules using the Dynamic Light Scattering (DLS) method (Malvern). The system 
contains the optical unit for collection of raw data from samples, cells to hold the samples 
and controls and software which calculates the results using established theories. The size 
measurements were conducted using standard operating procedures (SOP) and reflective 
index values for the water and oil phases. Nanoemulsions were diluted 1:100 in water and 
measured in polystyrene cuvettes at 25°C. 
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Refractive index 
The refractive indexes of nanoemulsion samples were measured with a refractometer (RFM 
34) at room temperature.  
 
Electrical conductivity (EC) 
Nanoemulsion phase change analysis can be carried out by observing changes in 
conductivity with the addition of water to the system. Phase changes are indicated by a 
“percolation point”, over which a drop in conductivity is observed. Clarification of the 
concentration ranges within which an O/W or W/O nanoemulsion is formed is confirmed 
using a Digitor 31/2 Digit multimeter model Q1563. The values of EC measurements were 
performed in triplicate using an electrical conductivity meter; this was done by using AgCl 
and Ag conductivity electrodes at room temperature. The O/W nanoemulsion is conductive, 
however, W/O emulsions show much greater resistance. Therefore, the conductivity 
switched between two plateaus corresponding to water-continuous and oil-continuous 
structure (202). 
 
Viscosity measurements  
The nanoemulsion viscosity was determined using a glass capillary viscometers or Ostwald 
viscometers (Figure 2), named after Wilhelm Ostwald, at ambient temperature (24°C ± 1). 
Another version is the Ubbelohde viscometer, which consists of a U-shaped glass tube held 
vertically in a room temperature. In one arm of the U is a vertical section of precise narrow 
bore (the capillary) glass. Above there is a bulb, with another bulb lower down on the other 
arm. In use, liquid is drawn into the upper bulb by suction, and then allowed to flow down 
through the capillary into the lower bulb. Two marks (one above and one below the upper 
bulb) indicate a known volume. The time taken for the level of the liquid to pass between 
these marks is proportional to the kinematic viscosity. Most commercial units are provided 
with a conversion factor, or can be calibrated by a fluid of known properties. The time 
required for the test liquid to flow through a capillary of a known diameter of a certain factor 
between two marked points is measured. By multiplying the time taken by the factor of the 
viscometer, the kinematic viscosity is obtained (268). 
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Figure 2 Ostwald viscometers measure the viscosity of a fluid with a known density (268) 
 
Zeta potential measurements 
Zeta potential is the potential at the slipping or shear plane at the boundary between the 
mobile/diffuse layer and immobile/stern layer. The Zeta potential of liposomes was 
determined by dynamic light scattering (Zetasizer Nano ZS, Malvern Instruments, Ltd, 
Malvern UK) at room temperature using polystyrene cuvettes after dilution with water to the 
ratio 1:50.  
 
Multiphoton microscopy (MPM) 
Multiphoton microscopy (MPM) was used to assess the effect of the formulations in the 
stratum corneum. A DermaInspect system (JenLab GmbH, Jena, Germany), coupled to an 
ultra-short-pulsed, mode-locked, 80-MHz Titanium Sapphire laser (Mai Tai, Spectra 
Physics, Mountain View, California, USA) was used to image the skin in Chapter 4. For the 
MPM, skin samples were prepared to match the experimental conditions of in vitro Franz 
cell studies. An infinite dose from F2 EU and OA was applied to full-thickness skin. Samples 
of untreated skin were used as controls. After 8 h, the donor from the Franz cell was removed 
and the epidermis swiped gently with water and blotted dry with tissue. Then, these skin 
pieces were placed onto a microscope slide with a drop of water on the skin surface and 
protected with a cover slide.(108) Images were captured at 740 nm two-photon excitation.  
The skin was imaged at four depths, from the superficial surface, corresponding to the 
stratum corneum (~5-10 µm), stratum granulosum (~15-20 µm), stratum spinosum (25-30 
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µm) and stratum basale (35-40 µm). Keratinocyte morphology was used to confirm each of 
these layers. 
 
LaVision Multiphoton Microscope  
LaVision Multiphoton Microscope (LaVision BioTec GmbH, Germany) was used to assess 
the effect of these formulations in hair follicles and the area around hair follicles. A 
multiphoton system, coupled to an ultra-short-pulsed Titanium Sapphire laser (Mai Tai, 
Spectra Physics, Mountain View, California, USA) was used to image the skin. Full-
thickness abdominal skin was mounted in Franz diffusion cells and a finite dose of acriflavine 
in the nanoemulsion formulations containing EU and OA and control (water) was applied. 
Samples of untreated skin were used as controls. After 24 h, the cells were dismantled and 
the skin was rinsed gently with water and blotted dry with a tissue. It was then placed directly 
on a microscope slide. Images were captured by two photon excitation at 740 nm. The skin 
was imaged at different depths, from the superficial surface, corresponding to the stratum 
corneum (~5-10 µm), stratum granulosum (~15-20 µm), stratum spinosum (25-30 µm) and 
stratum basale (35-40 µm). Keratinocyte morphology was used to confirm image depth in 
each of these layers. Image analysis was done using Image J (Wayne Rasband, National 
Institutes of Health, USA). These images were used in Chapter 5. 
 
 
